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1. INTRODUCTION 
     (Anjaneyulu Y. et al, 2006) 
  Analytical chemistry deals with quantitative analysis of composition of 
substances and complex materials in various matrices by measuring at physical and 
chemical properties of a distinctive constuent of the component or components. “A 
scientific discipline that develops and applies methods, instruments and strategies to 
obtain information on the composition and nature of matter in space and time”. 
Analytical chemistry that assume to be the supporting role of an in spreadable tool in 
advancing in depth knowledge in any a scientific field. A thorough back ground in 
analytical chemistry plays a vital role for a chemist in the following ways.  
1. To develop and evaluate new procedures. 
2. Separate simple and complex mixtures. 
3. Purity of samples. 
4. Write computer programmes statistically to evaluate the reliability of the data. 
Modern medicines for human use are required to standards which relate to their 
quality, safety and efficacy (quantity of the active ingredient). The evaluation of safety 
and efficacy and their maintenance in practice is dependent upon the existence of 
adequate methods for quality control of the product. The standard of purity must, 
therefore, be strictly defined in such a way as to ensure that successive batches are 
consistent in composition, irrespective of whether they come from the same or different 
manufactures. 
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 Now a day’s analytical chemists are expected to be a vital link an extra ordinary 
number of diverse fields as follows. 
 
 The multi-component formulations have gained a lot of importance now a days 
due to greater patient acceptability, increased potency and decreased side effects. The 
quantitative analysis of such multi-component formulations is very important. One of the 
quantitative procedures for multi-component formulations is the absorbance correction 
method, which utilizes the measurement of intensity of electromagnetic radiation emitted 
or absorbed by the analyte. There are various simultaneous estimation methods which are 
employed for the quantitative estimation of multi-component formulations. The 
spectrophotometer has become a useful instrument for drug analysis. Now it is the 
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instrument of choice in conducting quantitative estimation of coloured and colourless 
solutions. 
1.1 ANALYTICAL TECHNIQUES (Fifeld F.W and Kealey D. 2006) 
 A wide variety of parameters may be measured by using following techniques.  
S.No Group  Property measured 
1 Gravimetric Weight of pure analyte or of a stoichiometric compound 
containing it. 
2 Volumetric Volume of standard reagent reacting with the analyte 
3 Spectrometric Intensity of electromagnetic radiation emitted or 
absorbed by the analyte. 
4 Electrochemical Electrical properties of analyte  solutions 
5 Radiochemical Intensity nuclear radiations emitted by the analyte. 
6 Mass spectrometric Abundance of molecular fragments derived from the 
analyte. 
7 Chromatographic Physico- chemical properties of individual analytes after 
separation. 
8 Thermal Physico- chemical properties of the sample as it is heated 
and cooled. 
 
1.1.1 Factors Affecting the Choice of Analytical Method (Mendham et al., 1994) 
 Selection of particular analytical techniques differing in degrees of sophistication, 
Sensitivity and Selectivity differs in availability, cost and time. 
 1. Type of chemical analysis required: elemental or molecular, routine or occasional. 
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2. Problems arising from nature of materials to be investigated. 
    e.g radioactive substances, corrosive substances and substances affected by water. 
 3. Possible interferences from components of the material other than those of interest. 
4. The concentration range which needs to be investigated. 
5. The accuracy required. 
6. The time required for complete analysis. 
7. The number of analyses of similar type which have to be performed. 
1.1.2 The Typical Separation Procedures Include (Koh Hl., et al., 2003; Jan N., et al., 
2011; Segura 2009; Yvan Gaillard 2000 and Mario Theyis et al., 2007) 
 Traditionally pharmaceutical analysis referred to chemical analysis of drug 
molecules, in various combination techniques like chemometrics, micro dosing studies 
and nano technology. The analytical advances plays its role in drug discovery, analysis of 
natural products and nutraceuticals, analysis of systemic biology (proteomics, 
metabolimics and glycomics), biosensors and bioreactors, advances in chiral separations, 
drug binding analysis, forensic and anti-doping analysis, high sensitivity technologies for 
trace analysis (Micro and nano scale level), new trends in bio analysis (from urine, hair 
analysis and exhaled air), Therapeutic drug monitoring and toxicological analysis.  
a. Selectivity precipitation of interferants. 
b. Masking of specific interferants by complexing agent. 
c. Selective oxidation or reduction of interferants. 
d. Solvent extraction by converting to suitable form. 
e. Ion exchange. 
f. Chromatography 
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Advanced separating and detecting methods include 
     1. Gas Chromatography – Mass Spectrometry (GC - MS) 
     2. Liquid Chromatography – Mass Spectrophotometry (LC-MS) 
     3. Inductively coupled plasma – Mass Spectrometry (ICP - MS) 
     4. Large Geometry Secondary Ion Mass Spectrometry (LG - SIMS) 
     5. Super Critical Fluid Chromatography (SFC) 
     6. Capillary Zone Electrophoresis (CZE) 
 Usage of LC-MS and GC-MS in clinical, legal and forensic fields is appreciable 
in the technique of anti doping laboratories. It  is generally used to detect that the athlete 
has taken any drugs could be easily found out by observing the HCG (Human chorionic 
gonadotropin) level which is a natural anabolic steroid used for excessive strength for 
athlete. In postmortem drug analysis, LC-MS was generally used to detect special drugs 
like Heroin, Cocaine, Anti-depressants, Anti-psychotics and Benzodiazepines if present 
in unstable or degraded form. ICP-MS is required for the detection of metal analysis 
clinically, especially in heavy metal poisoning cases. Another easy method of detecting 
anabolic steroids in anti doping laboratories can be done by powdering the hair, treated 
with methanol and alkaline digestion with sodium hydroxide for the optimum recovery of 
the drug and could be easily analyzed by gas chromatography coupled to triple 
quadrapole mass spectrometry, here nitrogen gas was used as carrier gas for gas 
chromatography. LG-SIMS is used for the detection speed and sensitivity of nuclear 
material which is used for identification of source of material. Super critical fluid 
chromatography (SFC) is particularly suitable for moderately polar compounds or mass 
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sensitive detection. Capillary zone electrophoresis (CZE) has a promising future in 
analysis of drugs and in the field of biotechnological analysis. 
  HPLC and GC are most commonly used chromatographic techniques in 
analyzing starting materials, intermediates and active pharmaceutical ingredients (API) in 
research and development. HPTLC is very useful technique in solving various problems 
and can complement other chromatographic techniques also.  
 Methodology 
 In developing a quantitative method for determining an unknown concentration of 
given species by absorption spectrophotometry, the following steps are followed, 
1. To record the spectrum of a solution of known concentration of each component. 
2. From the spectra, choose the wavelength for each component based at which 
absorptive measurements are to be made. 
3. Prepare a working curve of each pure component at each of chosen wavelengths. 
Calibration curve for each component are recorded and if straight curves are 
obtained, such that it obey Beer’s law of absorption and absorptivity values are 
obtained for such curves. 
4. Write equations similar to all wavelengths by using absorptivity values 
5. Make sure that the absorbance are additive for each concentration at that 
particular selected wavelength. 
6. Determine the absorbance of mixture in all wavelengths selected for analysis and 
substitute in the equations obtained. 
7. Solve the equations simultaneously for each component’s concentrations by using 
matrix algebra (if needed). 
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1.2 INTRODUCTION TO UV SPECTROSCOPY 
 (B.K Sharma, 2006; Robert D. Braun et al., 2006; Gurudeep R. Chatwal et al, 2008) 
 The spectral methods of analysis are used for measuring the amount of 
electromagnetic radiation (EMR) that is absorbed, emitted or scattered by a sample to 
perform assay. EMR possess discrete energy particles called ‘photons’, which travel as a 
wave. In particular ultra-violet visible absorption usually corresponds to excitation of 
electrons from ground state to higher energy state, by the application of energy which 
will be generally in the form of photons (EMR). Absorption and emission of radiant 
energy is the basis for many methods in analytical chemistry. The interpretation of these 
data gives information regarding qualitative and quantitative analysis.  
 Qualitatively, the position of absorption  and emission lines or bands which occur 
in the electromagnetic spectrum serve as an indication of the presence of a specific 
substance. Quantitatively, the intensities of the same absorption and emission lines or 
bands for the unknown and standards are measured and the concentration of unknown is 
determined from these data. Depending on the wavelength of incident radiation and 
molecule can be excited to different vibrational and rotational level; as the energy 
different associated for an electron level are small. When the energy involved in the 
electronic transition is large, the absorption will take place primarily in ultra-violet. If the 
energy absorbed is greater for some visible wavelengths than for others, the emergent 
beam will appear coloured. The apparent colour of the solution is always the complement 
of the colour absorbed. 
 Ultra violet absorption spectra are attributed to a process in which the outer 
electron of atoms or molecules absorbs radiant energy and undergoes transitions to higher 
energy level. There transition are quantitized and depend on electronic structure of the 
8 
 
absorbent. Many molecules absorb ultraviolet or visible light. The absorbance of a 
solution increases as attenuation of the beam increases. Absorbance is directly 
proportional to the path length, b, and the concentration, c, of the absorbing species. 
Beer's Law states that   
 A = bc, Where,  is a constant of proportionality, called the absorptivity. 
 Different molecules absorb radiation of different wavelengths. An absorption 
spectrum will show a number of absorption bands corresponding to structural groups 
within the molecule.   
1.2.1 Beer - Lambert’s Law  
 When light is incident upon a homogeneous medium, a part of incident light is 
reflected, a part is absorbed by the medium and the remainder is allowed to transmit as 
such. 
I0 = Ia + It + Ir 
 Where,  
  I0 = Incident light 
  Ia = Absorbed light 
  It = Transmitted light 
  Ir = Reflected light 
Lambert’s Law states “when a beam of light is allowed to pass through a transparent 
medium, the rate of decrease of intensity with the thickness of the medium is directly 
proportional to the intensity of the light”. 
- ௗூ
ௗ௧
∝ ܫ 
  It = I0 e-kt       ---------- (1) 
(or) 
ܫ݊
ܫ₀
ܫ௧
= ݇ݐ 
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Beer’s Law states “The intensity of a beam of monochromatic light decreases 
exponentially with the increase in concentration of the absorbing substance”. 
     - ୢ୍
ୢୡ
∝ I 
  It = I0 e-k’c      ----------- (2) 
(or) 
ܫ݊
ܫ₀
ܫ௧
= −݇;ܿ 
By solving equations 1 and 2, on changing equations from natural logarithm, 
   It = I0. 10-0.4343kt = I0 10-kt   ----------- (3) 
   It = I0. 10-0.4343 k’c = I0-k’c       ----------- (4) 
On combining equations 3 and 4, 
It = I0 10-act log I₀I୲ = act 
Where k and k' are constants, C is the concentration of the absorbing substance and          
t denotes thickness of the medium. 
1.2.1.1 Limitations of Beer’s law 
 The linearity of the Beer-Lambert law is limited by chemical and instrumental 
factors. Causes of nonlinearity include:  
 deviations in absorptivity coefficients at high concentrations (>0.01M) due to 
electrostatic interactions between molecules in close proximity  
 scattering of light due to particulates in the sample  
 fluorescence or phosphorescence of the sample  
 changes in refractive index at high analyte concentration  
 shifts in chemical equilibria as a function of concentration  
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 non-monochromatic radiation, deviations can be minimized by using a relatively 
flat part of the absorption spectrum such as the maximum of an absorption band  
 stray light  
 1.2.1.2 Deviations from Beer’s law 
 According to Beer’s law, a straight line passing through the origin should be 
obtained, when a graph is plotted between absorbance and concentration. But there is 
always a deviation from linear relationship between absorbance and concentration and 
intact the shape of an absorption curve usually changes with changes in concentration of 
solution and unless precautions are observed. Deviations from the law may be positive or 
negative according to whether the resulting curve is concave upward or concave 
downward.                            
  
 
The latter two are generally known as instrumental deviation and chemical deviation. 
a. Instrumental deviations 
 Stray radiation, Improper slit width, Fluctuation in single beam. 
b.  Chemical deviations 
 Hydrolysis, Association, Polymerization, Ionization and Hydrogen bonding 
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1.2.1.3 Deviations from Beer’s law can arise due to the following factors 
1. Beer’s law will hold over a wide range of concentration provided the 
structure of coloured ion or of the coloured non electrolyte in the dissolved 
state does not change with concentration. If a coloured solution is having a 
foreign substance whose ions do not react chemically with the coloured 
components, its small concentration does not affect the light absorption and 
may also alter the value of extinction co - efficient. 
2. Deviations may also occur if the coloured solute ions dissociates or 
associates. 
3. Deviations may also occur due to the presence of impurities that fluorescence 
or absorb at absorption wavelength. 
4. Deviations may occur if monochromatic light is not used. 
5. Deviations may occur if the width of slit is not proper and therefore it allows 
undesirable radiations to fall on the detector. 
6. Deviations may occur if the solution undergoes polymerization. 
7. Beer’s law cannot apply to suspensions but the latter can estimated 
calorimetrically after preparing a reference curve with known concentrations. 
1.2.2 Choice of Solvent (William Kemp, 2006) 
 A suitable solvent for ultraviolet spectroscopy should meet the following 
requirements. 
(i) It should not itself absorb radiations in the region under investigation. 
(ii) It should be less polar so that it has minimum interaction with the solute molecule. 
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1.2.2.1 Solvents used in UV spectroscopy 
S.No. Solvent Cut-off  (nm) 
1. Ethanol 205 
2. Methanol 210 
3. Acetonitrile 210 
4. Hexane 210 
5. Cyclo hexane 210 
6. Diethyl ether 220 
7. Chloroform 245 
8. Carbon tetrachloride 265 
9. Toluene 280 
10. Acetone 330 
 
1.2.3 Electronic Transitions (B.K Sharma, 2006; Willard et al, 1986; Skoog et al, 2006) 
 All organic compounds or compounds are capable of absorbing EMR        
(Electro Magnetic Radiation) because all containing valance electrons that can be excited 
to higher energy levels. The electron that contributes to the absorption characteristics of 
an organic molecule includes, 
a) Electrons participating in bond formation between atoms of a molecule 
b) Non bonding or unshared outer electrons that are localized like oxygen, sulphur, 
nitrogen and halogens. 
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 There are three different types of electrons which may be present in an organic 
molecule include:  
a) Sigma (σ) electrons 
 - Associated with saturated bonds, so called as sigma electrons 
 - Electrons remains localized in direction of inter nuclear axis 
 - High energy bonds, so not absorbed in UV region 
 - Generally used as solvents in UV. 
b) Pi (π) electrons 
 - Associated with unsaturated bonds so called as Pi electrons 
 - Electrons remain localized in perpendicular to inter nuclear axis 
 - Moderate energy bonds, which could be excited by UV radiation so,                                                 
   compounds with pi electrons could be detected are examined by UV. 
c) Non bonding (n) electrons 
 - Less firmly held than any another electrons 
 - Present in atoms like oxygen, nitrogen, sulphur and halogens 
 - Easily excited by UV radiation. 
 - Generally forms coordinate covalent bonds 
 The excited states of any electrons which are involved in bond formation are 
called as anti-bonding orbitals. As ‘n’ electrons do not form bonds, there are no anti-
bonding orbitals associated with them. 
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1.2.3.1 Important types of electronic transitions with examples are shown below 
S.No Transition type 
Energy for 
excitation Examples 
1. σ - σ* Very high 
Alkanes – Methane,                          
                  Ethane. 
2. n - σ* High 
Alcohols, Ethers, Thiols and 
Disulphides. 
Alkyl halides – Methyl Iodide, 
                         Methyl chloride. 
3. π - π* Moderate 
Alkenes – Ethylene. 
Alkynes – Ethyne and Propyne. 
Carbonyl compounds. 
4. n - π* Low Carbonyl compounds, Pyridine 
 
 
 σ* -------------------------------------------- Anti bonding 
 π* -------------------------------------------- Anti bonding 
 n   -------------------------------------------- Non-bonding 
 π   --------------------------------------------- Bonding 
 σ   --------------------------------------------- Bonding 
  Figure: Electronic Transitions 
1.2.4 Instrumentation           
(Gurudeep R. Chatwal et al., 2008) 
(http://www2.chemistry.msu.edu/faculty/reusch/virtTxtJml/Spectrpy/UVVis/uvspec.html) 
  
 All photometers, colorimeters and spectrophotometers have the following basic 
components 
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1.2.4.1 Radiation source  
i) It must be stable. 
ii) It must be of sufficient intensity for the transmitted energy to be detected at  
the end of the optical path. 
iii) It must supply continuous radiation over the entire wavelength region in which 
it is used. 
1.2.4.1.1 UV region  
  Hydrogen discharge lamp, Deuterium discharge lamp, Xenon arc Lamp 
1.2.4.1.2 Visible region 
 The tungsten lamp and tungsten halogen lamp are the most common source of 
visible radiation. 
1.2.4.2 Filters and monochromators 
 The filters and monochromators are used to disperse the radiation according to the 
wavelength.  
1.2.4.2.1 Filters  
 A light filter is a device that allows light of the required wavelength to pass but 
absorbs light of other wavelengths wholly or partially. Thus, a suitable filter can be 
selecting a desired wavelength band. It means that a particular filter may be used for a 
specific analysis. If analysis is carried out for several species, a large number of filters 
have to be used and interchanged. This method is very useful for routine analysis. 
Types of filters 
 Filters are two types, 
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 i) Absorption filters 
ii) Interference filters 
 Absorption filters work by selective absorption of unwanted wavelengths and are 
made up of solid sheet of glass, coloured by a pigment or dispersed in glass and dyed 
gelatin. Interference filters work by selective transmission of selected wavelengths and 
they are made up of semitransparent metal film deposited on a glass plate and coated with 
dielectric material (MgF2). 
1.2.4.2.2 Monochromators  
 Monochromators successfully isolates band of wavelengths usually much more 
than a narrower filter. The essential elements of a monochromator are an entrance slit, a 
dispersing element (prim or gratings) and an exit slit. The entrance slit sharply defines the 
incoming beam of heterochromatic radiation. The dispersing element disperses the 
heterochromatic radiation into its component wavelengths where as exit slit allows the 
nominal wavelength together with a band of wavelength on either side of it. The position 
of the dispersing element is always adjusted by rotating it to vary the nominal wavelength 
passing through the exit slit. 
Types of monochromator 
 1) Prisms 
 2) Gratings  
 A prism is made up of quartz (for UV region), glass (for visual range) and alkali 
halides (for IR). The main advantage of prisms is that they undergo dispersion giving 
wavelengths which do not overlap, but the main disadvantage is that they give               
non – linear dispersion.  A grating consists of large number of parallel lines ruled on a 
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highly polished surface like alumina. Generally, gratings are difficult to prepare 
therefore, replica gratings are prepared from an original grating. This is done by coating 
the original grating with a film of an epoxy resin which after setting is removed to yield 
replica. Then replica is made reflective by aluminizing its surface. Gratings give linear 
dispersion but they suffer from an overlap of spectral orders. 
1.2.4.3 Sample cells 
These are containers for holding the sample and reference solutions and must be 
transparent to the radiation passing through generally with a thickness of 1 Cm. The 
choice of a sample cells are based on transmission characteristics at desired wave lengths, 
the path length, shape, size and the relative expense. The transmission characteristics are 
based on the construction materials. For UV region, the cells made up of quartz and for 
visible region, the cells are made of glass. 
1.2.4.4 Detectors 
Detectors used in UV-Visible spectrophotometers can be called as photometric 
detectors. In these detectors the light energy is converted to electrical signal which can be 
recorded. The types of detectors used are Barrier Layer cell (or) Photo Voltaic cell, Photo 
tubes (or) Photo emissive tubes, Photomultiplier tubes and Photo diode. 
1.2.4.5 Recorders 
 Detectors transmits the amount of light absorbed by a particular chemical species 
and only by that species is desired and by correcting the absorbance of solvent and other 
species in the solution. The recorders record the spectrum without any interferences 
compared with blank and they are user friendly. 
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Figure: Double Beam UV - Spectrophotometer 
1.2.5 Spectrophotometric Multi - Component Analysis 
 (A.H Bekette and Stenlake J.B., 2002)  
Absorption spectroscopy is one of the most useful and widely used tools available 
to the analyst for quantitative analysis. The relation between the concentration of analyte 
and the amount of light absorbed is the basis of most analytical applications of molecular 
spectroscopy. This method of analysis is gaining importance due to simple, rapid, precise, 
spectra of highly accurate and less time consuming. Spectrophotometric multi-component 
analysis can be applied where the drugs overlaps. In such cases of overlapping spectra, 
simultaneous equation can be framed to obtain the concentration of individual component 
otherwise multi-component analysis can be applied on any degree of spectral overlap 
provided that two or more spectra are not similar. The various spectroscopic techniques 
used for multi-component analysis include 
1. Simultaneous equation method 
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2. Absorption ratio method 
3. Geometric correction method 
4. Absorption correction method 
5. Orthogonal polynomial method 
6. Differential spectroscopy 
7. Derivative spectroscopy 
8. Area under curve method. 
The various chromatographic techniques helps in multi-component analysis include 
1. High performance liquid chromatography 
2. High performance thin layer chromatography 
3. Gas chromatography 
1.2.5.1 Different spectroscopic methods  
 The assay of an absorbing substance may be quickly carried out by preparing a 
solution in a transparent solvent and measuring its absorbance at a suitable wavelength. 
The wavelength normally selected is a wavelength of maximum absorption (max), where 
small errors in setting the wavelength scale have little effects on the measured 
absorbance. 
1.2.5.1.1 Assay of substances in single component samples 
 Absorption spectroscopy is one of the most useful tools available to the chemist 
for quantitative analysis. The most important characteristics of photometer and 
spectrophotometric method are high selectivity and ease of convenience. Quantitative 
analysis (assay of an absorbing substance) can be done using following methods. 
-    Use of Aଵ	ୡ୫ଵ% 	 values 
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-    Use of calibration graph (multiple standard method) 
-     By single or double point standardization method. 
1.2.5.1.1.1 Use of ࡭૚	ࢉ࢓
૚% 	 values 
 This method can be used for estimation of drug from formulations or raw 
material, when reference standard not available. The use of standard value Aଵ	ୡ୫ଵ%  avoids 
the need to prepare a standard solution of the reference substance in order to determine its 
absorptivity, and is of advantage in situations where it is difficult or expensive to obtain a 
sample of the reference substance. 
1.2.5.1.1.2 Use of calibration graph 
 In this procedure the absorbances of a number (typically 4 - 6) of standard 
solutions of the reference substance at concentrations encompassing the sample 
concentrations are measured and a calibration graph is constructed. The concentration of 
the analyte in the sample solution is read from the graph as the concentration 
corresponding to the absorbance of the solution. Calibration data are essential if the 
absorbance has a non-linear relationship with concentration, or if the absorbance or 
linearity is dependent on the assay conditions. In certain visible spectrophotometric 
assays of colourless substances, based upon conversion to coloured derivatives by heating 
the substance with one or more reagents, slight variation of assay conditions, e.g. PH, 
temperature and time of heating, may rise to a significant variation of absorbance, and 
experimentally derived calibration data are required for each set of samples. 
1.2.5.1.1.3 Single or double point standardization 
          The single point procedure involves the measurement of the absorbance of a 
sample solution and of a standard solution of the reference substance. The standard and 
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the sample solution are prepared in similar manner; ideally the concentration of the 
standard solution should be close to that of the sample solution. The concentration of the 
substance in the sample is calculated using following formula. 
                                    Ctest = A test × Cstd / Astd 
Where,  
Ctest and Cstd are the concentration in the sample and standard solutions 
respectively.  
Atest and Astd are the absorbance of the sample and standard solutions 
respectively. 
 In double point standardization, the concentration of one of the standard solution 
is greater than that of the sample while the other standard solution has a lower 
concentration than the sample. The concentration of the substance in the sample solution 
is given by                                         
ܥtest = (ܣ௧௘௦௧ − ܣ௦௧ௗଵ)(ܥ௦௧ௗଵ − ܥ௦௧ௗଶ) + ܥ௦௧ௗଵ(ܣ௦௧ௗଵ − ܣ௦௧ௗଶ)ܣ௦௧ௗଵ-ܣ௦௧ௗଶ  
Where, 
Cstd is the concentration of the standard solution.  
Atest and Astd are the absorbance of the sample and standard solution respectively. 
Std1 and Std2 are the more concentrated standard and less concentrated standard 
respectively. 
 
1.2.5.1.2 Assay of substances in Multicomponent Samples 
 The spectrophotometric assay of drugs rarely involves the measurement of 
absorbance of samples containing only one absorbing component. The pharmaceutical 
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analyst frequently encounters the situation where the concentration of one or more 
substances is required in samples known to contain other absorbing substances which 
potentially interfere in the assay. If the recipe of the sample formulation is available to 
the analyst, the identity and concentration of the interferents are known and the extent of 
interference is the assay may be determined. Alternatively, interference which is difficult 
to quantify may arise in the analysis of formulations from manufacturing impurities, 
decomposition products and formulation excepients.  Unwanted absorption from this 
source is termed irrelevant absorption and, if not removed, imparts a systematic error to 
the assay of the drug in the sample. 
 A number of modifications to the simple spectrophotometric procedure described 
above for single-component samples are available to the analyst, which may eliminate 
certain sources of interference and permit the accurate determination of one or all of the 
absorbing components.  Each modification of the basic procedure may be applied if 
certain criteria are satisfied.  The correct choice of procedure for a particular analytical 
problem provides the analyst with a opportunity to demonstrate his/her analytical 
expertise. 
The basic of all the spectrophotometric techniques for multicomponent samples is the 
property that at all wavelengths: 
a. The absorbance of a solution is the sum of absorbance of the individual 
components, or 
b. The measured absorbance is the difference between the total absorbance of the 
solution in the sample cell and that of the solution in the reference (blank) cell. 
 
23 
 
1.2.5.1.2.1 Simultaneous equations method 
 If a sample contains two absorbing drugs (X and Y) each of which absorbs at the 
max of the other, it may be possible to determine both drugs by the technique of 
simultaneous equations (Vierodt’s method) 
 
 The information required is: 
a. The absorptivities of X at 1 and 2, ax1 and ax2 respectively. 
b. The absorptivities of Y at 1 and 2, ay1 and ay2 respectively. 
c. The absorbances of the diluted sample at 1 and 2, A1 and A2 respectively. 
Let Cx and Cy be the concentrations of X and Y respectively for diluted sample. 
 Two equations are constructed based upon the fact that at 1 and 2 the absorbance 
of the mixture is the sum of individual absorbances of X and Y. 
At 1 
A1 = ax1bcx + ay1bcy    (1) 
At 2 
A1 = ax2bcx + ay2bcy    (2) 
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For measurements in 1 cm cells, b = 1 
Rearrange eq. (2) 
ܿ௬ = ܣଶ − ܽ௫ଶܿ௫ܽ௬ଶ  
Substituting for cy in eq. (1) and rearranging gives 
ܥ௫ = ܣଶܽ௬ଵ − ܣଵܽ௬ଶܽ௫ଶܽ௬ଵ − ܽ௫ଵܽ௬ଶ 
And 
ܥ௬ = ܣଵܽ௫ଶ − ܣଶܽ௫ଵܽ௫ଶܽ௬ଵ − ܽ௫ଵܽ௬ଶ 
 As an exercise you should derive modified equations containing a symbol (b) for 
path length, for application in situations where A1 and A2 are measured in cells other than 
1 cm path length. 
Criteria for obtaining maximum precision, based upon absorbance ratios, have been 
suggested that place limits on the relative concentrations of the components of the 
mixture.  The criteria are that the ratios 
ܣଶ ܣଵ⁄
ܽ௫ଶ ܽ௫ଵ⁄
ܽ݊݀	
ܽ௬ଶ ܽ௬ଵ⁄
ܣଶ ܣଵ⁄
 
should lie outside the range 0.1 - 2.0 for the precise determination of Y and X 
respectively, these criteria are satisfied only when the max of the two components are 
reasonably dissimilar. An additional criterion is that the two components do not interact 
chemically, thereby negating the initial assumption that the total absorbance is the sum of 
the individual absorbance. The additivity of the absorbance should always be confirmed 
in the development of a new application of this technique. 
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1.2.5.1.2.2 Absorbance Ratio Method 
 The absorbance ratio method is a modification of the simultaneous equations 
procedure.  It depends on the property that, for a substance which obeys Beer’s Law at all 
wavelengths, the ratio of absorbances at any two wavelengths is a constant value 
independent of concentration or path length.  For example, two different dilutions of the 
same substance give the same absorbance ratio A1/A2, 2.0.  In the USP, this ratio is 
referred to as a Q value.  The British Pharmacopoeia also uses a ratio of absorbance at 
specified wavelengths in certain confirmatory tests of identity.  
 In the quantitative assay of two components in admixture by the absorbance ratio 
method, absorbances are measured at two wavelengths one being the max of one of the 
components (2) and the other being a wavelength of equal absorptivity of the two 
components (1), i.e., an iso-absorptive point. Two equations are constructed as described 
above for the method of simultaneous equation (eq. (1) and eq. (2)). Their treatment is 
somewhat different, however, and uses the relationship ax = ay1 at (1).  
Assume b = 1 cm. 
A1 = ax1cx + ax1CY    (5) 
ܣଶ
ܣଵ
= ܽ௫ଶܿ௫ + ܽ௬ଶܿ௬
ܽ௫ଵܿ௫ + ܽ௫ଵܿ௬  
Divide each term by cx + cy and let Fx = cx/(cx + cy) and Fy = cy/(cx + cy) i.e. Fx and Fy are 
the fractions of X and Y respectively in the mixture: 
ܣଶ
ܣଵ
= ܽ௫ଶܨ௫ + ܽ௬ଶܨ௬
ܣ௫ଵܨ௫ + ܽ௫ଵܨ௬ 
But Fy = 1 – Fx’ 
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ܣଶ
ܣଵ
= ܨ௫ܽ௫ଶ − ܨ௫ܽ௬ଶ + ܽ௬ଶ
ܽ௫ଵ
 
 
ܣଶ
ܣଵ
= ܨ௫ܽ௫ଶ
ܽ௫ଵ
−
ܨ௫ܽ௬ଶ
ܽ௬ଵ
+ ܽ௬ଶ
ܽ௬ଵ
 
Let	ܳ௫ = ܽ௫ଶܽ௫ଵ ,ܳ௬ ܽ௬ଶܽ௬ଵ ܽ݊݀	ܳெ ܣଶܣଵ 
QM = Fx(Qx – Qy) + Qy 
	ܨ௫ = ொಾିொ೤ொೣିொ೤    (6) 
 Equation 6 gives the fraction, rather than the concentration of X (and 
consequently of Y) in the mixture in terms of absorbance ratios. As these are independent 
of concentration, only approximate, rather than accurate, dilutions of X, Y and the sample 
mixture are required to determine Qx, Qy and QM respectively. 
A1 = ax1 + ( cx + cY) 
ܿ௫ + ܿ௬ = 	ܣଵ									ܽ௫ଵ  
From eq. (6) 
ܿ௫
݂2ܿ௫ + ܿ௬ = 	 ܳ௠ − ܳ௬ܳ௫ − ܳ௬ܾ7. 
ܿ௫
ܣଵ ܽ௫ଵ⁄
= ܳெ − ܳ௬
ܳ௫ − ܳ௬
 
                ܿ௫ = ொ೘ିொ೤ொೣିொೊ . ஺భ௔ೣభ               (7) 
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Equation 7, gives the concentration of X in terms of absorbance ratios, the absorbance of 
the mixture and the absorptivity of the compounds at the iso-absorptive wavelength.  
Accurate dilutions of the sample solution and of the standard solutions of X and Y are 
necessary for the accurate measurement of A1 and ax1 respectively. 
1.2.5.1.2.3 Geometric Correction Method 
 A number of mathematical correction procedures have been developed which 
reduce or eliminate the background irrelevant absorption that may be present in samples 
of biological origin. The simplest of these procedures is the three-point geometric 
procedure, which may be applied if the irrelevant absorption is linear at the three 
wavelengths selected. 
Corrected absorbance, D = 
௬(஺ଶି஺ଷ)ା	௭(஺ଶି஺ଵ)(௒ା௓)(ଵି௥)  
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1.2.5.1.2.4 Orthogonal Polynomial Method 
 The technique of orthogonal polynomials is another mathematical correction 
procedure which involves more complex calculations than the three-point correction 
procedure.  The basis of the method is that an absorption spectrum may be represented in 
terms of orthogonal functions as follows 
A() = p0P0() + p1P1() + p2P2()….pnPn () 
Where, A = Absorbance  
   = Wave length 
  Po (), P1 (), P2 ()….Pn () represent the polynomial coefficient 
 Each coefficient is proportional to each other. These polynomials represent a 
series of fundamental shapes and the contribution that each shape, e.g.P2 makes to the 
absorption spectrum is defined by the appropriate coefficient, e.g. p2 for P2.  The 
coefficients are proportional to the concentration of the absorbing analyte, and a modified 
Beer – Lambert equation may be constructed: 
pj = jbc 
  For example, when b is 1 cm and concentration of the analyte (c), is in g/ dl. 
When irrelevant absorption so, present in a sample solution, the calculated coefficient (pi) 
comprises the coefficients of the analyte and of the irrelevant absorption (Z).  
  Thus, 
Pj = αjc + pj(Z) 
 Where, 
  Pj = polynomial coefficient 
  aj = proportionality constant 
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  b = path length 
  c = concentration 
With the correct choice of polynomial, number of wavelengths and the wavelength 
interval, the contribution from the irrelevant absorption may be negligible. In general, a 
quadratic (P2) polynomial eliminates linear or almost linear irrelevant absorption and a 
cubic (P3) polynomial eliminates parabolic irrelevant absorption. 
 The segment of the spectrum of the drug between 1and 8 shows a minimum 
around 3 and a maximum around 5. Its shape may therefore be represented by a cubic 
polynomial. The irrelevant absorption is a simple parabolic curve which does not contain 
a cubic contribution. The coefficient (P3) of the polynomial for each set of eight 
absorbances (A1……..A8) is calculated from: 
P 3 = [(-7) A1 + (+5) A2 + (+7) A3 + (+3) A4 + (-3) A5 + (-7) A6 + (-5) A7 + (+7) A8] 
Where the factors are those of an eight –point cubic polynomial obtained from standard 
texts of numerical analysis (e.g. Fischer and Yates, 1953). The contribution of the 
irrelevant absorption to the coefficient of the polynomial of the sample is eliminated  by 
the selection of these parameters, and the concentration of the drug in the sample may be 
calculate with reference to a standard solution of the drug, from the proportional 
relationship that exists between the calculated P3 value and concentration. 
 The accuracy of the orthogonal functions procedure depends on the correct choice 
of polynomial order and set of wavelengths. Usually, quadratic or cubic polynomials are 
selected depending on the shape of the absorption spectra of the drug and the irrelevant 
absorption. The set of wavelengths is defined by the number of wavelengths, the interval, 
and the mean wavelength of the set (max). approximately linear irrelevant absorption is  
30 
 
normally eliminated using six to eight wavelengths, although many more, up to 20, 
wavelengths may be required if the irrelevant absorption contains high frequency 
components. The wavelength interval and m are best obtained from convoluted 
absorption curve. This is a plot of the coefficient (Pj) for a specified order of polynomial, 
a specified number of wavelengths and a specified wavelength interval (on the ordinate) 
against the m of the set of wavelengths. The optimum set of wavelengths corresponds 
with a maximum or minimum in the convoluted curve of the analyte and with a 
coefficient of zero in the convoluted curve of the irrelevant absorption. In favourable 
circumstances the concentration of an absorbing drug in admixture with another may be 
calculated if the correct choice of polynomial parameters is made, thereby eliminating the 
contribution of one drug from polynomial of the mixture. For, example, the selective 
assay phenobarbitone, combined with phenytoin in a capsule formulation using a six-
point quadratic polynomial, has been reported. 
 The determination of the optimum set of wavelengths is readily accomplished 
with the aid of a microcomputer. A suitable exercise is to write a program to compute and 
plot the data for convoluted spectrum.  
1.2.5.1.2.5 Difference Spectrophotometry 
 The selectivity and accuracy of spectrophotometric analysis of samples containing 
absorbing interferants may be markedly improved by the technique of difference 
spectrophotometry. The essential feature of a difference spectrophotometric assay is that 
the measured value is the difference absorbance (A) between two equimolar solutions of 
the analyte in different chemical forms which exhibit different spectral characteristics. 
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The criteria for applying difference spectrophotometry to the assay of a substance in the 
presence of other absorbing substances are that: 
a. reproducible changes may be induced in the spectrum of the analyte by the addition of 
one or more reagents 
b. the absorbance of the interfering substances is not altered by the reagents. 
 The simplest and most commonly employed technique for altering the spectral 
properties of the analyte is the adjustment of the pH by means of aqueous solutions of 
acid, alkali or buffers.  The ultraviolet-visible absorption spectra of many substances 
containing ionisable functional groups, e.g. phenols, aromatic carboxylic acids and 
amines, are dependent on the state of ionization of the functional groups and 
consequently on the pH of the solution. 
 The absorption spectra of equimolar solutions of Phenylephrine, a phenolic 
sympathomimetic agent, in both 0.1M hydrochloric acid (pH 1) and 0.1M sodium 
hydroxide (pH 13) are shown in figure.  The ionization of the phenolic group in alkaline 
solution generates an additional n (non-bonded) electron that interacts with the with the 
ring π electrons to produce a bathochromic shift of the max from 271nm in acidic 
solution to 291 nm and an increase in absorbance at the max (hyperchromic effect).  The 
difference absorption spectrum is a plot of the difference in absorbance between the 
solution at pH 13 and that at pH 1 against wavelength. It may be generated automatically 
using a double-beam recording spectrophotometer with the solution at pH 13 in the 
sample cell and the solution at pH 1 in the reference cell. At 257 and 278 nm both 
solutions have identical absorbance and consequently exhibit zero difference absorbance. 
Such wavelengths of equal absorptivity of the two species are called isobestic                 
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or iso-absorptive points. Above 278 nm the alkaline solution absorbs more intensely than 
the acidic solution and the A is therefore positive. Between 257 and 278 nm it has a 
negative value. The measure value in a quantitative difference spectrophotometric assay 
is the A at any suitable wavelength measured to the baseline, e.g. A1 at 1 or 
amplitude between an adjacent maximum and minimum, e.g. A1 at 2 and 1. 
At 1 A = Aalk – Aacid 
 Where Aalk and Aacid are the individual absorbances in 0.1M sodium hydroxide 
and 0.1M hydrochloric acid solution respectively. If the individual absorbance, and are 
proportional to the concentration of the analyte and path length, the also obeys the     
Beer – Lambert’s law and a modified equation may be derived. 
Where A is the difference absorptivity of the substance at the wavelength of 
measurement. 
 If one or more other absorbing substances are present in the sample which at the 
analytical wavelength has identical absorbance in the alkaline and acidic solutions, its 
interference in the spectrophotometric measurement is eliminated. The selectivity of the 
A procedure depends on the correct choice of the pH values to induce the spectral 
change of the analyte without altering the absorbance of the interfering components of 
the sample. The use of 0.1M sodium hydrochloric acid to induce the A of the analyte is 
convenient and satisfactory when the irrelevant absorption arises from pH intensive 
substances.  
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1.2.5.1.2.6 Area under the curve method 
 From the spectra obtained for calculating the simultaneous equation, the area 
under the curve were selected at a particular wavelength range for both the drugs were 
each drug  have its absorption. The “X” values of the drugs were determined at the 
selected AUC range. The “X” value is the ratio of area under the curve at the selected 
wavelength range with the concentration of the component in mg/ml. These “X” values 
were the mean of six independent determinations. A set of two simultaneous equations 
were obtained by using mean “X” values. And further calculations are carried out to 
obtain the concentration of each drug present in the sample. 
1.2.5.1.2.7 Absorbance correction method 
 The method can be used to calculate the concentration of component of interest 
found in a mixture containing it along some unwanted interfering component. The 
absorption different between two points on the mixture spectra is directly proportional to 
the concentration of the component to be determined irrespective of the interfering 
component. If the identity, concentration and absorptivity of the absorbing interferences 
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are known, it is possible to calculate their contribution to the total absorbance of a 
mixture. The concentration of the absorbing component of interest is then calculated from 
the corrected absorbance (total absorbance minus the absorbance of the interfering 
substance) in a usual way. The data required for the construction of absorbance corrected 
for interference are 
i. The max of the drugs should be found out by using reference standards of the 
drugs. 
ii. The calibration curve is plotted for each drug and linearity range should be 
found out. 
iii. At one wavelength, one of the drugs shows no absorbance. Hence the other 
drug was calculated without any interference. 
iv. The absorbance values of every drug at the two wave lengths should be 
measured and the absorptivity values should be calculated. 
v. In another wavelength, the absorbance corrected for another drug and the first 
drug was determined. 
1.2.5.1.2.8 Derivative spectrophotometry 
 Derivative spectrophotometry involves the conversion of a normal spectrum to its 
first, second or higher derivative spectrum. The transformations that occur in the 
derivative spectra are understood by reference to a Gaussian band which represents an 
ideal absorption band. In the context of derivative spectrophotometry, the normal 
absorption spectrum is referred to as the fundamental, Zeroth order or D° spectrum.
 The first derivative (D1) spectrum is a plot of the ratio of change of absorbance   
with wavelength against wavelength, i.e. a plot of the slope of the fundamental spectrum 
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against wavelength or a plot of dA/dλ Vs λ. At λ2 and λ4, the maximum positive and 
maximum negative slope respectively in the D°. Spectrums correspond with maximum 
and a minimum respectively in the D1 spectrum. The λmax at λ3 is a wavelength of zero 
slope and gives dA/dλ = 0, i.e. a cross-over point, in the D1Spectrum. 
 
Figure: The zeroth (a), first (b) and second (c) derivative spectra of a Gaussian band 
The second derivative (D2) spectrum is a plot of the curvature of the D° spectrum  
 
against wavelength or a plot of d2A/dλ2 Vs λ. The maximum negative curvature at λ3 in 
the D° spectrum gives a minimum in the D2 spectrum, and at λ1 and λ5 the maximum 
positive curvature in the D° spectrum gives two small maxima called ‘satellite’ bands in 
the D2 spectrum. At λ2 and λ4 the wavelengths of maximum slope and zero curvature in 
the D° spectrum correspond with cross-over points in the D2 spectrum. 
In summary, the first derivative spectrum of an absorption band is characterized 
by a maximum, a minimum, and a cross-over point at the λmax of the absorption band. 
The-second derivative spectrum is characterized by two satellite maxima and an inverted 
band of which the minimum corresponds to the λmax of the fundamental band. As an 
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exercise, you should construct third and fourth derivative spectra (i.e. plots of d3A/d λ3 
and d4A/d λ4 respectively against wavelength) of the fundamental spectrum. 
These spectral transformations confer two principal advantages on derivative 
spectrophotometry. Firstly, an even order spectrum is of narrower spectral bandwidth 
than its fundamental spectrum. A derivative spectrum therefore shows better resolution of 
overlapping bands than the fundamental spectrum and may permit the accurate 
determination of the λmax of the individual bands. Secondly, derivative spectrophotometry 
discriminates in favors of substances of narrow spectral bandwidth against broad 
bandwidth substances. This is because ‘the derivative amplitude (D), i.e. the distance 
from a maximum to a minimum, is inversely proportional to the fundamental spectral 
bandwidth (14’) raised to the power (n) of the derivative order.  
Thus,                         D α (1/W)n 
Consequently, substances of narrow spectral bandwidth display larger derivative 
amplitudes than those of broad bandwidth substances. 
(a) The individual spectra of two components X and Y in admixture and their 
combined spectrum (b) The second derivative spectrum of the mixture showing improved 
resolution of the individual bands. 
These advantages of derivative spectrophotometry, enhanced resolution and 
bandwidth discrimination, permit the selective determination of certain absorbing 
substances in samples in which non-specific interference may prohibit the application of 
simple Spectrophotometric methods. For example, benzenoid drugs such as Ephedrine 
Hydrochloride, displaying fine structure of narrow spectral bandwidth in the region     
240 - 270 nm, are both weakly absorbing (A about 15) and formulated at a relatively low 
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dose in solid dosage preparations (typically 1 - 50 mg/ unit dose). The high 
excepients/drug ratio and high sample weight required for the assay may introduce into 
simple Spectrophotometric procedures serious irrelevant absorption from the formulation 
excepients. Second derivative spectrophotometry discriminates in favour of the narrow 
bands of the fine structure of the benzenoid drugs and eliminates the broad band 
absorption of the excepients. All the amplitudes in the derivative spectrum are 
proportional to the concentration of the analyte, provided that Beer’s Law is obeyed by 
the fundamental spectrum. The measured value in a quantitative assay is the largest 
amplitude that is unaffected by the presence of other, absorbing components of the 
sample spectrophotometric methods. The enhanced resolution and bandwidth 
discrimination, increases with increasing derivative order. However, it is also found that 
the concomitant increase in electronic noise. Inherent in the generation of the higher 
order spectra, the consequent reduction of the signal-to-noise ratio, place serious practical 
limitations on the higher order spectra. 
 
Figure: (a) The individual spectra of two components X and Y in admixture 
and their combined spectrum (b) The second derivative spectrum of the mixture 
showing improved resolution of the individual bands. 
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1.2.6 Different Chromatographic Techniques  
1.2.6.1 High performance liquid chromatography (HPLC) 
 This technique is based on the same method of separation as classical column 
chromatography, which works on the principle of adsorption, partition, ion exchange or 
gel permeation, but it differ from column chromatography, as mobile phase is pumped 
through the packed column under high pressure. The technique is most widely used for 
all the analytical separation due to its sensitivity, its ready adaptability to accumulate 
quantitative determinations and its suitability for separating nonvolatile species or 
thermally fragile ones. 
 In normal phase HPLC, polar compounds such as silica gel, alumina (Al2O3) or 
porous glass beads were used as column packing materials in stationary phase and        
non - polar solvents such as heptane, octane or chloroform are used as solvents in mobile 
phase. In case of reverse phase HPLC, non –polar columns like octa decyl silane (ODS) 
and C8 columns are used as stationary phase with polar solvents like water, acetonitrile 
and methanol are used as mobile phase. 
1.2.6.2 High performance thin layer chromatography (HPTLC) 
 The principle is based on planar chromatography. The mobile phase normally is 
driven by capillary action. The prominent advantages of this technique includes 
possibilities of separating of up to 70 samples and standard simultaneously on a single 
plate leading to high accuracy, low cost and the ability to construct calibration curves 
from standard chromatography under the same condition as the sample.  
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1.2.6.3 Gas chromatography (GC) 
 GC is one of the most extensively used separation technique in which separation 
is accomplished by partitioning solute between a mobile gas phase and stationary phase. 
The chief requirement is same degrees of stability at the temperature is necessary to 
maintain the substance in gas state. Here a carrier gas is used to carry the substance to the 
column which is having specific characteristics. 
1.3 INTRODUCTION FOR HPTLC (P.D sethi 1996) 
 HPTLC is the most simple separation technique today available to the analyst. It 
can be considered a time machine that can speed your work and allows you to do many 
things at a time usually not possible with other analytical techniques.  
1.3.1 Steps Involved in HPTLC 
 1. Selection of HPTLC plates and sorbent 
 2. Sample preparation including any clean up and pre – chromatographic 
 derivatization 
 3. Application of sample 
 4. Development (separation) 
 5. Detection including post – chromatographic derivatization 
 6. Quantitation 
 7. Documentation 
1.3.2. Plates  
1.3.2.1. Precoated plates 
 The pre – coated plates with different support material (Glass, Aluminum and 
plastic) and with different sorbent layers are available in the different format and 
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thickness by various manufacturers. Usually plates with sorbent thickness of 100 – 250 
m are used for qualitative and quantitative analysis, however for preparative TLC work, 
plates with sorbent thickness of 1.0 – 2.0 mm are available in addition to chemically 
modified layers. Aluminum Sheet (0.1 mm thick): Aluminum sheet as a support offer the 
same advantage as polyester support but with increased temperature resistance. However 
with eluents containing high concentration of mineral acids or concentrated ammonia, 
one may find problem as they will chemically attack aluminum. Aluminum sheets are 
otherwise compatible with organic solvents and organic acids such as formic acid and 
acetic acid. Aluminum Precoated plates in size of 20 x 20 cm are usually procured for 
economic reasons. These plates can be cut to size and shape (format) to suit particular 
analysis by using general purpose scissors. 
1.3.3 Prewashing of Precoated Plates  
 Sorbents with large surface area absorb not only water vapours and other 
impurities from atmosphere but other volatile substances often condense particularly after 
the packing has been opened and exposed to laboratory atmosphere for a long time. Such 
impurities including elutable components of the binder usually give dirty zones and fail 
to give reproducible results. It is only for these reasons that pre-coated plates are always 
packed with the glass or foil side upward (coated layer downward). To avoid any possible 
interference due to impurities with the chromatographic separations particularly in case 
of quantitative work, it is always recommended to clear the plates before actual 
chromatography. This process is called pre washing of plates. Excellent results are 
obtained if the plates are subjected to pre washing (in cleaning solvent) by continuous 
mode for some time in a chamber closed by a lid having a slit. After washing, the plates 
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must be dried for a sufficient time to ensure complete removal of the washing liquids 
(usually for methanol 30 – 60 minutes at 105° C is required). The washed plates should 
always be stored in a dust free atmosphere under ambient conditions. As a result of pre 
washing, signal to noise ratio is substantially low and base lines are straighter, which is 
essential for quantitative analysis by in situ densitometry.  Plates exposed to high 
humidity or kept on a hand for long time may have to be activated by placing in oven at 
110 – 120° C for 30 minutes prior to sample spotting. This step removes water that has 
been physically absorbed on the surface of the sorbent. 
1.3.4 Sample Preparation and Application  
 The sample preparation procedure is to dissolve the dosage form with complete 
recovery of intact compounds(s) of interest and minimum of matrix with a suitable 
concentration of analyte(s) for direct application on the HPTLC plate. Sample application 
is the most critical step for obtaining good resolution for quantification by HPTLC. The 
sample should be completely transferred to the layer, however, under no circumstances, 
the application process should damage the layer, as damaged layer results in unevenly 
shaped spots. Wherever possible, use of automatic application devices is recommended 
for quantitative analysis. Usually 0.5 – 5 l for HPTLC is recommended keeping the size 
of starting zone(s) down to minimum of 0.5 – 1 mm in concentration range of 0.1 – 1 g/ 
ml. Substance zones which are too large from the beginning because poor separation as 
during development spots does tend to become large and more diffused. It is therefore 
recommended that solution should be applied in small increments with intermediate 
drying (use cold or hot air or nitrogen in case of labile compounds, asymmetric 
accelerated evaporation of the solvent from the point of application can lead to local 
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changes in the concentration in spotted substances) particularly when the sample solution 
is predominantly  aqueous. 
1.3.5 Development (separation) 
 Poor grade of solvent used in preparing mobile phases have been found to 
decrease resolution, spot definition and Rf reproducibility. Mobile phases commonly 
called solvent system is traditionally selected by controlled process of trial and error and 
also based on one’s own experience in the field. Use of mobile phase containing more 
than three or four components should normally be avoided as it is often difficult to get 
reproducible ratios of different components. The chamber saturation has pronounced 
influence on the separation profile. When the plate is introduced in to an unsaturated 
chamber, during the course of development, the solvent evaporates from the plate mainly 
at the solvent front. Therefore larger quantity of the solvents shall be required for a given 
distance; hence resulting is increase in Rf values. If the tank is saturated (by lining with 
filter paper) prior to development, solvent vapors soon get uniformly distributed 
throughout the chamber as soon as the plate is placed in such a saturated chamber, it soon 
gets pre loaded with solvent vapors, hence less solvent shall be required to travel a 
particular distance, resulting in lower Rf values. Time required for saturation will depend 
on the nature and composition of mobile phase and layer thickness. 
  Development in a non-saturated or partially saturated atmosphere is 
recommended with solvents used in a composition leading to phase separation such as 
mixture of n - butanol, water and glacial acetic acid. However in case of RPTLC, it is 
always preferable to saturate the chamber with methanol as normally in RPTLC, mobile 
phase with high water contents are employed. If chromatographic procedure is to be 
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carried out at a controlled relative humidity of the chamber then suitable liquid is placed 
in one of the troughs of twin-trough chamber. Usually relative humidity of the room is 
controlled by dehumidifier. However, if experiments are required to be carried at specific 
relative humidity, then solution of sulphuric acid or salt solutions may be employed. 
After development the plate is removed from the chamber and mobile phase is removed 
as completely and as quickly as possible. These steps should preferably be performed in 
fume cup board to avoid contamination of laboratory atmosphere. The plates should 
always be laid horizontally so that while mobile phase evaporates the separated 
substances will migrate evenly to the surface where they can be easily detected. There are 
different factors influencing separation of components and resolution of spots are type of 
stationary phase – sorbent, particle size, activity, type of plates, layer thickness, pH of 
layer, binder for layer, melting point, solvent purity, size of chamber, saturation of 
chamber, solvent for sample phase, melting point level in chamber, size of spot, relative 
humidity, temperature, flow rate of solvent, separation distant and mode of development. 
1.3.6. Detection and visualization 
 One of the most characteristic features of HPTLC is the possibility to utilize post 
chromatographic off-line derivatization. With the availability of many visualization 
reagents, findings can be confirmed. These visualization reactions are possible for 
identification even if the separation is not optimally. As soon as the development process 
is complete, the plate is removed from the chamber and dried to remove the mobile phase 
completely. The zones can be located by various physical, chemical,                   
biological - physiological methods. There is apparently no difficulty in detecting color 
substances or colorless substances absorbing in short wave UV - region (254 nm) or with 
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intrinsic fluorescence such as riboflavin. The substance which do not have above 
properties has to be transferred in to detectable substances by means of chromogenic or 
fluorogenic reagents which are more expensive, time - consuming and complicated. 
Detection sensitivity depends on the specificity for the reagent employed. Iodine is the 
universal detection reagent, that detection is usually non-destructive and reversible but 
certain substances may be altered through non-reversible derivatization such as 
ethambutol, a totally non UV absorbing compound forms a UV absorbing complex with 
iodine through charge transfer. Detection under UV light is the first choice and is non-
destructive in most of the cases and is commonly employed for densitometric scanning. 
Derivatization reactions are essentially required for detection when individual compound 
does not respond to UV or does not have intrinsic fluorescence. It is not significant 
whether derivatization is pre or post chromatographic however, pre-chromatographic 
derivatization not only helps in detection but enhances the selectivity of the mobile phase. 
For post chromatographic derivatization, smaller the chromatographic zone, greater the 
concentration of the substance leading to increase in detection sensitivity. Other simple 
detection method is based on wetting and solubility phenomenon. Aluminium oxide, 
kieselguhr, silica gel or hydrophilic adsorbents. On dipping or spraying the 
chromatogram with water, lipophillic substances such as steroids, fatty acids, 
hydrocarbons appear as white (opaque) spot against semi-transparent back ground as 
such a substances being invisible with water or not wetted. This wetting effect is more 
prominent if the plate is fully saturated with water and held against light. The contrast is 
best immediately after dipping, disappears on drying. Other commonly used reagents are 
phosphomolybdic acid, antimony trichloride or pentachloride, anisaldehyde - sulphuric 
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acid, dimethyl amino benzaldehyde in sulphuric acid and fluorescein sodium. These 
reagents yield sufficient stable coloured spots for quantitative scanning.  
1.3.7 Quantitation (Evaluation) 
 Requirements for various steps in HPTLC are more stringent for quantitative 
analysis. Accurate and precise application of samples is the most critical.  Further, the 
chromatographic development should clearly and completely separate all the compounds 
of interest with no loss by decomposition, evaporation or irreversible adsorption during 
application or development.  Sample and standard as a rule should as a rule should be 
chromatographed on the same plate under similar conditions. 
 Earlier, a typical approach was scrapping the separated analyte zones from 
support material and extracting with a suitable solvent, compounds thus eluted could be 
analysed by any convenient analytical method; spectrophotometric, fluorometric or by 
suitable colour development method. To compensate for interference from the sorbent, 
usually a blank area of the layer is also eluted simultaneously and used as a blank for 
final analysis. Such blank’s values can be lowered by pre-washing of TLC layer with 
methanol, methanol-chloroform (1:1) or methylene chloride prior to chromatographic 
procedure. However, this method of separating and elution has limited  application as the 
compounds under analysis may be irreversibly bound to the HPTLC supporter 
elution/isolation steps may cause some chemical transformation or there is likelihood of 
analyte loss during extraction. Layers containing gypsum as binder are considerably 
softer and especially suited for preparative chromatography involving scrapping form 
plate and subsequent elution and estimation. 
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1.3.7.1 In situ densitometry 
 Densitometry is the in situ instrumental measurement of visible, UV absorbance, 
fluorescence or fluorescence quenching directly on the layer without resorting to 
scrapping and elution. Since chromatographic zones remit a lower light intensity than the 
environment around it, absorption spectra can be determined directly on the plate by 
comparison with substance free area on the sorbent layer. The measurements are usually 
made by reflection from the plate using single beam, double beam or single beam dual 
wavelength operation of scanning instruments. The purpose of the scanner is to convert 
the spot or band on the layer into chromatogram. The position of the scanned peaks on 
the recorder chart are related to Rf values of the spots on the layer and peak height or area 
is related to the concentration of the substance on the spot. The signals which are 
measured represent the adsorption of transmitted or reflected light that passes through the 
spot compared to blank portion of the sorbent layer. A calibration curve consisting of 
scan area of standard versus amount of analyte is constructed and amount of analyte in 
the sample represented by scan area is interpolated from the standard curve. 
1.3.7.2 Factors influencing in selection of detection wavelength 
 1. The absorption spectra of compound when recorded in solution or in situ from 
TLC plate are almost similar. Pre – recorded spectra of these compounds as available in 
literature may be considered for taking decision. 
 2. In situ spectra of each component of the formulation may be simultaneously 
considered for selecting the most suitable wavelength for scanning. 
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 3. Extinction coefficient (Eଵ	ୡ୫ଵ% ) and actual concentration of a compound in the 
formulation has to be taken into consideration, particularly in respect of compounds with 
low extinction coefficient. 
 4. While selecting single wavelength, the interest of minor component in the 
formulation shall need special consideration. 
 5. If absorption maxima of individual component of the formulation are quite 
apart, then the chromatogram must be scanned at individual absorption maxima for 
obtaining meaningful results. 
1.3.8 Documentation  
 The use of application scheme and labeling every single chromatogram can avoid 
mistake in respect of order of application. It is preferable to apply each sample and 
reference solution twice by following data pair method. A lead pencil can be used to 
write on the chromatoplate. The plate should never be marked below the starting point, as 
the layer is likely to get damaged affecting chromatographic distribution of the 
substances under analysis, which may ultimately lead to error in scanning. The best way 
to label the chromatoplate is to mark above the level of solvent point. Immediately after 
development is completed, the solvent point should be marked with both on left and right 
hand edges of the plate. To assist the analysts and researchers in practice of HPTLC,      
E. Merck has recently introduced HPTLC pre coated plates with an imprinted 
identification code. The data needed for traceability according to HPTLC such as 
supplier’s name, item number, batch number and individual plate number are imprinted 
near upper edge of the pre coated plates. This will not only help in the traceability of 
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analytical data, but will avoid manipulation of data at any stage as coding will 
automatically get recorded during the photo documentation. 
1.3.9 Stabilization of developed zones 
 After treatment with the reagent as part of chromatographic derivatization, 
coloured or fluorescent chromatographic zones are used for quantitative evaluation. It is 
therefore desirable that the colour or fluorescence thus produced should be stable at least 
for 30 minutes for carrying out various steps involved in quantitative analysis. There is 
no general procedure laid down to stabilize the coloured chromatographic zones except to 
store in atmosphere of nitrogen and protected from light till they are evaluated. However, 
fluorescent chromatographs can not only be stabilized but often intensified 
 
 
 
 
 
 
 
 
 
 
 
Figure: A detailed layout of HPTLC method development 
Sample and standard preparation  Selection of chromatographic layer 
Layer pre - washing 
Layer pre - conditioning 
Application of sample and standard 
Chromatographic development 
Detection of spots 
Scanning and documentation of chromatoplate 
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1.4 ANALYTICAL PARAMETERS USED IN ASSAY VALIDATION AS PER                        
ICH GUIDELINES (Code Q2A; Q2B, ICH Guidelines 1994 and 1996) 
The objective of validation of an analytical procedure is to demonstrate that it is 
suitable for its intended purpose. A tabular summation of the characteristics applicable to 
identification, control of impurities and assay procedures is included. 
Types of Analytical Procedures to be validated 
The discussion of the validation of analytical procedures is directed to the four 
most common types of analytical procedures 
Identification Tests 
 Quantitative tests for impurities content. 
 Limit tests for the control of impurities. 
 Quantitative tests of the active moiety in samples of drug substance or drug product 
or other selected component(s) in the drug product. 
A brief description of the types of tests considered in this document is provided 
below. 
Identification tests are intended to ensure the identity of an analyte in a sample this is 
normally achieved by comparison of a property of the sample (example spectrum, 
chromatographic behaviour, chemical reactivity etc.) to that of a reference standard. 
Testing for impurities can be either a quantitative test or a limit test for the impurity 
in a sample.  Either test is intended to accurately reflect the purity characteristics of the 
sample. Different validation characteristics are required for a quantitative test than for a 
limit test. 
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 Assay procedures are intended to measure the analyte present in a given sample. In 
the context of this document, the assay represents a quantitative measurement of the 
major component(s) in the drug substance. For the drug product, similar validation 
characteristics also apply when assaying for the active or other selected component(s). 
The same validation characteristics may also apply to assays associated with other 
analytical procedures.  
The objective of the analytical procedure should be clearly understood since this will 
govern the validation characteristics which need to be evaluated. 
 
Figure: Workflow for Evaluation and Validation of Standard Methods 
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1.4.1. Typical Validation Parameters 
 Accuracy 
 Precision 
 Range 
 Specificity 
 Linearity 
 Detection Limit 
 Quantification Limit 
 Ruggedness 
 Robustness 
1.4.1.1 Accuracy 
The accuracy of an analytical procedure expresses the closeness of agreement between 
the value which is accepted either as a conventional true value or on an accepted 
reference value and the value found. 
1.4.1.2 Precision 
 It expresses as degree of agreement among individual test results when procedure 
or method is applied to a homogeneous sample, usually expressed as SD or RSD. It is a 
measure of degree of repeatability or reproducibility under normal conditions. A more 
comprehensive definition proposed by the ICH divides precision into three types 
1. Repeatability. 
2. Intermediate Precision. 
3. Reproducibility. 
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1.4.1.3 Range     
   The range of a method can be defined as the upper and lower concentrations for 
which the analytical method has adequate accuracy, precision and linearity. The range of 
concentrations examined will depend on the type of method and its use. 
1.4.1.4 Specificity 
  Ability of the method to measure accurately and specifically the analyte of 
interest in presence of matrix and other components likely to be present in the sample 
matrix and impurities, degradation products and other related substances. For this, one 
may compare the test results of analysis of samples containing other ingredients or 
impurities or degradation products or related substances or placebo ingredients with 
those obtained from analysis of sample without these, i.e., the method must allow distinct 
analytical measurement of analyte of interest and exclusion of all other relevant 
interferences. If the impurities or degradation products or potential contaminants are not 
available one can apply a proposed method to the strain and stress (heat, light, humidity) 
samples. Degree of agreement among results will explain specificity of the method. If the 
impurities or degradation products are not available, one may carryout additional purity 
tests by chromatography-HPLC or HPTLC. 
1.4.1.5 Linearity 
  The linearity of an analytical procedure is its ability to obtain test results, which 
are directly proportional to the concentration of analyte in the sample. Linearity can be 
assessed by performing single measurements at several analyte concentrations.               
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A linearity correlation coefficient above 0.999 is acceptable for most methods, especially 
for major components in assay methods. The range of an analytical procedure is the 
interval between the upper and lower concentration of analyte in the sample. 
1.4.1.6 Detection limit 
The Detection Limit of an individual analytical procedure is the lowest amount of 
analyte in a sample which can be detected but not necessarily quantities as an exact 
value. The detection limit (LOD) may be expressed as 
LOD = 3.3σS  
Where, 
             = the standard deviation of the response. 
               S = the slope of the calibration curve (of the analyte). 
1.4.1.7 Quantification limit 
LOQ is defining as the lowest concentration of the substance (analyte) in a 
sample that can be estimated quantitatively with acceptable precision, accuracy and 
reliability by a given method under stated experimental conditions. Quantification Limit 
(LOQ) may be expressed as       
LOQ = 10σS  
Where, 
              = the standard deviation of the response. 
           S   = the slope of the calibration curve (of the analyte). 
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1.4.1.8 Ruggedness 
It is the measure of the capacity of the analytical method to remain unaffected by small but 
deliberate variations in procedure. It provides an indication about variability of the method 
during normal laboratory conditions. 
1.4.1.9 Robustness 
The concept of robustness of an analytical procedure has been defined by the ICH as 
“A measure of its capacity to remain unaffected by small, but deliberate variations in method 
parameters”. The most important aspect of robustness is to develop methods that allow for 
expected variations in the separation parameters. 
General acceptance limits 
S.No. Characteristics Acceptance Criteria 
1 Accuracy  Assay limit- 98-102% 
 Recovery - 80,100,120%.with a deviation of + 2  
 
2 
Precision 
A)Repeatability 
b)Intermediate           
precision 
 
% RSD < 2 
% RSD < 2 
3 Specificity/ selectivity No interference 
4 Detection Limit S/N > 2 or 3 
5 Quantitation  Limit S/N > 10 
6 Linearity r > 0.999 
7 Range 80-120% 
8 Stability >24hr or > 12hr 
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 1.5 PHARMACEUTICAL STATISTICS (Gupta S.P, 1994; Mendham, 1994)   
 Statistical techniques have been widely used in many diverse areas of scientific 
investigation. Statistical applications have been recognized as crucial to quality control 
procedure, test, specification and definitions. Principle of modern analytical techniques 
and skill in their application are necessary attribute of the successful pharmaceutical 
analyst, thus does not ensure the satisfactory solution of all the problem that may 
encountered. Some auxiliary knowledge methods those can aid the analyst in designing 
experiment, collecting data, and interpreting the result. 
1.5.1 Linear Regression 
 Linear regression is a statistical technique that defines the functional relationship 
between two variables by best-fitting straight line. Once a linear relationship has been 
shown to have a high probability by the value of the correlation coefficient ‘r’, then the 
best straight line through the data points has to be estimated. This can often be done be 
done by visual inspection of the calibration graph, but in many cases it is far more 
sensible to evaluate the best straight line by linear regression (the method of least 
squares). 
The equation of straight line is  
y = mx + c 
Where, y the dependent variable is plotted as result of changing x, the independent 
variable. 
         To obtain the regression line ‘y on x’ the slope ‘m’ of the line and the intercept ‘c’ 
on the y axis are given by the following equation. 
݉ = ே	∑ ௫௬ି(∑௫)	(∑௬)	
ே ∑ ௫మି	(∑௫)మ         and      ܿ = (∑௬)	൫∑௫మ൯ି	(∑௫)(∑௫௬)ே	 ∑ ௫మି	(∑௫)మ  
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1.5.2 Correlation Coefficient (r) 
 It is a procedure commonly used to characterize quantitatively the relationship 
between variable. Correlation is related to linear regression.  To establish whether there is 
a linear relationship between two variables x1 and y1, use Pearson’s correlation 
coefficient r. 
ݎ = ݊∑ݔଵ ݕଵ −	∑ ݔଵ ݕଵ{[݊∑ݔଵଶ − (∑ݔଵ)ଶ]	[݊∑ݕଵଶ − (∑ݕଵ)ଶ]}ଵ ଶൗ  
  Where n is the number of data points. 
 The value of r must lie between +1 and -1, the nearer it is to +1, the greater the 
probability that a definite linear relationship exists between the variables x and y, values 
close to +1 indicate positive correlation and values close to -1 indicate negative 
correlation values of ‘r’ that tend towards zero indicate that x and y are not linearly 
related (they made be related in a non-linear fashion). 
1.5.3 Standard Deviation (SD) 
          It is commonly used in statistics as a measure of precision statistics as a measure of 
precision and is more meaningful than is the average deviation. It may be thought of as a 
root-mean-square deviation of values from their average and is expressed mathematically 
as 
                                             
 
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xx
S
ni
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i


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
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  
Where, 
S is standard deviation. 
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If N is large (50 or more) then of course it is immaterial whether the term in the 
denomination is N -1 or N  
Σ       = sum 
x       = Mean or arithmetic average. 
x -x  = deviation of a value from the mean. 
N      = Number of observations. 
1.5 4 Percentage Relative Standard Deviation (%R.S.D) 
 It is also known as coefficient of variation (CV). It is defined as the standard 
deviation (S.D) expressed as the percentage of mean. 
CV	or	%	RSD = ܵ.ܦ
̅ݔ
	× 100 
          Where,  
S.D   = the standard deviation, 
 xത      = Mean or arithmetic average. 
 The variance is defined as S2 and is more important in statistics than S itself.  
However, the latter is much more commonly used with chemical data. 
1.5.5 Standard Error of Mean (S.E) 
 Standard error of mean can be defined as the value obtained by division of 
standard deviation by square root of number of observations. It is mathematically 
expressed as  
S. E = S. D
√n  
   Where, 
            S.D = Standard deviation. 
                           n = number of observation 
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1.5.6 Confidence Interval (CI) 
 A confidence interval gives an estimated range of values which is likely to 
include a unknown population parameter, the estimated range being calculated from a 
given set of sample data. A confidence interval with a particular confidence level (95% 
selected by the user) is intended to give the assurance that, if the statistical model is 
correct then the interval could deliver the true value. 
Confidence interval for a normal population, 
CI = ܻ	ഥ ± 	ܼఈ ଶ⁄ 	ߪ
√ܰ
 
Where  
   തܻ  = Sample mean 
          ܼఈ ଶ⁄  = upper ߙ 2⁄  critical value of standard normal distribution 
    N = Size of sample  
    σ = Standard deviation 
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2. LITERATURE REVIEW 
2.1. DRUG PROFILE  
2.1.1. Ambroxol Hydrochloride  
(IP 2007; BP 2009; Martindale, The extra Pharmacopoeia, 2005;The Merck Index 2006; 
Tripathi K.D, 2003; http://www.en.wikipedia.org/wiki/Ambroxol.html) 
Molecular structure 
NH
NH2
OH
Br
Br
. HCl
 
Chemical name 
 Trans-4-[(2-amino-3, 5-dibromobenzyl) amino] cyclohexanol hydrochloride 
Molecular formula 
 C13H18Br2N2O.HCl 
Molecular weight 
 414.6 g 
Category 
 Mucolytic expectorant  
Description  
 White or yellowish crystalline powder 
Solubility  
  Ambroxol Hydrochloride is sparignly soluble in water, soluble in methanol, 
practically insoluble in methylene chloride. 
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Storage  
 Store Protected from light.   
Identification 
i) Melting point 
Standard value Observed average value* 
233º C -234.5º C 233.66º C 
                         *Average of six observations 
ii) Infra red spectrum was recorded and shown in figure - 1  
Mechanism of action 
 It is an expectoration improver and mucolytic reagent used in the treatment of 
acute and chronic disorders characterized by production of excessive thick mucus, which 
plays an important role in the body’s natural defense mechanisms. Ambroxol is a 
metabolite of bromhexine, which helps in clearance of mucus, facilitates expectoration 
and eases productive cough. Ambroxol also provides pain relief in acute sore throat by its 
local anesthetic effect. 
Contraindications and Side effects 
 Generally there are no side effects, but may cause Rhinorrhoea, lacrymation, 
gastric irritation and Hypersensitivity. 
Drug interactions 
 Administration of Ambroxol together with antibiotics (amoxycilline, cefuroxime, 
erythromycin and doxycycline) leads to higher antibiotic concentration in the lung tissue. 
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Pharmacokinetics 
 Excretion : Cleared rapidly from the plasma mainly by hepatic metabolism. 
 Half-life : 4 - 5 minutes (initial); about 40 minutes (terminal). 
2.1.2. Levocetirizine Dihydrochloride  
(IP 2007; Martindale, The extra Pharmacopoeia, 2005; Goodman and Gillman’s 2001; 
The Merck Index 2006; Clarke’s Analysis of Drugs and Poisons 2004; 
http://www.en.wikipedia.org/wiki/Levocetirizine.html.) 
Molecular structure 
N
H
N
O COOHCl
. 2 HCl
 
Chemical name 
(R)-2-[2-[4-[(4-chlorophenyl)phenylmethyl]piperazin-1-yl]ethoxy]aceticacid 
dihydrochloride 
Molecular formula 
 C21H25N2O3Cl.2HCl 
Molecular weight 
 461.8 
Category  
 Anti histamine agent 
Description  
 White or almost white powder 
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Solubility  
 It is freely soluble in water, insoluble in acetone and dichloromethane. 
Identification 
i) Melting point 
Standard value Observed average value* 
228 ºC - 229ºC 228.5 ºC 
                    *Average of six observations 
       ii) Infra red spectrum was recorded and shown in figure – 2  
Storage  
 Store protected from moisture. 
Mechanism of action 
 It is third-generation non-sedative antihistamine which works by blocking 
histamine released from mast cells to bind to histaminic receptors, which in turn prevents 
the release of other allergy chemicals and increased blood supply to that area. 
Contraindications and Side effects 
 General side effects include slight sleepiness, headache, mouth dryness, 
lightheadedness, blurred vision and fatigue. 
Pharmacokinetics  
Absorption 
 Rapidly and extensively absorbed orally and peak plasma concentration attained 
in 0.9 hour. 
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Distribution 
 Apparent volume of distribution is 0.4 L/ kg, expected to distribute in to milk and 
Plasma protein binding was 91 – 92 % (Mainly Albumin) 
Metabolism 
 Metabolized to a limited extent (< 14 %) 
Elimination 
 Excreted in urine (85.4 %) and in feces (12.9 %) 
2.1.3. Montelukast Sodium  
(Goodman and Gillman’s, 2001, http://www.drugs.com/mtm/montelukast.html, 
www.en,wikepedia.org/wiki/Monte.html, Martindale The extra Pharmacopoeia, 2005, 
The Merck Index, 2006)  
Molecular structure 
NCl
S COONa
+
OH
CH3
CH3
 
Chemical name  
 [R – (E)]-1-[[[1-[3-[2-(7-chloro–2–quinolinyl)ethenyl]phenyl]– 3 – [2-( 7-chloro-
2-quinolinyl) ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio] methyl 
cyclopropane acetic acid sodium 
Molecular Formula 
 C35H35ClNNaO3S    
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Molecular weight 
 608.17 
Category  
 Used in the treatment of Asthma, Allergic Rhinitis and Urticaria. 
Description  
 It is a white to off – white powder. 
Solubility  
 It is freely soluble in methanol, ethanol and water and practically insoluble in 
acetonitrile 
Storage  
 Store between 59°F to 86°F. Protect from moisture and light.  
Identification 
i) Melting point 
Standard value Observed average value* 
135.5ºC 133.66ºC 
   * Average of six observations 
       ii) Infra red spectrum was recorded and shown in figure – 3   
Mechanism of action 
 It binds to cysteinyl leukotriene type 1 (CysLT1) receptor in the upper and lower 
airways to prevent leukotriene – mediated effects associated with asthma and allergic 
rhinitis. 
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Contraindications  
Montelukast should not be taken along with Gemfibrozil and prednisolone as the effect of 
Montelukast (Anti asthmatic) will be enhanced. 
Side effects 
 Consumption of Montelukast may cause cardiac complications, headache, fatigue, 
abnormal dreams, anxiousness, depression and hallucination.  
Pharmacokinetics  
Absorption 
 Oral route of administration and peak plasma concentration was attained within   
3 – 4 hours.  
Distribution  
 99 % is bound to plasma and may cross the placenta. 
 Metabolism 
 It is extensively metabolized in gastrointestinal tract and liver. 
Elimination 
 It is excreted principally in feces (about 86 %) via bile as unchanged drug. 
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2.2. REPORTED METHODS 
2.2.1. Analytical Methods 
2.2.1.1 Ambadas R.Rote et al., (2011) reported “Determination of Montelukast Sodium 
and Levocetirizine Dihydrochloride by HPTLC and First Derivative 
Spectrophotometry”. This method was performed by using precoated silica gel 60 - F254 
aluminium plate. The mobile phase consists of ethylacetate, methanol and 
triethanolamine (5:5:0.02 v/v/v) using Paracetamol as internal standard. The detection 
wavelength was 240 nm. The second method is based on the derivative 
spectrophotometric method at zero crossing wavelengths of Montelukast Sodium at  
291.6 nm and 238.2 nm for Levocetirizine by using methanol as solvent. 
2.2.1.2 Arindam Basu et al., (2011) reported “Simultaneous RP-HPLC Estimation of 
Levocetirizine hydrochloride and Montelukast Sodium in Tablet Dosage Form”. The 
method was developed by using Waters HPLC system on a L7 column                        
(Hypersil Gold: 250 mm x 4.6 mm, 5 m) using a mixture of methanol and 0.05 M 
potassium dihydrogen phosphate buffer at pH 7.5 in 80:20 v/v in an isocratic elution 
mode at a flow rate of 1.2 ml/ min at 35° C and the UV detection was carried out at     
225 nm.  
2.2.1.3 Patel P.A. et al., (2011) reported “Spectrophotometric Simultaneous 
Estimation of Salbutamol and Ambroxol in Bulk and Formulation” A simultaneous 
equation method and area under curve method were developed. The solvent used was   
0.1 N Hydrochloric acid for both the methods. For simultaneous equation method the 
wavelength selected were 223 nm and 244 nm. The wavelengths selected for Area Under 
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Curve method were in the range of 232 - 217 nm for Salbutamol and 252 - 237 nm for 
Ambroxol. 
2.2.1.4 Rahul P.Gunjal et al., (2011) reported “HPLC and LC-MS Studies on Stress 
Degradation Behavior of Levocetirizine and Development of a Validated Specific 
Stability – Indicating Method”. The drug was subjected to stress conditions of 
hydrolysis, photolysis and thermal decomposition and its separation from degradation 
products was achieved by a C18 Supelco column using water and acetonitrile in        
(50:50 v/v) at a flow rate of 1 ml/ min. Detection was carried out at 230 nm and degraded 
products were characterized by LC-MS. 
2.2.1.5 Sunil R.Dhaneshwar et al., (2011) reported “Validated HPTLC Method for 
Simultaneous Estimation of Levocetirizine Hydrochloride and Nimesulide in 
Formulation”. Chromatographic separation of drugs was performed on silica gel          
60 - F254 aluminium plates by using a solvent system toluene, ethyl acetate, methanol and 
ammonia (9:1:1:0.5v/v/v/v) with densitometric evaluation of separated zones at 238 nm. 
2.2.1.6 Eswarudu M.M et al., (2011) reported “RP-HPLC Method Development and 
Validation for Simultaneous Estimation of Montelukast Sodium and Levocetirizine 
Dihydrochloride in Tablet Dosage Form”. The separation was achieved by using 
Hypersil C18 (250x4.66mm, 5m) column as a stationary phase and a mixture of 
acetonitrile and acetate buffer at pH 3.5 (75:25 v/v) at a flow rate of 1 ml/ min with UV 
detection at     230 nm. 
2.2.1.7 Rakshit Kanubhai Trivedi et al., (2011) reported “A Rapid, Stability Indicating 
RP-UPLC Method for Simultaneous Determination of Ambroxol Hydrochloride, 
Cetirizine Hydrochloride and Antimicrobial Preservatives in Liquid 
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Pharmaceutical Formulation”. An Agilent eclipse plus C18 (50 x 2.1 mm, 1.8 m) 
column was used for the separation with gradient elution technique. The mobile phase 
used was Acetonitrile and 0.01 M phosphate buffer in 0.1 % triethylamine at a flow rate 
of 0.5 ml/ min and the detection was carried out at 270 nm. 
2.2.1.8 Priyanka A. Patel et al., (2011) reported “Simultaneous Determination of 
Salbutamol and Ambroxol in Fixed Dose Combination by Spectrophotometry”. An 
absorbance correction method was developed using 0.1 M Hydrochloric acid. The 
wavelengths selected were 300 nm for Ambroxol Hydrochloride and 223 nm for 
Salbutamol and the interference due to Ambroxol was corrected at 223 nm. In first order 
derivative spectroscopy the wavelengths used for the analysis were 252 nm for 
Salbutamol and 232 nm for Ambroxol using 0.1 N Hydrochloric acid. 
2.2.1.9 Umadevi B. et al., (2011) reported “Development and Validation of UV 
Spectrophotometric Determination of Doxofylline and Ambroxol Hydrochloride in 
Bulk and Combined Tablet Formulation”. A simultaneous equation method and an 
absorbance correction method were developed. The solvent used was distilled water for 
both the methods. For simultaneous equation method the wavelength selected were       
274 nm and 244.5 nm and for absorbance correction method 308 nm for Ambroxol and 
274 nm for Doxofylline and Ambroxol hydrochloride. The interference due to Ambroxol 
was corrected at 274 nm. 
2.2.1.10 Vidhya K.Bhusari et al., (2010) reported “Application of a Stability-Indicating 
TLC Method for the Quantitative Determination of Levocetirizine in 
Pharmaceutical Dosage Forms”. The method employs TLC aluminium plates precoated 
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with silicagel 60 F254 as stationary phase and mobile phase was a mixture of ethyl acetate, 
methanol and ammonia (9:2.5:1.5 v/v/v) with densitometric detected at 230 nm. 
2.2.1.11 Jain P.S. (2010) reported “Stability-Indicating HPTLC Determination of 
Ambroxol Hydrochloride in Bulk Drug and Pharmaceutical Dosage Form”. The 
method employed the usage of pre coated silica gel 60 F254 aluminium plates and 
developed a chromatogram by using methanol and triethylamine (4:6 v/v) and determined 
densitometrically at 254 nm. 
2.2.1.12 Choudhari V. et al., (2010) reported “Simultaneous Determination of 
Montelukast Sodium and Levocetirizine Dihydrochloride in Pharmaceutical 
Preparations by Ratio Derivative Spectroscopy”. The first derivative UV spectroscopy 
was measured at 250.4 nm for Montelukast Sodium and 238.4 nm for Levocetirizine 
Dihydrochloride by using methanol as solvent. 
2.2.1.13 Shaikh K.A. et al., (2010) reported “A Stability-Indicating LC Method for the 
Simultaneous Determination of Levocetirizine Dihydrochloride and 
Pseudoephedrine Sulfate in Tablet Dosage Forms”. A CosmoSil C8 (250 x 4.6mm,      
5 m) column with a mobile phase of consists of 0.05M potassium dihydrogen phosphate 
buffer at pH 3 and 0.25% 1 - octane sulphonic acid sodium salt and acetonitrile were used 
for separation with gradient elution technique. The flow rate was 1 ml/ min and the 
detection wavelength was 242 nm using a photo diode array detector. 
 2.2.1.14 Smitha Sharma et al., (2010) reported “Development and Validation of TLC-
Densitometry Method for Simultaneous Quantification of Montelukast Sodium and 
Levocetirizine Dihydrochloride Pharmaceutical Solid Dosage Form”. The separation 
was achieved by using 10 x 10 cm precoated Silicagel 60 - F254 aluminium sheets using a 
70 
 
mixture of mobile phase consisting of   chloroform, methanol, toluene and glacial acetic 
acid (10:5:3:0.5v/v/v/v) and developed by using CAMAG TLC Scanner III at 302 nm. 
2.2.1.15 Singh R.M. et al., (2010) reported “Development and Validation of a           
RP-HPLC Method for Estimation of Montelukast Sodium in Bulk and in Tablet 
Dosage Form”. The separation was achieved using a Sunfire C18 (250 x 4.6 mm, 5 m) 
column by using Acetonitrile and 1 mM sodium acetate buffer at pH 6.3 (90:10 v/v) at a 
flow rate of 1.5 ml/ min and UV detection was carried out at 285 nm. 
2.2.1.16 Prasanthi N.L. et al., (2010) reported “Estimation of Ambroxol Hydrochloride 
and Guiaphensin in Tablet Dosage Form by Simultaneous Equation Method”. The 
reported method was simultaneous equation method. The wavelengths selected were      
242 nm and 272 nm for the simultaneous estimation Ambroxol and Guiaphensin using 
methanol as solvent. 
2.2.1.17 Ashokkumar. S. et al., (2009) reported “RP-HPLC Method Development and 
Validation for Simultaneous Estimation of Montelukast Sodium and Levocetirizine 
Dihydrochloride”. Separation of components were achieved by Phenomenex-Luna,    
C18 column (250 x 4.6 mm, 5 m) using a mixture of acetonitrile and phosphate buffer at 
pH 5.5 (35:65 v/v) at flow rate of 1.5 ml/ min. The detection wavelength was 230 nm. 
2.2.1.18 Hadad Ghada M. et al., (2008) reported “HPLC and Chemometrics – Assisted 
UV Spectroscopy Methods for Simultaneous Determination of Ambroxol and 
Doxocycline in capsule”. Separation was achieved on reverse phase C18 column by using 
a mixture of acetonitrile and 20 mM potassium dihydrogen phosphate buffer at              
pH 6   (1:1 v/v) and detection was performed at 245 nm. 
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2.2.1.19 Mirza shahed et al., (2008) reported “Simultaneous Determination of 
Gatifloxacin and Ambroxol Hydrochloride from Tablet Dosage Form using 
Reversed - Phase High Performance Liquid Chromatography”. A HiQ sil C18       
(250 x 4.6 mm, 5 m) column using dihydrogen ortho phosphate buffer at pH 3 and 
acetonitrile (70:30 v/v) at flow rate of 1 ml/ min and components were detected by UV 
detector at 247 nm. 
2.2.1.20 Bhatia M. Neela et al., (2008) reported “RP-HPLC and Spectrophotometric 
Estimation of Ambroxol Hydrochloride and Cetirizine Hydrochloride in Combined 
Dosage Form”. The chromatographic methods were standardized using a HIQ SIL-C18 
column (250 x 4.6 mm i.d., 10 m particle size) with UV detection at 229 nm and mobile 
phase consisting of methanol, acetonitrile and water (40:40:20 v/v/v). Ambroxol 
hydrochloride and cetirizine hydrochloride have absorbance maxima at 243 nm and     
229 nm, respectively. The iso absorptive wavelength for both the drugs was 236 nm. For 
absorbance ratio method, the wavelengths selected were 243 nm and 236 nm.    
2.2.1.21 Lakshmana Prabhu S. et al., (2008) reported “Simultaneous UV 
Spectrophotometric Estimation of Ambroxol hydrochloride and Levocetirizine 
Dihydrochloride”. The method involved solving simultaneous equations based on 
measurement of absorbance at 242 nm for Ambroxol Hydrochloride and at 231 nm for 
Levocetirizine Dihydrochloride by using distilled water as solvent. 
2.2.1.22 Al Omari Mahmoud M. et al., (2007) reported “Effect of Light and Heat on 
the Stability of Montelukast Sodium in Solution and in its Solid State”. A 
simultaneous measurement of Montelukast and its degradation products was determined 
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using a selective HPLC method. The HPLC system comprised a reversed phase column 
(C18) as the stationary phase and a mixture of ammonium acetate buffer of pH 3.5 and 
methanol (15:85 v/v) as the mobile phase. The UV detection was conducted at 254 nm. 
2.2.1.23 Krupa M. Kothekar et al., (2007) reported “Quantitative Determination of 
Levofloxacin and Ambroxol Hydrochloride in Pharmaceutical Dosage Form by 
Reversed - Phase High Performance Liquid Chromatography”. A Hypersil BDS    
C18 column (25 x 4.6mm, 5m) using a mixture of acetonitrile, methanol and phosphate 
buffer at pH 5.2, (25:10:65) at a flow rate of 1 ml/ min and were detected at 220 nm. 
2.2.1.24 Satinsky Dalibor et al., (2006) reported “Determination of Ambroxol 
Hydrochloride, Methyl paraben and Benzoic acid in Pharmaceutical Preparations 
Based on Sequential Injection Technique Coupled with Monolithic Column”. The 
HPLC separation Chromolith Speed ROD RP-18e (50 x 4.6 mm, 5 m) column with 
acetonitrile tetra hydro furan and water at pH 3.75 (with acetic acid) in 10:10:90 v/v/v at 
flow rate of 0.48 ml/ min and detection was performed at 245 nm.  
2.2.1.25 Dincerzafer et al., (2003) reported “Quantitative Determination of Ambroxol 
in Tablets by Derivative UV Spectrophotometric Method and HPLC”. RP-HPLC 
separation of ambroxol was achieved by C18 column with acetonitrile, glacial acetic acid 
and 0.01 M phosphate buffer at pH 3.12 (40:1:59 v/v/v) and was detected at 252 nm. In 
first order derivative spectrophotometric method was developed with the analytical 
wavelength of 255 nm. 
2.2.1.26 Grzegorz Bazylak et al., (2003) reported “Simultaneous High-Throughput 
Determination of Clenbuterol, Ambroxol and Bromohexine in Pharmaceutical 
Formulations by HPLC with Potentiometric Detection”. A cyano RP-HPLC with 
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Uptisphere UP5SCN-25QS silica column (250 x 4.6 mm i.d) eluted with acetonitrile, 
ethanol and 1.66 m water at pH 2.45 with perchloric acid in ratio of 60:2:38 v/v/v and 
detection was performed potentiometrically. 
2.2.1.27 Radhakrishna T et al., (2003) reported “Simultaneous Determination of 
Montelukast and Loratidine by HPLC and Derivative Spectrophotometric 
Methods”. The separation was achieved by using symmetry C18 column using 
Acetonitrile and sodium phosphate buffer at pH 3.7 (80:20 v/v), at flow rate of 1 ml/ min. 
UV detection was performed at 225 nm. In second order derivative spectrophotometry 
276.1 nm was selected as wavelength for Loratidine and 359.7 nm for Montelukast 
Sodium by using methanol as solvent. 
2.2.2 Clinical Methods 
2.2.2.1 Kang Seung Woo et al., (2010) reported “Enantio Selective Determination of 
Cetirizine in Human Plasma by Normal – Phase Liquid Chromatography – 
Atmospheric Pressure Chemical Ionization – Tandem Mass spectrometry”. 
Enantioselective separation was achieved on a Chiralpak AD-H column in a isocratic 
mode of elution with n-hexane, ethanol, diethylamine and acetic acid           
(60:40:0.1:0.1 v/v/v/v). Levocetirizine – D8 was used as internal standard (IS). 
Levocetirizine and IS were detected by multiple - reaction Monitoring (MRM).    
2.2.2.2 Arayne M.S et al., (2010) reported “Simultaneous Determination of 
Gliquidone, Fexofenadine, Buclizine and Levocetirizine in Dosage Formulation and 
Human Serum by RP-HPLC.”. A RP-HPLC separation was achieved by methanol and 
water adjusted to pH 3.5 (80:20 v/v) at a flow rate of 1ml/ min and UV detection was 
performed at 230 nm. 
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2.2.2.3 Balasekharareddy Challa et al., (2010) “Method Development and Validation 
of Montelukast Sodium in Human Plasma by HPLC Coupled with ESI-MS/MS: 
Application to a Bioequivalence Study”. Chromatographic separation was performed 
with YMC-Pack Pro C18 (50 x 4.6 mm) S – 3 column with an isocratic mobile phase 
composed of acetonitrile and 10 mM ammonia formate at pH 4 (80:20 v/v) at a flow rate 
of  0.8 ml/ min. The detection system was Multiple Reaction Monitoring System (MRM).   
2.2.2.4 Xiao – Lin Zhang et al., (2009) reported “Matrine Determination and 
Pharmacokinetics in Human Plasma using LC-MS/MS”. A liquid chromatography/ 
tandem mass spectrometry (LC – MS/MS) method was developed for the determination 
of matrine in human plasma extracted by isopropanol: ethyl acetate (5:95).                 
Rapid chromatographic separation was achieved in the mobile phase composition of 
acetonitrile and 5mM aqueous ammonium acetate buffer (70:30 v/v) at a flow rate of  
0.20 ml/ min.  Detection was carried out using Positive - Ion electroscopy Tandem Mass 
Spectroscopy on a SCIEX API 3000. 
2.2.2.5 Morita M.R. et al., (2008) reported “Determination of Levocetirizine in Human 
Plasma by Liquid Chromatography – Electrospray Tandem Mass Spectrometry: 
Applications to a Bioequivalence Study”. The drug was extracted by Liquid - Liquid 
Extraction and the separation was achieved using C18 column as stationary phase and 
acetonitrile, water and formic acid (80:19.9:0.1 v/v/v) as mobile phase. The 
chromatograms are monitored by using positive electrospray source with tandem mass 
spectrometry. 
2.2.2.6 Wanqun Hu et al., (2008) reported “Rapid and Sensitive Liquid 
Chromatography Tandem Mass Spectrometry Method for the Quantification of 
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Ambroxol in Human Plasma”. Chromatographic separation was performed on a 
Lichrospher CN column with a mobile phase of methanol and water                  
(containing 0.1% formic acid) in 70:30 v/v. The analytes were detected by mass 
spectrometry with electrospray ionization source in positive selected reaction monitoring 
mode. 
2.2.2.7 Aidong Wen et al., (2008) reported “Simultaneous Determination of 
Amoxicillin and Ambroxol in Human Plasma by LC-MS/MS: Validation and 
Application to Pharmacokinetic Study”. Separation was achieved on a Lichrospher   
C18  column (150 x 4.6 mm, ID, dp 5m) using methanol and water (containing 0.2% 
formic acid) as a mobile phase by gradient elution at a flow rate of 1ml/ min. Detection 
was performed using electrospray ionization in positive ion multiple reaction Monitoring 
(MRM) mode. 
2.2.2.8 Sripalakit Pattana et al., (2008) reported “A Simple Bioanalytical Assay for 
Determination of Montelukast Sodium in Human Plasma: Application to a 
Pharmacokinetic Study”. Chromatographic separation was carried out using a Zorbax 
eclipse XBD C8 (150 x 4.6 mm, i.d., 5 m) with mobile phase consisted of methanol, 
acetonitrile and 0.04 M disodium hydrogen ortho phosphate buffer at pH 4.9        
(22:22:56 v/v/v). The wavelengths of fluorescence detection were set at 350 nm for 
excitation and 450 nm for emission. 
2.2.2.9 Fenli Su et al., (2007) reported “Determination of Ambroxol in Human Plasma 
by High Performance Liquid Chromatography - Electrospray Ionization Mass 
Spectrometry (HPLC-MS/ESI)”. Separation was performed by using BDS Hypersil C18 
(250 x 4.6 mm, 5 m) column with the mobile phase consisting of 30mM ammonium 
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acetate buffer (0.4% formic acid) and acetonitrile (64:36 v/v) at a flow rate of                
1.2 ml/ min. The detection was carried out with mass spectrophotometer. Fentanyl was 
used as internal standard (IS). 
2.2.2.10 Chauhan.B et asdl., (2006) reported “A New Liquid - Liquid Extraction 
Method for Determination of Montelukast in Small Volume Human Plasma using 
RP-HPLC”. A Kromosil C8 (150 x 4.6 mm, 5 m) column was used for separation using 
isocratic elution technique. The mobile phase used was acetonitrile and 10mM 
ammonium acetate buffer at pH 3 (65:35) at a flow rate of 1ml/ min and detection was 
performed by using fluorescence detector at 350 nm as excitation wavelength and 400 nm 
as emission wave length. 
2.2.2.11 Hohyun kim et al., (2003) reported “Determination of Ambroxol in Human 
plasma using LC-MS/MS”. A sensitive and selective liquid chromatographic method 
coupled with tandem mass spectrometry (LC – MS/ MS) was developed for the 
quantification of Ambroxol in human plasma. Domperidone was used as internal 
standard. The reconstituted samples were injected into a C18 XTerra MS column              
(2.1 x 30 mm with 3.5 m particle size) with mobile phase was composed of 20 mM 
ammonium acetate buffer at pH 8.8 and acetonitrile (90:10 v/v) at a flow rate of 0.25 ml/ 
min. the mass spectrometer was operated in positive ion mode using turbo electrospray 
ionization with multiple reaction Monitoring (MRM) mode. 
2.2.2.12 Heinanen Maarit et al., (2001) reported “Validation of an HPLC Method for 
the Quantification of Ambroxol Hydrochloride and Benzoic acid in Syrup as 
Pharmaceutical form Stress Test for Stability Evaluation”. Separation of components 
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were performed by Column symmetry shield RP C8 (250 x 4.6 mm, 5 m) as a stationary 
phase and methanol : 8.5 mM phosphate buffer at pH 2.8 (40:60 v/v) as a mobile phase. 
The UV detection was performed at 247 nm. 
2.2.2.13 Al-Rawithi Sameer et al., (2001) reported “Expedient Liquid 
Chromatographic Method with Fluorescence Detection for Montelukast Sodium in 
Micro - Samples of Plasma”. After simple extraction of plasma a C8 (4 m) column was 
used for separation at 40° C using a single pump. The mobile phase used was acetonitrile 
and 0.025M sodium acetate buffer at pH 4 (80:20 v/v) and detection was performed at 
350 nm as excitation wavelength and 400 nm as emission wavelength. 
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3. AIM AND PLAN OF WORK 
3.1 AIM OF WORK 
 Asthma is the chronic inflammatory disease of the airways characterized by 
variable and recurring symptoms, reversible airflow obstruction and bronchospasm. The 
first line of treatment includes single drug therapy and second treatment is the multiple 
drug therapy. The combined dosage form especially was used to prevent breathing 
problems during exercise and seasonal allergic rhinitis. There are no adequate methods 
for the simultaneous estimation of multi drug formulation. So, it is essential to develop 
newer analytical methods which are simple, precise, accurate, specific, linear and rapid. 
 In the view of the literature cited, method for estimation of Montelukast sodium, 
Levocetirizine Dihydrochloride and Ambroxol Hydrochloride were reported individually 
and in combination with other drugs. But no method was reported for the simultaneous 
estimation of Montelukast Sodium, Levocetirizine Dihydrochloride and Ambroxol 
Hydrochloride in bulk and in combined dosage form.  
 Hence the present work aims to develop simple, precise and accurate methods for 
the simultaneous estimation of Montelukast Sodium, Levocetirizine Dihydrochloride and 
Ambroxol Hydrochloride in bulk and in combined capsule dosage form by UV 
spectrophotometry and HPTLC. The developed methods were validated as per ICH 
guidelines.  
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3.2 PLAN OF WORK 
3.2.1 Survey on Literature 
 A complete literature survey was made on drugs Montelukast Sodium, 
Levocetirizine Dihydrochloride and Ambroxol Hydrochloride for the various 
physiochemical properties such as solubility, melting point, storage conditions and 
analytical techniques individually. These surveys give some basic information of drugs 
which helps in the process of analytical method development. 
3.2.2 Procurement of raw materials and formulation 
 The bulk drugs Montelukast Sodium was obtained as gift sample from               
Dr. Reddy’s Laboratories Pvt. Ltd, Hyderabad, Levocetirizine Dihydrochloride and 
Ambroxol hydrochloride were gifted by Madras Pharmaceuticals Pvt. Ltd, Chennai. The 
formulation RENEA Capsules was purchased from a local Pharmacy in Chennai. 
3.2.3 Method development 
 The solubility of the individual drugs was checked and from the list of solvents 
the common solvent was selected for both UV spectroscopy and HPTLC must be cheap 
and readily available. 
The various steps involved in the method development are as follows,  
UV spectroscopy 
1. Selection of appropriate analytical wavelength and selection of suitable method 
2. Determination of working concentration range 
3. Analysis of synthetic mixture 
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4. Simultaneous analysis of formulation by using the developed method 
HPTLC 
1. Determination of suitable detection wavelength 
2. Optimization of chromatographic conditions 
3. Analysis of formulation 
3.2.4 Validation 
 The developed method should be validated as per ICH and USFDA guidelines. 
The various parameters of validation are Linearity, Range, Precision, Accuracy, Limit of 
Detection, Limit of Quantification and Ruggedness. 
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4. MATERIALS AND METHODS 
4.1. MATERIALS USED 
4.1.1. Drugs  
Levocetirizine Dihydrochloride and Ambroxol Hydrochloride were gifted by 
Madras Pharmaceuticals Pvt. Ltd., Chennai and Montelukast Sodium was gifted by      
Dr. Reddy’s Laboratories Pvt. Ltd., Hyderabad.  
4.1.2 Formulation 
RENEA (Shield Healthcare Pvt. Ltd, Chennai) capsule formulation containing 
Montelukast sodium 10 mg, Levocetirizine Dihydrochloride 5 mg and Ambroxol 
Hydrochloride 75 mg was purchased from a local Pharmacy in Chennai. 
4.1.3. Reagents and Chemicals 
All  the  chemicals  used  were  of  analytical   grade  and  HPLC  grade procured  
from  Qualigens India Pvt. Ltd, Mumbai and Loba Chemie India Limited, Mumbai.  The 
chemicals used for the study were Methanol (AR grade), Ethyl acetate (AR grade), 
Toluene (AR grade) and Ammonia Solution 25 % pure (AR grade). Silica gel 60-F254 
aluminum sheets were procured from, E.Merck and Co, Germany. 
4.1.4 Instruments  
 Different instruments used to carry out the present work,  
a) SHIMADZU AUX - 220 Digital balance 
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b) SHIMADZU - 1700 Double Beam UV - Visible Spectrophotometer with a 
pair of 10 mm matched quartz cells. 
c) ELICO SL - 210 Double Beam UV - Visible Spectrophotometer with a 
pair of 10 mm matched quartz cells. 
d) CAMAG HPTLC System with LINOMAT - 5 Applicator 
e) CAMAG TLC Scanner 3 and WINCATS Software 
f) ELICO LI - 127 pH meter 
g) SOLTEC  - Sonica Ultrasonic Cleaner – Model 2200 MH 
h) REMI -  Centrifuge Apparatus 
4.1.5 Specifications of instruments 
4.1.5.1 Shimadzu AUX - 220 Digital balance   
      (Shimadzu Instruction Manual) 
 
Specifications 
     Weighing capacity 200 gm 
     Minimum display 0.1 mg 
     Standard deviation  0.1 mg 
     Operating temperature range 5 to 40°C 
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4.1.5.2 Double beam UV - visible spectrophotometer  
      (Shimadzu and Elico Instruction Manuals) 
 Shimadzu UV- 1700 and Elico SL – 210, Cuvettes: 1 cm matched quartz cells 
 
Specification Shimadzu UV-1700 Elico SL -210 
Light source 20 W halogen lamp 
 Deuterium lamp  
Light source position automatic 
adjustment mechanism 
Tungsten halogen lamp (W) 
      Deuterium lamp (D) 
Light source position automatic 
adjustment mechanism 
Monochromator  Aberration - correcting concave 
blazed holographic grating 
Concave holographic grating with 
1200 lines/ mm 
Detector Silicon photodiode Photodiode 
Stray Light 0.04% or less (220 nm: NAI 10 g/lt) 
0.04% or less (340 nm: NaNo2 50 g/lt) 
<0.05% T at 220 nm with NAI  
10g/ lt 
Measurement 
Wavelength 
range 
 
190 ~ 1100 nm 
 
190 ~ 1100 nm 
Spectral Band 
width 
1 nm or less (190 to 900 nm) 1.8 nm 
Wave length 
Accuracy 
± 0.5 nm on broad automatic 
wavelength calibration mechanism 
 
± 0.5 nm  
Recording 
range 
Absorbance: - 3.99 ~3.99 Abs 
Transmittance: - 399 ~ 399% 
Absorbance: ± 3.000 Abs 
Photometric 
accuracy 
± 0.004 Abs (at 1.0 Abs) 
± 0.002 Abs (at 0.5 Abs) 
 0.005 Abs (at 1.0 Abs) 
 0.010 Abs (at 0.5 Abs) 
Operating  
Temperature 
Humidity 
 
Temperature range: 15 to 35˚C 
Humidity range: 
35 to 80% (15 to below 35˚C) 
35 to 70% (30 to below 35˚C) 
Temperature range: 15 to 35˚C 
Humidity range: 
35 to 80% (15 to below 35˚C) 
35 to 70% (30 to below 35˚C) 
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 4.1.5.3 HPTLC Instrument Specificatio 
 4.1.5.3.1 Pre Coated Silica Gel Plates 
 Silica gel 60 - F254 aluminum sheets  
 Plate size            -   20 x 10 cm 
 Material              - Silica gel 60-F254 aluminum sheets  
 Pre washing        -     No 
 Modification       -    No 
4.1.5.3.2 Instrument - CAMAG HPTLC System  
Specification 
Spray gas Inert gas 
Solvent used Methanol 
Dosage speed 150 nl/ s 
Pre dosage volume 0.2 µl 
Syringe size 100 µl 
Application volume 10 mm 
Band length 8 mm 
 
4.1.5.3.3 Development – Glass Tank 
 Chamber type  - Twin trough chamber 20 x 10 cm 
 Solvent front position - 50.0 mm 
 Volume  - 10.0 ml 
 Drying device  - Oven 
 Temperature  -  60C 
 Time   - 5 minutes 
85 
 
4.1.5.3.4 Detection  
CAMAG TLC Scanner 3 TLC scanner 3 
 Display scaling - Automatic 
4.2 METHODS 
 In the present work, an attempt was made to develop and validate simple, precise 
and accurate methods for the simultaneous estimation of Montelukast Sodium, 
Levocetirizine Dihydrochloride and Ambroxol Hydrochloride in pure and in combined 
capsule dosage form by UV-Spectrophotometry and HPTLC. 
4.2.1 Spectrophotometric Methods 
4.2.1.1 Absorbance correction method 
If the identity, concentration and absorptivity of the absorbing interferences are 
known, it is possible to calculate their contribution to the total absorbance of mixture. 
The concentration of the absorbing component of interest is then calculated from the 
corrected absorbance (total absorbance minus the absorbance of the interfering substance) 
in the usual way. The data required for the construction of absorbance corrected for 
interference are, the max of the drug should be found out by using reference standards of 
the drugs. At one wave length, one of the drugs shows no absorbance. Hence the drug 
was calculated without any interference. In another wavelength, the absorbance corrected 
for another drug and the first drug was determined. 
4.2.1.2 Selection of solvent 
The solubility of Montelukast Sodium, Levocetirizine Dihydrochloride and Ambroxol 
Hydrochloride was determined in variety of solvents as per Indian Pharmacopoeia 
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standards. From the solubility studies, methanol was chosen as solvent for UV 
Spectrophotometry. 
4.2.1.3 Preparation of standard stock solution 
  25 mg of Montelukast Sodium, Levocetirizine Dihydrochloride and Ambroxol 
Hydrochloride standard substances were weighed and transferred into 25 ml volumetric 
flasks separately. Dissolved in methanol and made up to the volume with methanol         
(1 mg/ ml).  
4.2.1.4 Selection of wavelength for absorbance correction method 
 The standard stock solutions were further diluted with methanol to get the 
concentration of 10 g/ml. The solution was scanned between 200 - 400 nm using 
methanol as blank. The spectra were recorded and overlaid. From the overlain spectra, 
the max of Montelukast Sodium, Levocetirizine Dihydrochloride and Ambroxol 
Hydrochloride were found to be 345 nm, 230 nm and 307 nm respectively. At 345 nm, 
the absorbance of Ambroxol Hydrochloride and Levocetirizine Dihydrochloride are zero. 
The stability of the drug solution was observed at different time intervals. Montelukast 
Sodium was stable for 2 hours, Ambroxol hydrochloride was stable for 3 hours and       
30 minutes and Levocetirizine Dihydrochloride was stable for 2 hours and 30 minutes. 
Hence this was selected for the analysis of Montelukast Sodium. At 307 nm 
Levocetirizine Dihydrochloride absorbance was zero. But both Ambroxol Hydrochloride 
and Montelukast Sodium had absorbance. To determine the amount of Ambroxol 
hydrochloride, the absorbance of Montelukast Sodium was corrected at 307 nm.             
At 230 nm, Montelukast Sodium, Ambroxol Hydrochloride and Levocetirizine 
Dihydrochloride were exhibiting the absorbance. The absorbance of Montelukast Sodium 
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and Ambroxol Hydrochloride were corrected and the amount of Levocetirizine 
Dihydrochloride was determined without any interference. 
 4.2.1.5 Preparation of calibration graph 
4.2.1.5.1 For Montelukast Sodium 
 Working standard solution was prepared by pipetting 1 ml of the standard stock 
solution into a 50 ml volumetric flask and made up to the volume with methanol to get 
the concentration 20 g/ ml. 1 – 6 ml were transferred into a series of 10 ml volumetric 
flasks and made up to mark with methanol to get the concentration range of                      
2 – 12 µg/ ml. The absorbance was measured at 345 nm, 307 nm and 230 nm against 
methanol as blank. The calibration curve was plotted using concentration against 
absorbance. The procedure was repeated for six times. 
4.2.1.5.2 For Levocetirizine Dihydrochloride 
 1 ml of the standard stock solution of Levocetirizine Dihydrochloride was 
transferred into a 50 ml volumetric flask and made up to the volume with methanol to get 
the concentration 20 g/ ml. From that, 0.5 – 6 ml were transferred into a series of 10 ml 
volumetric flasks and made up to mark with methanol to get the concentration range of   
1 – 12 µg/ ml. The absorbance was measured at 230 nm against methanol as blank. The 
calibration curve was plotted using concentration against absorbance. The procedure was 
repeated for six times. 
4.2.1.5.3 For Ambroxol Hydrochloride 
 Working standard solution was prepared by pipetting 5 ml of the standard stock 
solution into a 50 ml volumetric flask and made up to the volume with methanol to get 
the concentration 100 g/ ml.  1 – 7 ml were transferred into a series of 10 ml volumetric 
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flasks and made up to mark with methanol to get the concentration range 10 – 70 µg/ ml. 
The absorbance was measured at 230 nm and 307 nm against methanol as blank.   The 
calibration curve was plotted using concentration against absorbance.  The procedure was 
repeated for six times. 
4.2.1.6 Quantification of formulation 
           Twenty capsules (RENEA containing 10 mg of Montelukast sodium, 5 mg of 
Levocetirizine Dihydrochloride and 75 mg of Ambroxol Hydrochloride) were weighed 
accurately. The average weight of each capsule content was found and powdered. The 
mixed contents of capsule  powder equivalent to 25 mg of Ambroxol Hydrochloride was 
weighed and transferred into 25 ml volumetric flask and added about 20 ml of methanol 
and sonicated for 15 minutes. The solution was made up to the volume to 25 ml. The 
solution was centrifuged for 15 minutes at 2000 rpm and filtered through Whatmann 
filter paper No. 41. From the clear solution, further dilutions were made by diluting 5 ml 
into 50 ml with methanol. 3 ml was pipetted out into a series of 10 ml volumetric flasks 
and made up to the mark with methanol to get the concentration of 2 g/ ml of 
Levocetirizine Dihydrochloride, 4 g/ ml of Montelukast Sodium and 30 g/ ml of 
Ambroxol Hydrochloride, theoretically. The absorbance was measured at 345 nm,       
307 nm and 230 nm for all the solutions. The procedure was repeated for six times. The 
amount Montelukast Sodium, Levocetirizine Dihydrochloride and Ambroxol 
Hydrochloride were found by applying absorbance correction method. 
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4.2.1.7 Recovery studies 
4.2.1.7.1 Preparation of raw material stock solution 
 125 mg of Montelukast Sodium and Levocetirizine Dihydrochloride were 
accurately weighed and transferred in to separate 100 ml volumetric flasks, 100 mg of 
Ambroxol Hydrochloride was accurately weighed and transferred into 10 ml volumetric 
flask, dissolved in methanol and made up to the mark with methanol to get a 
concentration of 1.25 mg/ ml of Montelukast Sodium, Levocetirizine Dihydrochloride 
and 10 mg/ ml of Ambroxol Hydrochloride, respectively. 
4.2.1.7.2 Recovery procedure 
 The recovery experiment was done by adding known concentrations of 
Montelukast Sodium, Levocetirizine Dihydrochloride and Ambroxol Hydrochloride 
working standard to the pre analyzed formulations. The mixed contents of capsule 
powder equivalent to 25 mg of Ambroxol Hydrochloride was weighed accurately and 
added 2 ml, 3 ml and 4 ml of Montelukast Sodium, 1 ml, 2 ml and 3 ml of Levocetirizine 
Dihydrochloride and 2 ml, 2.5 ml and 3 ml of Ambroxol hydrochloride standard solutions 
were added into a series of 25 ml volumetric flasks, dissolved in methanol and sonicated 
for 15 minutes. After sonication the solution was made up to 25 ml with methanol. Then 
the solution were centrifuged for 15 minutes at 2000 rpm and the solutions were filtered 
through Whatmann filter paper No. 41. From each solution, 5 ml of clear filtrate was 
transferred into a series of 50 ml volumetric flasks and made up to the volume with 
methanol. Further dilution was made by pipetting 3 ml into a series of six 10 ml 
volumetric flasks and made up to the volume with methanol. The absorbances of the 
resulting solutions were measured at their selected wavelengths (345 nm, 307 nm and 230 
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nm). The procedure was repeated for three times for each concentration. The amount of 
each drug recovered from the formulations was calculated for all the drugs by using 
absorbance correction method. 
4.2.1.8 Validation of developed method  
4.2.1.8.1 Linearity 
 A calibration curve was plotted between concentration and absorbance. 
Montelukast Sodium was linear with the concentration range of 2 – 12 g/ ml at 345 nm, 
307 nm and 230 nm Levocetirizine Dihydrochloride was linear with the concentration 
range of 1 – 12 g/ ml at 230 nm and Ambroxol Hydrochloride showed the linearity in 
the range of 10 – 70 g/ ml at 307 nm and at 230 nm. 
4.2.1.8.2 Accuracy  
           Accuracy of the method was confirmed by recovery studies. To the pre analyzed 
formulations, a known quantity of working standards of Montelukast Sodium, 
Levocetirizine Dihydrochloride and Ambroxol Hydrochloride were added and the 
procedure was followed as per the analysis of formulations. The amount of each drug 
recovered was calculated. This procedure was repeated for three times for each 
concentration. The percentage RSD and Confidence Interval were calculated. 
4.2.1.8.3 Precision 
The repeatability of the method was confirmed by the analysis of formulations 
was repeated for six times with the same concentration. The amount of each drug present 
in the tablet formulations was calculated. The percentage RSD and Confidence Interval 
were calculated.   
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The intermediate precision of the method was confirmed by intraday and inter day 
analysis where the analysis of formulation was repeated three times in the same day and 
one time on three successive days. The amount of drugs was determined, percentage RSD 
and Confidence Interval were calculated.     
4.2.1.8.4 Ruggedness 
           Ruggedness of the method was confirmed by the analysis of formulation was done 
with different analysts and with the different instruments. The amount, percentage RSD 
and Confidence Interval were calculated. 
4.2.1.8.5 Limit of Detection (LOD) and Limit of Quantification (LOQ) 
Preparation of calibration curve from the serial dilutions of standards and was repeated 
for six times. The Limit of detection and limit of quantification was calculated by using 
the average value of slope and standard deviation of the intercept. 
4.2.2. Derivative Spectrophotometric Method 
 A simple, accurate, rapid and precise first order derivative spectrophotometric 
method was developed and validated. The first derivative spectrum is a plot of the rate of 
change of absorbance with wavelength against wavelength, i.e. a plot of the slope of the 
fundamental spectrum against wavelength. 
4.2.2.1 Selection of solvent 
   The solubility of Montelukast Sodium, Levocetirizine Dihydrochloride and 
Ambroxol Hydrochloride was determined in variety of solvents as per Indian 
Pharmacopoeia standards. From the solubility studies, methanol was chosen as solvent 
for UV Spectrophotometry. 
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4.2.2.2 Preparation of standard stock solution 
 25 mg of Montelukast Sodium, Levocetirizine Dihydrochloride and Ambroxol 
Hydrochloride standard substance were weighed and transferred into 25 ml volumetric 
flasks separately and dissolved in methanol and made up to the volume with methanol    
(1 mg/ ml).  
4.2.2.3 Selection of absorption maxima 
 The standard stock solutions were further diluted with methanol 10 g/ ml. The 
spectra were recorded between 200 - 400 nm using methanol as blank. The spectra were 
derivatised into first order derivative spectrum. The first order derivative spectra were 
overlaid and showed that at 365.5 nm, the absorbance of Ambroxol Hydrochloride and 
Levocetirizine are zero, hence for the analysis of Montelukast Sodium was done at this 
wavelength. At 248 nm Ambroxol Hydrochloride showed no absorbance but Montelukast 
Sodium and Levocetirizine Dihydrochloride had absorbance. By correcting the interferent 
Montelukast Sodium, the absorbance of Levocetirizine Dihydrochloride was determined. 
At 256.5 nm Levocetirizine Dihydrochloride and Montelukast Sodium had no absorbance 
but, Ambroxol Hydrochloride had absorbance. Hence it was selected as the analytical 
wavelength for Ambroxol Hydrochloride. The stability of the drug solution was observed 
at different time intervals. Montelukast Sodium was stable for 2 hours, Ambroxol 
hydrochloride was stable for 3 hours and 30 minutes and Levocetirizine Dihydrochloride 
was stable for 2 hours and 30 minutes.  
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 4.2.2.4 Preparation of calibration graph 
4.2.2.4.1 For Montelukast Sodium 
 Working standard solution was prepared by pipetting 1 ml of the standard stock 
solution into a 50 ml volumetric flask and made up to the volume with methanol to get 
the concentration 20 g/ ml.  1 – 6 ml   were transferred into a series of 10 ml volumetric 
flasks and made up to mark with methanol to get the concentration range of                       
2 – 12 µg/ ml. The absorbance was measured at 365.5 nm and 248 nm against methanol 
as blank. The calibration curve was plotted using concentration against absorbance.  The 
procedure was repeated for six times. 
4.2.2.4.2 For Levocetirizine Dihydrochloride 
 1 ml of the standard stock solution of Levocetirizine Dihydrochloride was 
transferred into a 50 ml volumetric flask and made up to the volume with methanol to get 
the concentration 20 g/ ml. From that 1 – 6 ml were transferred into a series of 10 ml 
volumetric flasks and made up to mark with methanol to get the concentration range of                      
1 – 12 µg/ ml. The absorbance was measured at 248 nm against methanol as blank.      
The calibration curve was plotted using concentration against absorbance.  The procedure 
was repeated for six times. 
4.2.2.4.3 For Ambroxol Hydrochloride 
 Working standard solution was prepared by pipetting 5 ml of the standard stock 
solution into a 50 ml volumetric flask and made up to the volume with methanol to get 
the concentration 100 g/ ml. 1 – 7 ml were transferred into a series of 10 ml volumetric 
flasks and made up to mark with methanol to get the concentration range of                     
10 – 70 µg/ ml. The absorbance was measured at 256.5 nm against methanol as blank. 
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The calibration curve was plotted using concentration against absorbance.  The procedure 
was repeated for six times. 
4.2.2.5 Quantification of formulation 
   Twenty capsules (RENEA containing 10 mg of Montelukast sodium, 5 mg of 
Levocetirizine Dihydrochloride and 75 mg of Ambroxol Hydrochloride) were weighed 
accurately. The average weight of each capsule content was found and powdered. The 
mixed contents of capsule  powder equivalent to 25 mg of Ambroxol Hydrochloride was 
weighed and transferred into 25 ml volumetric flask and added about 20 ml of methanol 
and sonicated for 15 minutes. The solution was made up to the volume to 25 ml. The 
solution was centrifuged for 15 minutes at 2000 rpm and filtered through Whatmann 
filter paper No. 41. From the clear solution, further dilutions were made by diluting 5 ml 
into 50 ml with methanol. 3 ml was pipetted out into a series of 10 ml volumetric flasks 
and made up to the mark with methanol to get the concentration of 2 g/ ml of 
Levocetirizine Dihydrochloride, 4 g/ ml of Montelukast Sodium and 30 g/ ml of 
Ambroxol Hydrochloride, theoretically. The absorbance was measured at 365.5 nm, 
256.5 nm and 248 nm for all the solutions. The procedure was repeated for six times. The 
amount Montelukast Sodium, Levocetirizine Dihydrochloride and Ambroxol 
Hydrochloride were found by applying absorbance correction in derivative method. 
4.2.2.6 Recovery studies 
4.2.2.6.1 Preparation of raw material  standard stock solutions 
 125 mg of Montelukast Sodium and Levocetirizine Dihydrochloride were 
accurately weighed and transferred in to separate 100 ml volumetric flasks, 100 mg of 
Ambroxol Hydrochloride was accurately weighed and transferred into 10 ml volumetric 
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flask, dissolved in methanol and made up to the mark with methanol to get a 
concentration of 1.25 mg/ ml of Montelukast Sodium, Levocetirizine Dihydrochloride 
and 10 mg/ ml of Ambroxol Hydrochloride, respectively.  
4.2.2.6.2 Recovery procedure 
 The recovery experiment was done by adding known concentrations of 
Montelukast Sodium, Levocetirizine Dihydrochloride and Ambroxol Hydrochloride 
working standard to the pre analyzed formulations. The mixed contents of capsule 
powder equivalent to 25 mg of Ambroxol Hydrochloride was weighed accurately and 
added 2 ml, 3 ml and 4 ml of Montelukast Sodium, 1 ml, 2 ml and 3 ml of Levocetirizine 
Dihydrochloride and 2 ml, 2.5 ml and 3 ml of Ambroxol hydrochloride standard solutions 
were added into a series of 25 ml volumetric flasks, dissolved in methanol and sonicated 
for 15 minutes. After sonication the solution was made up to 25 ml with methanol. Then 
the solution were centrifuged for 15 minutes at 2000 rpm and the solutions were filtered 
through Whatmann filter paper No. 41. From each solution, 5 ml of clear filtrate was 
transferred into a series of 50 ml volumetric flasks and made up to the volume with 
methanol. Further dilution was made by pipetting 3 ml into a series of six 10 ml 
volumetric flasks and made up to the volume with methanol. Spectra zero order spectra 
was derivatised to first order spectra and the absorbances of the resulting solutions were 
measured at their selected wavelengths (365.5 nm, 256.5 nm and 248 nm). The procedure 
was repeated for three times for each concentration. The amount of each drug recovered 
from the formulations was calculated for all the drugs by using absorbance correction 
method in first order derivative spectrophotometry. 
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4.2.2.7 Validation of developed method  
4.2.2.7.1 Linearity 
 A calibration curve was plotted between concentration and absorbance. 
Montelukast Sodium was linear with the concentration range of 2 – 12 g/ ml at       
365.5 nm, 256.5 nm and 248.0 nm Levocetirizine Dihydrochloride was linear with the 
concentration range of 2 – 12 g/ ml at 248.0 nm and Ambroxol Hydrochloride showed 
the linearity in the range of 10 – 70 g/ ml at 256.5 nm. 
4.2.2.7.2 Accuracy  
 Accuracy of the method was confirmed by recovery studies. To the pre analyzed 
formulations, a known quantity of working standards of Montelukast Sodium, 
Levocetirizine Dihydrochloride and Ambroxol Hydrochloride were added and the 
procedure was followed as per the analysis of formulations. The amount of each drug 
recovered was calculated. This procedure was repeated for three times for each 
concentration. The percentage RSD and Confidence Interval were calculated. 
4.2.2.7.3 Precision  
 The repeatability of the method was confirmed by the analysis of formulations 
was repeated for six times with the same concentration. The amount of each drug present 
in the tablet formulations was calculated.  The percentage RSD and Confidence Interval 
were calculated. 
   The intermediate precision of the method was confirmed by intraday and inter 
day analysis where the analysis of formulation was repeated three times in the same day 
and one time on three successive days. The amount of drugs was determined, percentage 
RSD and Confidence Interval were calculated.   
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4.2.2.7.4 Ruggedness 
 Ruggedness of the method was confirmed by the analysis of formulation was done 
with different analysts and with the different instruments. The amount, percentage RSD 
and Confidence Interval were calculated. 
4.2.2.7.5 Limit of detection (LOD) and Limit of Quantification (LOQ) 
 Preparation of calibration curve from the serial dilutions of standards was 
repeated for six times. The Limit of detection and limit of quantification was calculated 
by using the average value of slope and standard deviation of the intercept. 
4.2.3. HPTLC Method 
4.2.3.1 Choice of Mobile Phase  
 The initial separation was made with precoated aluminum sheets. The standard 
and sample solutions of Montelukast Sodium, Levocetirizine Dihydrochloride and 
Ambroxol Hydrochloride were spotted and the chromatograms were observed in UV 
chamber. The following mixture of solvents were tried to optimize the mobile phase. 
From the above list of mobile phases, the mobile phase selected for separation was Ethyl 
acetate: Methanol: Toluene: Ammonia (7:2.5:2.5:1) 
TRIAL NO MOBILE PHASE RATIO 
1. Ethyl acetate: Methanol 8:2 
2. Ethyl acetate: Methanol : 1% Ammonia 8:2:1 
3. Ethyl acetate: Methanol : Toluene: Ammonia 8.5:2.5:1:1 
4. Ethyl acetate: Methanol: Toluene: Ammonia 7:4:1:1 
5. Ethyl acetate: Methanol : Toluene: Ammonia 7:2.5:2.5:1 
6. Ethyl acetate: Methanol : Triethonalamine 5:5:1 
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4.2.3.2 Selection of detection wavelength 
  10 g/ ml of Montelukast Sodium, Levocetirizine Dihydrochloride and 
Ambroxol Hydrochloride were prepared and the spectra were recorded in the range of 
200 – 400 nm individually. The spectra were overlaid and from the overlain spectra,    
224 nm was selected as detection wavelength, where all the three drugs showed marked 
absorbance. 
4.2.3.3 Optimized Chromatographic Conditions 
Stationary phase    : Silica gel 60-F 254 aluminum sheets 
Mobile phase     : Ethyl acetate: Methanol: Toluene: 1% Ammonia 
 Mobile phase ratio         : 7:2.5:2.5:1% v/v 
 Detection Wavelength   : UV detection at 224 nm 
 Development mode    : Ascending mode 
 Temperature     : 60° C 
 Development chamber   : Twin trough chamber 
4.2.3.4 Preparation of Standard Stock Solution 
20 mg of Montelukast Sodium, 20 mg of Levocetirizine Dihydrochloride and     
75 mg of Ambroxol Hydrochloride were weighed accurately and transferred in to 50 ml 
volumetric flasks separately. Dissolved in methanol and made up to the volume to 50 ml 
with methanol. The standard stock solutions contain 400 µg/ ml of Montelukast Sodium, 
400 µg/ ml of Levocetirizine Dihydrochloride and 1500 µg/ ml of Ambroxol 
Hydrochloride. 1 ml of each of the standard stock solution was transferred in to a 10 ml 
volumetric flask and the solution was diluted to 10 ml with methanol. (This solution 
contains 40 µg/ ml of Montelukast Sodium, 40 µg/ ml of Levocetirizine Dihydrochloride 
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and 150 µg/ ml of Ambroxol Hydrochloride) From the solution, 0.5 – 5 µl were applied 
on silica gel 60- F254 aluminum sheets. Concentration range selected were 20 – 200 ng/ µl 
for Montelukast Sodium, 20 – 200 ng/ µl for Levocetirizine Dihydrochloride and           
75 – 750 ng/ µl for Ambroxol Hydrochloride. The calibration graph was plotted using 
peak area Vs concentration. 
4.2.3.5 Quantification of formulation 
Twenty capsules (RENEA containing 10 mg of Montelukast Sodium, 5 mg of 
Levocetirizine Dihydrochloride and 75 mg of Ambroxol Hydrochloride) were accurately 
weighed and average weight was found. Powdered the mixed contents of the capsule 
powder, weighed accurately a quantity of the capsule powder equivalent to 75 mg of 
Ambroxol Hydrochloride and transferred in to a 25 ml volumetric flask, added about     
20 ml of methanol, sonicated for 20 minutes and made up to the mark with methanol. The 
solution was centrifuged at 2000 rpm for 10 minutes and filtered through           
Whatmann filter paper No.41. 1ml of the above solution was diluted to 10 ml with 
methanol. 1 µl quantity of the sample was spotted and the chromatogram was recorded. 
The peak area of the Montelukast Sodium, Levocetirizine Dihydrochloride and Ambroxol 
Hydrochloride were measured and the amount was calculated from the regression 
equation of the calibration graph. The procedure was repeated for six times. 
4.2.3.6 Recovery studies 
4.2.3.6.1 Preparation of raw material  stock solutions   
 50 mg of Montelukast sodium, 25 mg of Levocetirizine Dihydrochloride and    
375 mg of Ambroxol Hydrochloride raw materials were weighed accurately into 25 ml 
volumetric flasks separately, dissolved with methanol and made up to the volume with 
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methanol to get a concentration of 2 mg/ ml, 1 mg/ ml and 15 mg/ ml of Montelukast 
Sodium, Levocetirizine Dihydrochloride and Ambroxol Hydrochloride respectively. 
4.2.3.6.2 Recovery procedure 
 The capsule powder equivalent to 75 mg of Ambroxol Hydrochloride was 
weighed accurately to three separate 50 ml volumetric flasks. To this 4 ml, 5 ml and 6 ml 
of Montelukast sodium, Levocetirizine Dihydrochloride and Ambroxol Hydrochloride 
stock solutions were added into 50 ml volumetric flasks. Dissolved in methanol and 
sonicated for 15 minutes. The solution was then made up to the mark with methanol. The 
solution was centrifuged for 15 minutes at 2000 rpm and filtered through whatmann filter 
paper No.41. Further, 1 ml of the stock solution was diluted to a series of six 10 ml 
volumetric flasks. From this solution, 2 µl quantity of sample were spotted and the 
chromatogram was recorded. From the peak area, the amounts of drug recovered were 
calculated for each concentration and repeated for three times.   
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5. RESULTS AND DISCUSSION 
 The simultaneous estimation of three drugs in a formulation has more advantages 
such as accurate, less use of reagent and less time requirement for the simultaneous 
estimation rather than individual estimation of three drugs.  Three simple, precise and 
accurate analytical techniques were developed for the simultaneous estimation of 
Montelukast Sodium, Levocetirizine Dihydrochloride and Ambroxol Hydrochloride in 
combined dosage form.  The methods include  
1. UV spectroscopic method 
i. Absorption correction method 
ii. First order derivative spectroscopy 
2. HPTLC method 
5.1 UV SPECTROSCOPIC METHOD 
5.1.1 Absorbance Correction Method 
 The identification of Ambroxol Hydrochloride, Levocetirizine Dihydrochloride 
and Montelukast Sodium were confirmed by melting point analysis and IR spectral 
studies (Figures 1 - 3). The solubility of Montelukast Sodium, Levocetirizine 
Dihydrochloride and Ambroxol Hydrochloride were determined in variety of solvents as 
per Indian pharmacopeal standards. Solubility was carried out in polar and non - polar 
solvents.  The common solvents were distilled water, methanol and phosphate buffer at 
pH 9 for the analysis of these drugs. The solvent (phosphate buffer 9) was not selected as 
solvent because of its spectral interaction and it is not readily available. Distilled water 
was not selected as solvent due to formation of opalescence with Montelukast Sodium 
during solubility. Hence it was avoided to be used as solvent.  Finally, methanol was 
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selected as solvent on account of its solubility factor and cut off wavelength. The 
solubility profile of Montelukast Sodium, Levocetirizine Dihydrochloride and Ambroxol 
Hydrochloride are given in table 1, 2 and 3 respectively. 
 The sample solution of 10µg/ ml of Montelukast Sodium, Levocetirizine 
Dihydrochloride and Ambroxol Hydrochloride in methanol were prepared individually 
and the solutions were scanned between 200 – 400 nm by using methanol as blank. From 
the overlain spectra by observing the spectral characteristics absorbance correction 
method was selected for the simultaneous estimation of Montelukast Sodium, 
Levocetirizine Dihydrochloride and Ambroxol Hydrochloride in combined dosage form. 
In this method λmax of Montelukast Sodium, Levocetirizine Dihydrochloride and 
Ambroxol Hydrochloride were selected as analytical wavelengths i.e. 345 nm, the λmax of 
Montelukast Sodium 307 nm, the λmax of Ambroxol Hydrochloride and 230 nm the λmax 
of Levocetirizine Dihydrochloride. At 345 nm Montelukast Sodium has absorbance but 
Ambroxol Hydrochloride and Levocetirizine Dihydrochloride has zero absorption. Hence 
the amount of Montelukast Sodium was calculated by using its absorptivity value at     
345 nm without any interference. At 307 nm Levocetirizine Dihydrochloride absorbance 
was zero.  But both Ambroxol Hydrochloride and Montelukast Sodium had absorbance. 
To determine the amount of Ambroxol Hydrochloride the absorbance of Montelukast 
Sodium was corrected at 307 nm. At 230 nm, Montelukast Sodium, Levocetirizine 
Dihydrochloride and Ambroxol Hydrochloride were exhibiting the absorbance values. 
The absorbance of Montelukast Sodium and Ambroxol Hydrochloride were corrected for 
interference and the amount of Levocetirizine Dihydrochloride was determined without 
any interference. The overlain spectrum of Montelukast Sodium, Levocetirizine 
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Dihydrochloride and Ambroxol Hydrochloride was shown in figure 4.  The stability of 
the drug solution was observed at different time intervals.  Montelukast Sodium was 
stable for 2 hours, Ambroxol Hydrochloride was stable for 3 hours and 30 minutes and 
Levocetirizine Dihydrochloride was stable for 2 hours and 30 minutes. 
 Aliquots of Montelukast Sodium, Levocetirizine Dihydrochloride and Ambroxol 
Hydrochloride were prepared were prepared in concentration range of 2 – 12 µg/ ml for 
Montelukast Sodium, 1 – 12 µg/ ml for Levocetirizine Dihydrochloride and                   
10 – 70 µg/ ml for Ambroxol Hydrochloride. The calibration curve was plotted with 
absorbance versus concentration for the three drugs. The optical characteristics such as 
correlation coefficient slope, intercept, LOD and LOQ were calculated and regression 
equation was constructed for Montelukast Sodium, Levocetirizine Dihydrochloride and 
Ambroxol Hydrochloride. The correlation coefficient was found to be 0.9994 for 
Montelukast Sodium at 345 nm, 0.9990 and 0.9994 for Montelukast Sodium and 
Ambroxol Hydrochloride at 307 nm and 0.9991, 0.9994 and 0.9993 for Montelukast 
Sodium, Levocetirizine Dihydrochloride and Ambroxol Hydrochloride at 230 nm 
respectively.  At 345 nm the LOD and LOQ were found to be 0.6755 µg/ ml and   
2.04715 µg/ ml for Montelukast Sodium. At 307 nm the LOD and LOQ were found to be 
0.4205 µg/ ml and 1.26149 µg/ ml for Montelukast sodium and 1.61590 µg/ ml and 
4.89667 µg/ ml for Ambroxol Hydrochloride. At 230 nm, the LOD and LOQ were found 
to be 0.4130 µg/ ml and 1.2515 µg/ ml for Montelukast Sodium, 0.05280 µg/ ml and 
0.1600829 µg/ ml for Levocetirizine Dihydrochloride and 1.1978 µg/ ml and          
3.6297 µg/ ml for Ambroxol Hydrochloride. The correlation coefficient values at all the 
selected wavelengths are found to be above 0.999. Hence the selected concentrations are 
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linear and obeyed Beer’s law. The calibration graphs for Montelukast Sodium at 345 nm, 
307 nm and 230 nm are shown in figure 5, 6 and 7 respectively. The calibration graphs 
for Ambroxol Hydrochloride at 307 nm and 230 nm are shown in figure 8 and 9. The 
calibration graph for Levocetirizine Dihydrochloride at 230 nm is in figure 10 shown 
optical characteristic at 345 nm, 307 nm and 230 nm are shown in tables 4, 5 and 6 
respectively. 
The capsule formulation, RENEA (containing 5 mg of Levocetirizine 
Dihydrochloride, 10 mg of Montelukast Sodium and 75 mg of Ambroxol Hydrochloride) 
was selected for analysis. The drugs Montelukast Sodium, Levocetirizine 
Dihydrochloride and Ambroxol Hydrochloride are in ratio 2:1:15 in the formulation. The 
percentage purity of drugs in the formulation was found to be 100.45 ± 0.6253 for 
Montelukast Sodium, 100.38 ± 1.7426 for Levocetirizine Dihydrochloride and        
100.32 ± 1.1773 for Ambroxol Hydrochloride. The precision of the method was 
confirmed by the repeated analysis of the formulation for six times.  The percentage RSD 
was calculated.  The percentage RSD of Montelukast Sodium, Levocetirizine 
Dihydrochloride and Ambroxol Hydrochloride were found to be 0.6224, 1.7359 and 
1.1735 respectively. Confidence Interval (95 %) were found to be 99.79 – 101.10 for 
Montelukast Sodium, 98.55 – 102.20 for Levocetirizine Dihydrochloride and             
99.08 – 101.55 for Ambroxol hydrochloride, respectively. The low RSD values suggest 
that the method has good precision. The results are shown in table 7. 
 Further, precision of the method was confirmed by Intraday and Inter day 
analysis.  Intraday and Interday analysis of formulation was done on three times on same 
day and one time on three consecutive days. The percentage RSD for the Intraday and 
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Interday precision was found to be 0.2310 and 0.2651 for Montelukast Sodium, 0.6116 
and 0.3376 for Levocetirizine Dihydrochloride and 0.8731 and 0.0300 for Ambroxol 
Hydrochloride. The low RSD values suggest that the precision of the method was further 
confirmed. Confidence Interval (95 %) were found to be 99.71 – 100.20 and                
99.52 – 100.07 for Montelukast Sodium, 101.4 – 102.75 and 102.23 – 103.61 for 
Levocetirizine Dihydrochloride and 100.86 – 102 73 and 101.51 – 101.58 for Ambroxol 
hydrochloride, for intraday and interday, respectively. The results of analysis are given in 
table 8. 
 The ruggedness of the method was validated by using different analysts and 
different instruments. The percentage RSD for analyst 1 and analyst 2 were found to be 
0.6224 and 0.4666 for Montelukast Sodium, 1.7359 and 1.8957 for Levocetirizine 
Dihydrochloride and 1.1735 and 0.4660 for Ambroxol Hydrochloride respectively. The 
percentage RSD value for the instrument 1 and instrument 2 was found to be 0.6026 and 
1.0188 for Montelukast Sodium, 0.8306 and 0.7499 for Levocetirizine Dihydrochloride 
and 1.2706 and 1.1656 for Ambroxol Hydrochloride respectively. Confidence Interval 
(95 %) were found to be 98.69 – 99.94 and 98.91 – 101.05 for Montelukast Sodium, 
100.61 – 102.38 and 101.08 – 102.68 for Levocetirizine Dihydrochloride and            
98.07 – 101.34 and 98.43 – 100.87 for Ambroxol hydrochloride, for Instrument 1 and 
Instrument 2 respectively. Confidence Interval (95 %) were found to be 99.79 – 101.1 
and 99.11 – 100.08 for Montelukast Sodium, 98.55 – 102.2 and 99.71 – 103.86 for 
Levocetirizine Dihydrochloride and 99.08 – 101.55 and 101.18 – 102.17for Ambroxol 
hydrochloride, for analyst 1 and analyst 2, respectively.  The results of the analysis are 
given in table 9 and 10 respectively. 
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 The accuracy of the method was confirmed by recovery studies.  To the pre 
analysed formulation a known quantity of the raw material is added and the percentage 
recovery was calculated.  The percentage of raw material added was 80 %, 100 % and 
120 % for Montelukast Sodium, Levocetirizine Dihydrochloride and Ambroxol 
Hydrochloride.  The percentage recovery was found to be in the range of                    
98.45 to 100.35% for Montelukast Sodium, 97.77 to 102.42 % for Levocetirizine 
Dihydrochloride and 98.27 to 102.57 % for Ambroxol Hydrochloride. Percentage RSD 
values were found to be 0.5286, 1.4463 and 0.5541 for Montelukast Sodium, 
Levocetirizine Dihydrochloride and Ambroxol Hydrochloride, respectively. The low 
percentage RSD indicated that there was no interference due to excepients used in 
formulation. Hence, the accuracy of the method was conformed. The data for recovery 
studies are given in table 11, 12 and 13. 
5.1.2 First Order Derivative Spectrophotometry 
 A simple, precise, accurate and rapid derivative spectrophotometric method was 
developed and validated.  From the overlain first order derivative spectrum (figure 11), 
365.5 nm was selected for estimation of Montelukast Sodium without any interference 
because of both Ambroxol Hydrochloride and Levocetirizine Dihydrochloride have zero 
absorbance at 365.5 nm. At 256.5 nm Ambroxol Hydrochloride has absorbance where, 
both Montelukast Sodium and Levocetirizine Dihydrochloride have zero absorbance. 
Hence Ambroxol Hydrochloride can be estimated without any interference. At 248 nm 
Ambroxol Hydrochloride has zero absorbance, where Levocetirizine Dihydrochloride 
and Montelukast Sodium had absorbance. By correcting the interference due to 
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Montelukast Sodium at 248 nm, the Levocetirizine Dihydrochloride could be estimated.  
Hence all drugs can be estimated without prior separation. 
 Different aliquots of Montelukast Sodium, Levocetirizine Dihydrochloride and 
Ambroxol Hydrochloride were prepared in the concentration range were prepared in 
concentration range of 2 – 12 µg/ ml, 2 – 12 µg/ ml and 10 – 70 µg/ ml respectively. The 
zero order spectra was derivatised to first order derivative spectra and the absorbance 
were measured at 365.5 nm and 248 nm for Montelukast Sodium, 256.5 nm for 
Ambroxol Hydrochloride and 248 nm for Levocetirizine Dihydrochloride. The 
calibration curve was constructed with absorbance versus concentration for three drugs. 
The optical characteristics such as correlation coefficient slope, intercept, LOD and LOQ 
were calculated and regression equation was constructed for Montelukast Sodium, 
Levocetirizine Dihydrochloride and Ambroxol Hydrochloride. The correlation coefficient 
was found to be 0.9992 for Montelukast Sodium at 365.5 nm, 0.9993 and 0.9993 for 
Montelukast Sodium and Levocetirizine Dihydrochloride at 248 nm and 0.9989 for 
Ambroxol Hydrochloride at 256.5 nm respectively. At 365.5 nm the LOD and LOQ were 
found to be       0.6961 µg/ ml and 2.0883 µg/ ml for Montelukast Sodium, at 248 nm the  
LOD and LOQ were found to be 0.4483 µg/ ml and 1.3587 µg/ ml for Levocetirizine 
Dihydrochloride and 0.4568 µg/ ml and 1.3844 µg/ ml for Montelukast Sodium. At 256.5 
nm the LOD and LOQ were found to be 1.7282 µg/ ml and 5.2371 µg/ ml for Ambroxol 
Hydrochloride. The correlation coefficient values at all the selected wavelengths are 
found to be around 0.999. Hence the selected concentrations are linear and obeyed beer’s 
law. The calibration graphs for Montelukast Sodium at 365.5 nm and 248 nm are shown 
in figure 12 and 13 respectively. The calibration graph for Ambroxol Hydrochloride at 
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256.5 nm is shown in figure 14. The calibration graph for Levocetirizine Dihydrochloride 
at 248 nm is shown in figure 15.  The optical characteristics at 365.5 nm, 248 nm and 
256.5 nm are shown in tables 14, 15 and 16 respectively. 
 The capsule formulation, RENEA (containing 5 mg of Levocetirizine 
Dihydrochloride, 10 mg of Montelukast Sodium and 75 mg of Ambroxol Hydrochloride) 
was selected for analysis. The drug Montelukast Sodium, Levocetirizine Dihydrochloride 
and Ambroxol Hydrochloride are in ratio 2:1:15 in the formulation.  The percentage 
purity of drugs in the formulation was found to be 99.2 ± 0.8854 for Montelukast 
Sodium, 101.21 ± 0.8900 for Levocetirizine Dihydrochloride and 99.82 ± 1.0461 for 
Ambroxol Hydrochloride. The precision of the method was confirmed by the repeated 
analysis of the formulation for six times. The percentage RSD was calculated and the 
percentage RSD of Montelukast Sodium, Levocetirizine Dihydrochloride and Ambroxol 
Hydrochloride were found to be 0.8925, 0.8794 and 1.0479 respectively. Confidence 
Interval (95 %) were found to be 98.27 – 100.12 for Montelukast Sodium,                
100.27 – 102.14 for Levocetirizine Dihydrochloride and 98.72 – 100.91 for Ambroxol 
hydrochloride, respectively. The low percentage RSD values suggest that the method has 
good precision.  The results were shown in table 17. 
 The intermediate precision is checked by Intraday and Interday analysis.  Intraday 
and Interday analysis of formulation was done on three times on same day and one time 
on three consecutive days. The percentage RSD for the Intraday and Inter day precision 
was found to be 0.5296 and 0.0116 for Montelukast Sodium, 0.7579 and 0.1123 for 
Levocetirizine Dihydrochloride and 1.2816 and 1.2361 for Ambroxol Hydrochloride. 
Confidence Interval (95 %) were found to be 98.63 – 99.74 and 99.67 – 99.90 for 
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Montelukast Sodium, 100.50 – 101.11 and 102.60 – 102.81 for Levocetirizine 
Dihydrochloride and 99.69 – 101.40 and 99.15 – 101.76 for Ambroxol hydrochloride, for 
intraday and interday, respectively. The low percentage RSD suggests that the methods 
have a good precision.  The results of the analysis are given in table 18.   
The ruggedness of the method was validated by using different analysis and 
different instruments.  The percentage RSD for analyst 1 and analyst 2 were found to be 
0.8925 and 0.7136 for Montelukast Sodium, 0.8794 and 1.8801 for Levocetirizine 
Dihydrochloride and 1.0479 and 0.7363 for Ambroxol Hydrochloride respectively.  The 
percentage RSD value for the instrument 1 and instrument 2 were found to be 0.7053 and 
1.1018 for Montelukast Sodium, 1.7752 and 0.8363 for Levocetirizine Dihydrochloride 
and 0.8063 and 1.1839 for Ambroxol Hydrochloride, respectively. Confidence Interval 
(95 %) were found to be 98.61 – 100.08 and 98.99 – 101.3 for Montelukast Sodium, 
99.02 – 102.77 and 100.30 – 102.07 for Levocetirizine Dihydrochloride and               
99.55 – 101.24 and 99.59 – 102.1 for Ambroxol hydrochloride, for Instrument 1 and 
Instrument 2 respectively. Confidence Interval (95 %) were found to be 98.27 – 100.12 
and 98.41 – 99.90 for Montelukast Sodium, 100.27 – 102.14 and 99.16 – 103.11 for 
Levocetirizine Dihydrochloride and 98.72 – 100.19 and 98.68 – 100.21 for Ambroxol 
hydrochloride, for analyst 1 and analyst 2, respectively. The results of analysis are given 
in table 19 and 20 respectively. 
The accuracy of the method was confirmed by recovery studies.  To the pre 
analysed formulation a known quantity of the raw material is added and the percentage 
recovery was calculated. The percentage of raw material added was 80%, 100% and 
120% for Montelukast Sodium, Levocetirizine Dihydrochloride and Ambroxol 
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Hydrochloride.  The percentage recovery was found to be in the range of 97.68 to 100 % 
for Montelukast Sodium, 98.46 to 103.4 % for Levocetirizine Dihydrochloride and   
96.89 to 99.55 % for Ambroxol Hydrochloride. RSD values were found to be 0.6684, 
1.1912 and 0.8238 for Montelukast Sodium, Levocetirizine Dihydrochloride and 
Ambroxol Hydrochloride, respectively. The low percentage RSD indicated that there was 
no interference due to excepients used in formulation. Hence, the accuracy of the method 
was conformed. The data for recovery studies are given in table 21, 22 and 23. 
5.2 HPTLC METHOD 
An effort was made to develop a simple, precise and accurate method for the 
simultaneous estimation of Montelukast Sodium, Levocetirizine Dihydrochloride and 
Ambroxol Hydrochloride in bulk and in combined dosage form by HPTLC method. 
The initial separation was mode using various mobile phase using ethylacetate, 
methanol, ammonia, triethonalamine and toluene in different combinations.  Finally, 
ethylacetate: methanol: toluene: ammonia in the ratio of 7:2.5:2.5:1 v/v was selected for 
the method.  Since, all the three drugs were eluted and separated with good resolution 
between them. The optimized chromatograms are shown in figure 16, 17 and 18 for 
Montelukast Sodium, Ambroxol Hydrochloride and Levocetirizine Dihydrochloride, 
respectively.   
The detection wavelength was assigned from the spectral characters of all the 
three the drugs by comparing with standard solution and sample solution. 224 nm was 
selected as detection wavelength for the analysis. This is shown in figure 19. 400 µg/ ml 
of Montelukast Sodium, 400 µg/ ml of Levocetirizine Dihydrochloride and 1500 µg/ ml 
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of Ambroxol Hydrochloride were prepared in methanol. Form the stock solution 
concentration range of 20 to 200 µg/ ml for Montelukast Sodium, 20 to 200 µg/ ml for 
Levocetirizine Dihydrochloride and 75 to 750 µg/ ml for Ambroxol Hydrochloride were 
prepared and developed in twin through chamber. The linearity chromatograms are 
shown in figure 20 to 29. The calibration graph was plotted with concentration versus 
peak area and the correlation coefficient was found to be 0.9992, 0.9990 and 0.9993 for 
Montelukast Sodium, Levocetirizine Dihydrochloride and Ambroxol Hydrochloride, 
respectively. The calibration graph for Montelukast Sodium, Levocetirizine 
Dihydrochloride and Ambroxol Hydrochloride are shown in figure 30, 31 and 32 
respectively. The optical characteristic such as LOD, LOQ, slope, intercept, regression 
equation and correlation coefficient are shown in table 24. 
The capsule content equivalent to 75 mg of Ambroxol Hydrochloride was taken 
and dissolved in 20 ml of methanol, sonicated for 20 minutes and made up to 25 ml with 
methanol.  The solution was centrifuged at 2000 rpm for 10 min and the filtered through 
whatmann filter paper No.41. This solution was diluted to get a final solution containing 
40 µg/ ml of Montelukast Sodium, 20 µg/ ml of Levocetirizine Dihydrochloride and    
300 µg/ ml of Ambroxol Hydrochloride theoretically. The chromatogram was developed 
and peak areas were noted. The percentage purity of Montelukast Sodium, Levocetirizine 
Dihydrochloride and Ambroxol Hydrochloride were found to be 99.97 ± 0.4881,     
101.89 ± 1.6881 and 100.02 ± 0.5487 respectively. The percentage RSD values for 
Montelukast Sodium, Levocetirizine Dihydrochloride and Ambroxol Hydrochloride are 
0.4882, 1.6567 and 0.5486, respectively. Confidence Interval (95 %) were found to be 
99.45 – 100.48 for Montelukast Sodium, 100.11 – 103.66 for Levocetirizine 
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Dihydrochloride and 98.39 – 101.64 for Ambroxol hydrochloride, respectively. The 
chromatograms are given in figure 33 to 38.The data is given in table 25.  
The intermediate precision is checked by Intraday and Inter day analysis. The 
percentage RSD for Intraday and Interday precision was found to be 0.2379 and 0.5234 
for Montelukast Sodium, 1.1657 and 0.3168 for Levocetirizine Dihydrochloride and 
0.2508 and 0.3269 for Ambroxol Hydrochloride. Confidence Interval (95 %) were found 
to be 99.71 – 100.7 and 99.61 – 100.62 for Montelukast Sodium, 99.44 - 101.95 and 
101.91 – 102.31 for Levocetirizine Dihydrochloride and 100.06 – 101.03 and            
99.13 – 100.12 for Ambroxol hydrochloride, for intraday and interday, respectively. The 
low percentage RSD suggests that the method have a good precision.  The results of the 
analysis are given in table 26. 
The accuracy of the method is confirmed by recovery analysis. To the pre 
analysed formulation known quantities of standard drugs were added at three different 
concentrations.  The amount of Levocetirizine Dihydrochloride was in the range of 96.34 
to 100.73 %, 96.90 to 100 % for Montelukast Sodium and 98.17 to 100.35 % for 
Ambroxol Hydrochloride. RSD values were found to be 1.1517, 1.0042 and 0.5977 for 
Levocetirizine Dihydrochloride, Montelukast Sodium and Ambroxol Hydrochloride, 
respectively. The low RSD values indicate that there are no interference of excepients 
during the analysis. The peaks of the developed chromatogram are given in                
figure 39 to 41. The data of recovery analysis are given in table 27, 28 and 29. 
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6. SUMMARY AND CONCLUSION 
 Three simple, rapid and accurate methods were developed for the simultaneous 
estimation of Montelukast Sodium, Levocetirizine Dihydrochloride and Ambroxol 
Hydrochloride in bulk and in combined dosage forms. 
The methods developed were 
1. UV spectrophotometric method 
i. Absorption correction method 
ii. First order derivative spectroscopy 
2. HPTLC method 
6.1 UV SPECTROPHOTOMETRIC METHOD 
6.1.1 Absorbance Correction Method 
 From the solubility profile of the three drugs methanol was chosen as the common 
solvent for the simultaneous estimation of Montelukast Sodium, Levocetirizine 
Dihydrochloride and Ambroxol Hydrochloride. 
A 10 µg/ ml solution of all the three drugs and spectra were recorded from the 
overlain spectra, 345 nm, 307 nm and 230 nm were selected for the analysis. The 
concentration of 2 to 12 µg/ ml for Montelukast Sodium, 1 to 12 µg/ ml for 
Levocetirizine Dihydrochloride and 10 to 70 µg/ ml for Ambroxol Hydrochloride were 
prepared and the absorbance were measured at 345 nm, 307 nm and 230 nm.  The 
calibration graph was plotted.  The correlation coefficients for all the three drugs are 
more than 0.999.  The optical parameters like the slope, intercept, correlation coefficient, 
LOD, LOQ, sandell’s sensitivity and molar absorptivity were calculated. 
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RENEA capsule containing 10 mg of Montelukast Sodium, 5 mg of 
Levocetirizine Dihydrochloride and 75 mg of Ambroxol Hydrochloride was taken for the 
analysis.  The percentage of drugs in the formulation was found to be 100.45 ± 0.6253 for 
Montelukast Sodium, 100.38 ± 1.7426 for Levocetirizine Dihydrochloride and        
100.32 ± 1.1773 for Ambroxol Hydrochloride. Further the method was validated for 
precision, accuracy and ruggedness. The precision was confirmed by low percentage 
RSD values for Intraday and Interday analysis. The percentage RSD for Intraday and 
Inter day analysis were found to be 0.2310 and 0.2651 for Montelukast Sodium, 0.6116 
and 0.3376 for Levocetirizine Dihydrochloride and 0.8731 and 0.0300 for Ambroxol 
Hydrochloride, respectively. The ruggedness was confirmed by different instrument 
analysis and by performing the analysis with different analysts.  The percentage RSD for 
the analyst1 and analyst 2 found to be 0.6224 and 0.4666 for Montelukast Sodium, 
1.7359 and 1.8957 for Levocetirizine Dihydrochloride and 1.1735 and 0.4660 for 
Ambroxol Hydrochloride respectively. The percentage RSD for instrument 1 and 
instrument 2 are 0.6026 and 1.0188 for Montelukast Sodium, 0.8306 and 0.7499 for 
Levocetirizine Dihydrochloride and 1.2706 and 1.1656 for Ambroxol Hydrochloride 
respectively. The percentage recovery was found to be in the range of 98.45 to 100.35 % 
for Montelukast Sodium, 98.77 to 102.47 % for Levocetirizine Dihydrochloride and 
98.27 to 102.57 % for Ambroxol Hydrochloride. 
6.1.2 First Order Derivative Spectrophotometry 
 A 10 µg/ ml solution of all the three drugs and spectra were recorded. The zero 
order spectra were derivatised to first order spectra and form the overlain spectra,     
365.5 nm, 256.5 nm and 248 nm were selected for the analysis. 
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 The concentration of 2 to 12 µg/ ml for Montelukast Sodium, 2 to 12 µg/ ml for 
Levocetirizine Dihydrochloride and 10 to 70 µg/ ml for Ambroxol Hydrochloride were 
prepared and the absorbance were measured at 365.5 nm, 256.5 nm and 248 nm. The 
calibration graph was plotted. The optical parameters like the slope, intercept, correlation 
coefficient, LOD, LOQ, sandell’s sensitivity and molar absorptivity were calculated. 
RENEA capsules containing 10 mg of Montelukast Sodium, 5 mg of Levocetirizine 
Dihydrochloride and 75 mg of Ambroxol Hydrochloride was taken for the analysis. The 
percentage of drugs in the formulation was found to be 99.2 ± 0.8854 of Montelukast 
Sodium, 101.21 ± 0.8900 for Levocetirizine Dihydrochloride and 99.82 ± 1.0461 for 
Ambroxol Hydrochloride. 
Further the method was validated for precision, accuracy and ruggedness.  The 
precision was confirmed by low percentage values for Intraday and Inter day analyst. The 
percentage RSD for Intraday and Interday analysis were found to be 0.5296 and 0.0116 
for Montelukast Sodium, 0.7579 and 0.1123 for Levocetirizine Dihydrochloride and 
1.2816 and 1.2361 for Ambroxol Hydrochloride respectively. The ruggedness was 
confirmed by different instrument analysis and by performing the analysis with different 
analysts. The percentage RSD for the analyst 1 and analyst 2 were found to be        
0.8925 and 0.7136 for Montelukast Sodium, 0.8794 and 1.8801 for Levocetirizine 
Dihydrochloride and 1.0479 and 0.7363 for Ambroxol Hydrochloride, respectively. The 
percentage recovery was found to be in the range of 97.68 – 100 % for Montelukast 
Sodium, 98.46 - 103.4 % for Levocetirizine Dihydrochloride and 96.89 - 99.55% for 
Ambroxol Hydrochloride. 
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6.2 HPTLC 
 A simple and rapid HPTLC method was developed for the simultaneous 
estimation Montelukast Sodium, Levocetirizine Dihydrochloride and Ambroxol 
Hydrochloride in bulk and in combined dosage form.   
 The mobile phase consisting of ethyl acetate: methanol: toluene: ammonia in the 
ratio of 7: 2.5: 2.5: 1 % v/v was selected for analysis. With the optimized conditions, the 
linearity range was fixed as 20 - 200 µg/ ml for Montelukast Sodium, 20 - 200 µg/ ml for 
Levocetirizine Dihydrochloride and 75 - 750 µg/ ml for Ambroxol Hydrochloride. The 
correlation coefficient for all three drugs was found to be more than 0.999. The optical 
characters such as the LOD, LOQ, slope, and intercept were calculated. 
 The capsule dosage form RENEA was selected for the analysis. The percentage 
purity was found to be 99.97 ± 0.4881 for Montelukast Sodium, 101.8933 ± 1.6881 for 
Levocetirizine Dihydrochloride and 100.02 ± 0.5487 for Ambroxol Hydrochloride.  The 
percentage RSD was found to be 0.4882 for Montelukast Sodium, 1.6567 for 
Levocetirizine Dihydrochloride and 0.5486 for Ambroxol Hydrochloride. 
 The precision of the method was confirmed by low percentage RSD values for 
Intraday and Interday analysis.  The percentage RSD for Intraday and Inter day analysis 
were found to be 0.2379 and 0.5234 for Montelukast Sodium, 1.1657 and 0.3168 for 
Levocetirizine Dihydrochloride and 0.2508 and 0.3269 for Ambroxol Hydrochloride 
respectively. 
 The recovery study confirms the accuracy of the method.  The percentage 
recovery of Montelukast Sodium, Levocetirizine Dihydrochloride and Ambroxol 
Hydrochloride were in the range of 96.90 to 100 % for Montelukast Sodium,             
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96.34 to 100.73 % for Levocetirizine Dihydrochloride and 98.17 to 100.35 % for 
Ambroxol Hydrochloride. 
 The three methods were found to be accurate, precise and rapid for the 
simultaneous estimation of the drugs. This was confirmed by percentage RSD values.  
The spectrophotometric method is found to be economical when compared to HPTLC 
method. But the HPTLC method is found to be more sensitive compared to spectroscopic 
methods. The low percentage RSD value in the recovery studies suggest that the 
excepients do not interfere in the analysis of the formulation and all methods are 
accurate.  HPTLC method is found to be more sensitive than the other methods. Because 
of its linearity range, LOD and LOQ were less in HPTLC method.  Hence it is suggested 
that the three methods can be applied successfully for the routine quality control analysis 
of the drugs Montelukast Sodium, Levocetirizine Dihydrochloride and Ambroxol 
Hydrochloride in bulk and in combine formulation and the obtained result will be 
presented elsewhere. 
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FIGURE – 1 IR SPECTRUM OF AMBROXOL HYDROCHLORIDE 
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FIGURE – 2 IR SPECTRUM OF LEVOCETIRIZINE DIHYDROCHLORIDE 
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FIGURE – 3 IR SPECTRUM OF MONTELUKAST SODIUM 
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FIGURE - 4 
UV OVERLAIN SPECTRUM OF MONTELUKAST SODIUM, 
LEVOCETIRIZINE DIHYDROCHLORIDE AND AMBROXOL 
HYDROCHLORIDE IN METHANOL 
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FIGURE - 5 
CALIBRATION CURVE OF MONTELUKAST SODIUM IN  
METHANOL AT 345 nm 
(ABSORBANCE CORRECTION METHOD) 
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FIGURE – 6  
CALIBRATION CURVE OF MONTELUKAST SODIUM 
 IN METHANOL AT 307 nm 
(ABSORBANCE CORRECTION METHOD) 
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FIGURE – 7 
CALIBRATION CURVE OF MONTELUKAST SODIUM  
IN METHANOL AT 230 nm 
(ABSORBANCE CORRECTION METHOD) 
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FIGURE – 8 
CALIBRATION CURVE OF AMBROXOL HYDROCHLORIDE 
 IN METHANOL AT 307 nm 
(ABSORBANCE CORRECTION METHOD) 
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FIGURE – 9 
CALIBRATION CURVE OF AMBROXOL HYDROCHLORIDE 
 IN METHANOL AT 230 nm 
(ABSORBANCE CORRECTION METHOD) 
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FIGURE – 10   
CALIBRATION CURVE OF LEVOCETIRIZINE DIHYDROCHLORIDE  
IN METHANOL AT 230 nm 
(ABSORBANCE CORRECTION METHOD) 
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FIGURE - 11 
UV OVERLAIN SPECTRUM OF MONTELUKAST SODIUM, 
LEVOCETIRIZINE DIHYDROCHLORIDE AND AMBROXOL 
HYDROCHLORIDE IN METHANOL (FIRST ORDER DERIVATIVE) 
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FIGURE – 12  
CALIBRATION CURVE OF MONTELUKAST SODIUM 
 IN METHANOL AT 365.5 nm 
(FIRST ORDER DERIVATIVE SPECTROPHOTOMETRY) 
 
 
 
 
 
 
 
0
0.005066667
0.0306
0.015283333
0.02065
0.026183333
0.0317
y = 0.0026x - 0.0003
0
0.005
0.01
0.015
0.02
0.025
0.03
0.035
0 2 4 6 8 10 12
AB
SO
R
B
AN
C
E
CONCENTRATION [g/ ml]
  
 
 
FIGURE – 13 
CALIBRATION CURVE OF MONTELUKAST SODIUM 
 IN METHANOL AT 248 nm 
(FIRST ORDER DERIVATIVE SPECTROPHOTOMETRY) 
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FIGURE – 14  
CALIBRATION CURVE OF AMBROXOL HYDROCHLORIDE 
 IN METHANOL AT 256.5 nm 
(FIRST ORDER DERIVATIVE SPECTROPHOTOMETRY) 
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FIGURE – 15  
CALIBRATION CURVE OF LEVOCETIRIZINE DIHYDROCHLORIDE 
 IN METHANOL AT 248 nm 
(FIRST ORDER DERIVATIVE SPECTROPHOTOMETRY) 
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FIGURE – 16 
OPTIMIZED CHROMATOGRAM FOR MONTELUKAST SODIUM (200 ng)  
 
Peak Start 
Rf 
Start 
height 
Max 
Rf 
Max 
height 
Max 
% 
End Rf End 
height 
Area Area 
% 
Substance 
1. 0.56 1.3 0.58 90.61 100 0.60 1.1 3451.07 100 MON  
 
 
 
RETENTION FACTOR 
P
E
A
K
 
A
R
E
A 
 
  
 
 
FIGURE – 17 
OPTIMIZED CHROMATOGRAM FOR AMBROXOL HYDROCHLORIDE  
(200 ng)  
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FIGURE – 18  
OPTIMIZED CHROMATOGRAM FOR LEVOCETIRIZINE 
DIHYDROCHLORIDE (200 ng) 
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FIGURE – 19 
OVERLAIN UV – SPECTRUM OF MONTELUKAST SODIUM, AMBROXOL 
HYDROCHLORIDE AND AMBROXOL HYDROCHLORIDE FOR THE 
SELECTION OF DETECTION WAVELENGTH  
 
 
 
 
 
  
 
 
FIGURE - 20 
LINEARITY CHROMATOGRAM OFMONTELUKAST SODIUM, 
LEVOCETIRIZINE DIHYDROCHLORIDE AND                                  
AMBROXOL HYDROCHLORIDE (20, 20, 75 ng) 
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2. 0.56 2.6 0.59 32.1 44.01 0.61 1.9 431.32 37.98  MON 
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FIGURE – 21 
LINEARITY CHROMATOGRAM OFMONTELUKAST SODIUM, 
LEVOCETIRIZINE DIHYDROCHLORIDE AND                                   
AMBROXOL HYDROCHLORIDE (40, 40, 150 ng) 
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FIGURE – 22  
LINEARITY CHROMATOGRAM OFMONTELUKAST SODIUM, 
LEVOCETIRIZINE DIHYDROCHLORIDE AND                                  
AMBROXOL HYDROCHLORIDE (60, 60, 225 ng) 
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FIGURE – 23  
LINEARITY CHROMATOGRAM OFMONTELUKAST SODIUM, 
LEVOCETIRIZINE DIHYDROCHLORIDE AND                                 
AMBROXOL HYDROCHLORIDE (80, 80, 300 ng) 
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FIGURE – 24  
LINEARITY CHROMATOGRAM OFMONTELUKAST SODIUM, 
LEVOCETIRIZINE DIHYDROCHLORIDE AND                                  
AMBROXOL HYDROCHLORIDE (100, 100, 375 ng) 
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FIGURE – 25  
LINEARITY CHROMATOGRAM OFMONTELUKAST SODIUM, 
LEVOCETIRIZINE DIHYDROCHLORIDE AND                                    
AMBROXOL HYDROCHLORIDE (120, 120, 450 ng) 
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FIGURE – 26  
LINEARITY CHROMATOGRAM OFMONTELUKAST SODIUM, 
LEVOCETIRIZINE DIHYDROCHLORIDE AND                                  
AMBROXOL HYDROCHLORIDE (140, 140, 525 ng) 
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FIGURE – 27 
LINEARITY CHROMATOGRAM OFMONTELUKAST SODIUM, 
LEVOCETIRIZINE DIHYDROCHLORIDE AND                                  
AMBROXOL HYDROCHLORIDE (160, 160, 600 ng) 
 
Peak Start 
Rf 
Start 
height 
Max 
Rf 
Max 
height 
Max 
% 
End Rf End 
height 
Area Area 
% 
Substance 
1. 0.18 3.3 0.2   41.1 25.77 0.22 3.6 2043.56 26.54  LEVO  
2. 0.56 2.6 0.59 112.1 44.01 0.61 1.9 2888.21 35.43  MON 
3. 0.76 1.4 0.78  78.1 37.36 0.79 0.9 2598.23 35.61  AMB 
 
RETENTION FACTOR 
P
E
A
K
 
A
R
E
A 
  
 
 
FIGURE – 28 
LINEARITY CHROMATOGRAM OFMONTELUKAST SODIUM, 
LEVOCETIRIZINE DIHYDROCHLORIDE AND                                  
AMBROXOL HYDROCHLORIDE (180, 180, 675 ng) 
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2. 0.56 2.6 0.59 129.1 44.01 0.63 1.9 3266.87 33.76  MON 
3. 0.76 1.4 0.79 88.9 37.36 0.81 0.9 2799.87 32.43  AMB 
 
RETENTION FACTOR 
P
E
A
K
 
A
R
E
A 
  
 
 
FIGURE – 29  
LINEARITY CHROMATOGRAM OFMONTELUKAST SODIUM, 
LEVOCETIRIZINE DIHYDROCHLORIDE AND                                   
AMBROXOL HYDROCHLORIDE (200, 200, 750 ng) 
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FIGURE – 30 
CALIBRATION CURVE OF AMBROXOL HYDROCHLORIDE  
BY HPTLC 
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FIGURE – 31 
CALIBRATION CURVE OF LEVOCETIRIZINE DIHYDROCHLORIDE  
BY HPTLC 
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FIGURE – 32  
CALIBRATION CURVE OF MONTELUKAST SODIUM BY HPTLC 
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FIGURE – 33  
ANALYSIS OF FORMULATION – RENEA 
REPEATABILITY - 1 
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2. 0.56 2.6 0.59 33.1 44.01 0.62 0.67  772.7 32.21  MON 
3. 0.76 1.4 0.78 47.6 37.36 0.79 0.5 1298.9 51.21  AMB 
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FIGURE – 34 
ANALYSIS OF FORMULATION - RENEA  
REPEATABILITY – 2  
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1. 0.18 3.3 0.20 15.3 25.77 0.22 1.2  253.3 25.24  LEVO  
2. 0.56 2.6 0.59 32.1 44.01 0.61 0.7  776.7 31.4  MON 
3. 0.76 1.4 0.78 48.1 37.36 0.79 0.2 1291.9 51.23  AMB 
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FIGURE – 35  
ANALYSIS OF FORMULATION – RENEA 
REPEATABILITY - 3 
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1. 0.18 3.3 0.21 13.4 25.77 0.22 2.9  256.6 21.34  LEVO  
2. 0.56 2.6 0.59 32.1 44.01 0.61 1.4  771.7 36.2  MON 
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FIGURE – 36 
ANALYSIS OF FORMULATION – RENEA 
REPEATABILITY - 4 
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height 
Max 
Rf 
Max 
height 
Max 
% 
End Rf End 
height 
Area Area 
% 
Substance 
1. 0.18 3.3 0.21 15.1 25.77 0.22 2.2  260.6 19.32  LEVO  
2. 0.56 2.6 0.59 32.1 44.01 0.61 0.8  766.7 35.21  MON 
3. 0.76 1.4 0.78 47.9 37.36 0.79 1.7 1292.9 51.21  AMB 
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FIGURE – 37  
ANALYSIS OF FORMULATION – RENEA 
REPEATABILITY – 5  
 
Peak Start 
Rf 
Start 
height 
Max 
Rf 
Max 
height 
Max 
% 
End Rf End 
height 
Area Area 
% 
Substance 
1. 0.18 3.3 0.20 15.6 25.77 0.22 0.9   261.2 20.65  LEVO  
2. 0.56 2.6 0.59 32.1 44.01 0.61 1.1   769.9 35.21  MON 
3. 0.76 1.4 0.78 49.9 37.36 0.79 1.3 1287.9 51.11  AMB 
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FIGURE – 38 
ANALYSIS OF FORMULATION – RENEA 
REPEATABILITY - 6 
 
Peak Start 
Rf 
Start 
height 
Max 
Rf 
Max 
height 
Max 
% 
End Rf End 
height 
Area Area 
% 
Substance 
1. 0.18 3.3 0.21 13.9 25.77 0.22 0.2  262.3 20.31  LEVO  
2. 0.56 2.6 0.59 32.1 44.01 0.61 1.2  769.1 35.31  MON 
3. 0.76 1.4 0.78 45.6 37.36 0.79 0.76 1279.9 52.1  AMB 
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FIGURE – 39 
RECOVERY ANALYSIS OF FORMULATION- RENEA  
RECOVERY - 1 
 
 
Peak Start 
Rf 
Start 
height 
Max 
Rf 
Max 
height 
Max 
% 
End Rf End 
height 
Area Area 
% 
Substance 
1. 0.18 3.3 0.20 17.6 16.83 0.24 4.2  487.54 15.31  LEVO  
2. 0.56 2.6 0.59 35.21 35.21 0.63 1.2 1317.4 35.54  MON 
3. 0.76 1.4 0.78 71.8 32.12 0.83 0.56 2292.23 50.32  AMB 
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FIGURE – 40 
RECOVERY ANALYSIS OF FORMULATION- RENEA  
RECOVERY - 2 
 
Peak Start 
Rf 
Start 
height 
Max 
Rf 
Max 
height 
Max 
% 
End Rf End 
height 
Area Area 
% 
Substance 
1. 0.18 3.3 0.21 18.6 25.77 0.22 1.2  509.89 14.21  LEVO  
2. 0.56 2.6 0.59 81.4 44.01 0.61 2.6 1446.1 36.21  MON 
3. 0.76 1.4 0.78 83.5 37.36 0.81 2.1 2543.54 50.21  AMB 
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FIGURE – 41 
RECOVERY ANALYSIS OF FORMULATION- RENEA  
RECOVERY - 3 
 
Peak Start 
Rf 
Start 
height 
Max 
Rf 
Max 
height 
Max 
% 
End Rf End 
height 
Area Area 
% 
Substance 
1. 0.18 3.3 0.20 21.2 25.77 0.22 1.6  537.98 15.2  LEVO  
2. 0.56 2.6 0.59 83.2 44.01 0.61 0.6 1586.2 34.21  MON 
3. 0.76 1.4 0.78 96.3 37.36 0.79 1.2 2798.98 48.91  AMB 
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TABLE-1 
SOLUBILITY PROFILE OF MONTELUKAST SODIUM  
IN POLAR AND NON-POLAR SOLVENTS 
S.No. SOLVENTS EXTENT OF 
SOLUBILITY 
CATEGORY 
1 Distilled water 10 mg in 100l Freely soluble 
2 0.1M Hydrochloric acid 10 mg in more than  10 ml Insoluble 
3 0.1M Sodium Hydroxide 10 mg in more than 10 ml Insoluble 
4 Methanol 10 mg in 20l Freely soluble 
5 Ethanol 10 mg in 40l Freely soluble 
6 Chloroform 10 mg in 30l     Freely soluble 
7  DMF  10 mg in 60l Freely soluble 
8 Acetone 10 mg in 30l Freely soluble 
9 Toluene 10 mg in 50l Freely soluble 
10 n – Butanol 10 mg in 1.1 ml Slightly soluble 
11 Acetonitrile 10 mg in 40l Freely soluble 
12 n – Hexane 10 mg in more than 10 ml Insoluble 
13 Isopropyl alcohol 10 mg in 1.2 ml Slightly soluble 
14 Ethyl acetate 10 mg in 60l Freely Soluble 
15 Diethyl ether 10 mg in more than 10 ml Insoluble 
16 Pthalate buffer (pH 3.0) 10 mg in more than 10 ml Insoluble 
17 Pthalate buffer (pH 5.0) 10 mg in more than 10 ml Insoluble 
18 Phosphate buffer (pH 7.0) 10 mg in more than10 ml Insoluble 
19 Borate buffer (pH 9.0) 10 mg in1.9 ml Slightly soluble 
20 Benzene  10 mg in1.9 ml Slightly Soluble 
21 Dichloromethane 10 mg in 20l Freely soluble 
  
 
TABLE-2 
SOLUBILITY PROFILE OF LEVOCETIRIZINE DIHYDROCHLORIDE 
IN POLAR AND NON-POLAR SOLVENTS 
S.No. SOLVENTS EXTENT OF 
SOLUBILITY 
CATEGORY 
1 Distilled water 10 mg in 20l  Freely soluble 
2 0.1M Hydrochloric acid 10 mg in 50 l Freely soluble 
3 0.1M Sodium Hydroxide 10 mg in more than 1 ml Sparingly soluble 
4 Methanol 10 mg in 20l Freely Soluble 
5 Ethanol 10 mg in 60l  Freely soluble 
6 Chloroform 10 mg in more than10 ml         Insoluble 
7  DMF  10 mg in 60l Freely soluble 
8 Acetone 10 mg in more than 10 ml Insoluble 
9 Toluene 10 mg in more than 10 ml Insoluble 
10 n – Butanol 10 mg in 5 ml Slightly Soluble 
11 Acetonitrile 10 mg in more than 10 ml  Insoluble 
12 Benzene  10 mg in more than 10 ml Insoluble 
13 Isopropyl alcohol 10 mg in more than 10 ml In soluble 
14 Dichloro methane 10 mg in more than 10 ml In soluble 
15 10% Glacial acetic acid 10 mg in  1.3 ml Slightly soluble 
16 Phthalate buffer (pH 3.0) 10 mg in  ml 20 l Freely soluble 
17 Phthalate buffer (pH 5.0) 10 mg in 40 l  Freely soluble 
18  Phosphate buffer (pH 7.0) 10 mg in 10 l Freely soluble 
19 Borate buffer (pH 9.0) 10 mg in 60 l Freely soluble 
20 Benzene  10 mg in more than 10 ml  Insoluble 
21 Diethyl ether 10 mg of solute in 40 l Freely soluble 
  
 
TABLE – 3  
SOLUBILITY PROFILE OF AMBROXOL HYDROCHLORIDE  
IN POLAR AND NONPOLAR SOLVENTS 
S.No. SOLVENTS EXTENT OF 
SOLUBILITY 
CATEGORY 
1 Distilled water 10 mg in 600l Sparingly soluble 
2 0.1M Hydrochloric acid 10 mg in 1 ml Sparingly soluble 
3 0.1M Sodium Hydroxide 10 mg in more than 10 ml In soluble 
4 Methanol 10 mg in 80l Freely soluble 
5 Ethanol 10 mg in 500l Sparingly soluble 
6 Chloroform 10 mg in more than 10 ml         In soluble 
7  DMF  10 mg in 60l Freely soluble 
8 Acetone 10 mg in more than 10 ml Insoluble 
9 Toluene 10 mg in more than 10 ml Insoluble 
10 n – Butanol 10 mg in 8 ml Slightly Soluble 
11 Acetonitrile 10 mg in more than 10 ml  Insoluble 
12 n-Hexane 10 mg in more than 10 ml Insoluble 
13 Isopropyl alcohol 10 mg in 5 ml Slightly soluble 
14 Ethyl acetate 10 mg in more than 10 ml In soluble 
15 10% Glacial acetic acid 10 mg in 1 ml Sparingly soluble 
16 Phthalate buffer (pH 3.0) 10 mg in 1 ml Sparingly soluble 
17 Phthalate buffer (pH 5.0) 10 mg in 5 ml  Slightly soluble 
18  Phosphate buffer (pH 7.0) 10 mg in 7 ml Slightly soluble 
19 Borate buffer (pH 9.0) 10 mg in 7 ml Slightly soluble 
20 Benzene  10 mg in more than 10 ml  Insoluble 
21 Dichloro methane 10 mg in more than 10 ml In soluble 
  
 
TABLE - 4  
 
OPTICAL CHARACTERISTICS OF MONTELUKAST SODIUM AT 345 nm  
BY ABSORBANCE CORRECTION METHOD 
 
PARAMETERS MONTELUKAST SODIUM at 345 nm* 
Beer’s law limit (μg/ ml) 2 - 12 
Molar Absorptivity 
(L mol-1 cm-1) 
28636.06094 
Sandell’s Sensitivity 
(μg/ cm2/0.001 A.U.) 
0.021560459 
Correlation Coefficient (r) 0.9994 
Regression Equation (y=mx+c) Y=0.0467x+0.0031847 
Slope (m) 0.0467671 
Intercept (c) 0.00318476 
LOD (μg/ ml) 0.6755608 
LOQ (μg/ ml) 2.047154 
Standard Error 0.00092495 
 
 * Mean of six observations 
 
 
 
 
  
 
TABLE - 5  
 
OPTICAL CHARACTERISTICS OF MONTELUKAST SODIUM 
 AND AMBROXOL HYDROCHLORIDE AT 307 nm  
BY ABSORBANCE CORRECTION METHOD 
 
PARAMETERS 
MONTELUKAST 
SODIUM 
at 307 nm* 
AMBROXOL 
HYDROCHLORIDE 
at 307 nm* 
Beer’s law limit 
 (μg/ ml) 
2 - 12 10 - 70 
Molar Absorptivity 
(L mol-1 cm-1) 
13685.1577 2999.211464 
Sandell’s Sensitivity 
(μg/ cm2/0.001 A.U.) 
0.026588916 0.140949722 
Correlation Coefficient 
(r) 0.9990 0.9994 
Regression Equation 
(y=mx+c) Y=0.0379x-0.000357 Y = 0.0071039+0.0013 
Slope (m) 0.037961607 0.007103988 
Intercept (c) -0.00357616 0.0013 
LOD (μg/ ml) 0.4205930 1.61590329 
LOQ (μg/ ml) 1.261494 4.896676 
Standard Error 0.00770206 0.00041593 
 
 * Mean of six observations 
 
 
 
  
 
TABLE - 6 
 
OPTICAL CHARACTERISTICS OF MONTELUKAST SODIUM, 
LEVOCETIRIZINE DIHYDROCHLORIDE AND  
AMBROXOL HYDROCHLORIDE AT 230 nm  
BY ABSORBANCE CORRECTION METHOD 
 
PARAMETERS 
MONTELUKAST 
SODIUM 
at 230 nm* 
LEVOCETIRIZINE 
DIHYDROCHLORIDE 
at 230 nm* 
AMBROXOL 
HYDROCHLORIDE 
at 230 nm* 
Beer’s law limit 
(μg/ ml) 2 – 12 1 – 12 10 - 70 
Molar 
Absorptivity 
(L mol-1 cm-1) 
30329.57404 11876.57714 8796.3211 
Sandell’s 
Sensitivity 
(μg/ cm2/0.001 
A.U.) 
0.0184409 0.033291836 0.0678888 
Correlation 
Coefficient (r) 0.9991 0.9994 0.9993 
Regression 
Equation 
(y=mx+c) 
Y=0.0545x-0.0025 Y =  0.0300x+0.0049126 Y = 0.0147+0.00535 
Slope (m) 0.05454 0.0030048413 0.001473956 
Intercept (c) -0.00252916 0.00491267 0.00535015 
LOD (μg/ ml) 0.413010 0.0528027375 1.1978301 
LOQ (μg/ ml) 1.25254 0.16000829 3.629788 
Standard Error 0.010383 0.000482027 0.0141386 
 
* Mean of six observations 
  
 
TABLE – 7 
 
QUANTIFICATION OF FORMULATION (RENEA)  
BY ABSORBANCE CORRECTION METHOD 
Drug 
Sample 
No. 
Labelled 
amount 
(mg/tab) 
Amount 
found 
(mg/tab)* 
Percentage 
Obtained* 
 
Average 
(%)  ± 
SD 
 
% RSD SE 
 
 
CI@ 
MON 
 
1 
2 
3 
4 
5 
6 
10 
10 
10 
10 
10 
10 
10.11 
10.11 
10.05 
10.05 
10.00 
9.95 
101.1 
101.1 
100.5 
100.5 
100.00 
99.5 
100.45 
± 
0.6253 
0.6224 0.0173 
 
99.79 
to 
101.10 
LEVO 
 
 
1 
2 
3 
4 
5 
6 
5 
5 
5 
5 
5 
5 
5.09 
4.94 
5.02 
4.90 
5.05 
5.12 
101.83 
98.8 
100.05 
98.06 
101 
102.55 
100.38 
± 
1.74261 
1.7359 0.0484 
98.55 
to 
102.20 
AMB 
1 
2 
3 
4 
5 
6 
75 
75 
75 
75 
75 
75 
73.75 
75.2 
75.42 
75.81 
76.36 
74.96 
98.33 
100.26 
100.50 
101.08 
101.81 
99.95 
100.32 
± 
1.1773 
1.1735 0.0327 
 
 
99.08 
to 
101.55 
 
MON = Montelukast Sodium, LEVO = Levocetirizine Dihydrochloride,  
AMB = Ambroxol Hydrochloride 
     * Mean of six observations 
      CI@ = confidence interval (95 %) 
  
 
TABLE – 8 
 
INTRADAY AND INTERDAY ANALYSIS OF FORMULATION  
(RENEA) BY ABSORBANCE CORRECTION METHOD 
 
Drug Sample No. 
Labelled 
amount 
(mg/tab) 
Percentage obtained* ± SD % RSD 
Intraday  
 
Interday 
 
Intra 
day 
Inter 
 day 
Intra 
day 
Inter 
day 
MON 
1 
2 
3 
10 
10 
10 
100.1 
99.7 
100.1 
100.1 
99.6 
99.7 
0.2309 0.2645 0.2310 0.2651 
Mean 
Confidence interval (95 %) 
99.96 
99.71-100.20 
99.8 
99.52-100.07 
 
LEVO 
1 
2 
3 
5 
5 
5 
102.3 
102.6 
101.4 
102.4 
103 
102.4 
0.6245 0.3464 0.6116 0.3376 
Mean 
Confidence interval (95 %) 
102.1 
101.4-102.75 
102.6 
102.23-103.61 
 
AMB 
1 
2 
3 
75 
75 
75 
102.5 
100.8 
102.1 
101.52 
101.56 
101.58 
0.8888 0.0305 0.8731 0.0300 
Mean 
Confidence interval (95 %) 
101.8 
100.86-102.73 
101.55 
101.51-101.58 
 
 
MON = Montelukast Sodium, LEVO = Levocetirizine Dihydrochloride,  
AMB = Ambroxol Hydrochloride 
*Mean of three observations 
 
  
 
TABLE – 9 
 
RUGGEDNESS STUDY OF FORMULATION (RENEA) BY    
 ABSORBANCE CORRECTION METHOD 
(DIFFERENT ANALYST) 
 
S. 
No Drug Condition 
Mean 
%* ± SD 
% 
RSD SE CI
@ 
1 
Montelukast 
Sodium 
Analyst 1 100.45 0.6253 0.6224 0.0173 
99.79 to 
101.10 
2 Analyst 2 99.6 0.4648 0.4666 0.0729 
99.11 to 
100.08 
3 
Levocetirizine 
Dihydrochloride 
Analyst 1 100.38 1.7426 1.7359 0.0484 
98.55 to 
102.20 
4 Analyst 2 101.74 1.9288 1.8957 0.0535 
99.71 to 
103.76 
5 
Ambroxol 
Hydrochloride 
Analyst 1 100.32 1.1773 1.1735 0.0327 
99.08 to 
101.55 
6 Analyst 2 101.68 0.4739 0.4660 0.0131 
101.18 to 
102.17 
 
*Mean of six observations 
CI@ = confidence interval (95 %) 
 
 
 
 
 
 
 
 
 
  
 
TABLE – 10 
 
RUGGEDNESS STUDY OF FORMULATION (RENEA) BY    
 ABSORBANCE CORRECTION METHOD 
(DIFFERENT INSTRUMENT) 
 
S. 
No 
Drug Condition 
Mean 
%* 
± SD 
% 
RSD 
SE 
 
CI@ 
1 
Montelukast 
Sodium 
Instrument 1 99.32 0.5980 0.6026 0.0166 
98.69 to 
99.94 
2 Instrument  2 99.98 1.0186 1.0188 0.0282 
98.91 to 
101.05 
3 
Levocetirizine 
Dihydrochloride 
Instrument  1 101.50 0.8431 0.8306 0.0234 
100.61 to 
102.38 
4 Instrument 2 101.89 0.7640 0.7499 0.0212 
101.08 to 
102.69 
5 
Ambroxol 
Hydrochloride 
Instrument 1 100.01 1.2708 1.2706 0.0353 
98.07 to 
101.34 
6 Instrument  2 99.65 1.1617 1.1656 0.0332 
98.43 to 
100.87 
 
*Mean of six observations 
CI@ = confidence interval (95 %) 
 
 
 
 
 
 
 
 
 
  
 
TABLE – 11 
 
RECOVERY ANALYSIS OF FORMULATION – RENEA BY 
 ABSORBANCE CORRECTION METHOD (80 % Recovery) 
 
MON = Montelukast Sodium, LEVO = Levocetirizine Dihydrochloride,  
AMB = Ambroxol Hydrochloride 
*Mean of three observations 
CI@ = confidence interval (95 %) 
 
 
 
Drug Sample No 
Amount 
present 
(µg/ml) 
Amount 
added 
(µg/ml) 
Amount 
recovered 
(µg/ml) 
% Recovered* SD % RSD 
 
 
MON 
1 
2 
3 
6.94 
6.87 
6.83 
2.91 
2.84 
2.84 
2.92 
2.85 
2.81 
100.34 
100.35 
98.94 
 
0.8111 
 
 
0.8121 
 
 Mean 
CI@ 
99.87 
99.01 – 100.72 
 
LEVO 
1 
2 
3 
3.53 
3.52 
3.33 
1.51 
1.53 
1.35 
1.52 
1.51 
1.32 
100.66 
98.69 
97.77 
 
1.4764 
 
 
1.4907 
Mean 
CI@ 
99.04 
97.49 – 100.58 
 
AMB 
1 
2 
3 
53.85 
53.05 
54.43 
 
24.05 
23.05 
24.51 
23.78 
23.05 
24.51 
98.87 
99.26 
98.27 
 
0.4986 
 
0.5047 
Mean 
CI@ 
98.8 
98.27 – 99.32 
  
 
TABLE – 12 
 
RECOVERY ANALYSIS OF FORMULATION – RENEA 
BY ABSORPTION CORRRECTION METHOD (100 % Recovery) 
 
MON = Montelukast Sodium, LEVO = Levocetirizine Dihydrochloride,  
AMB = Ambroxol Hydrochloride 
*Mean of three observations 
CI@ = confidence interval (95 %) 
 
 
Drug Sample No 
Amount 
present 
(µg/ml) 
Amount 
added 
(µg/ml) 
Amount 
recovered 
(µg/ml) 
% Recovered* SD % RSD 
 
 
MON 
1 
2 
3 
8.49 
8.53 
8.49 
4.52 
4.55 
4.54 
4.47 
4.51 
4.47 
98.89 
99.12 
98.45 
 
0.3404 
 
 
0.3445 
 
 Mean 
CI@ 
98.82 
98.46 – 99.17 
 
LEVO 
1 
2 
3 
4.92 
4.80 
4.97 
 
2.88 
2.80 
2.89 
2.91 
2.79 
2.96 
101.04 
99.64 
102.42 
 
1.3900 
 
 
1.3857 
Mean 
CI@ 
101.03 
99.57 – 102.48 
 
AMB 
1 
2 
3 
59.80 
60.06 
60.34 
 
29.08 
29.72 
29.95 
29.83 
30.09 
30.37 
102.57 
101.24 
101.40 
 
0.7261 
 
0.7137 
Mean 
CI@ 
101.73 
100.96 – 102.49 
  
 
TABLE – 13 
 
RECOVERY ANALYSIS OF FORMULATION – RENEA 
BY ABSORBANCE CORRECTION METHOD (120 % Recovery) 
 
MON = Montelukast Sodium, LEVO = Levocetirizine Dihydrochloride,  
AMB = Ambroxol Hydrochloride 
*Mean of three observations 
CI@ = confidence interval (95 %) 
 
 
 
Drug Sample No 
Amount 
present 
(µg/ml) 
Amount 
added 
(µg/ml) 
Amount 
recovered 
(µg/ml) 
% Recovered* SD % RSD 
 
MON 
1 
2 
3 
9.97 
9.95 
9.95 
 
6.02 
5.97 
5.93 
5.95 
5.93 
5.93 
98.83 
99.32 
100 
 
0.5875 
 
 
0.5912 
 
 Mean 
CI@ 
99.38 
98.76 – 99.17 
 
LEVO 
1 
2 
3 
6.59 
6.56 
6.59 
 
4.49 
4.59 
4.53 
4.58 
4.55 
4.58 
102.00 
99.12 
101.10 
 
1.4733 
 
 
1.4625 
Mean 
CI@ 
100.74 
99.19 – 102,28 
 
AMB 
1 
2 
3 
66.08 
66.17 
66.24 
 
36.18 
36.20 
36.27 
36.11 
36.20 
36.27 
99.80 
100.22 
100.69 
 
0.4452 
 
0.4441 
Mean 
CI@ 
100.23 
99.76 – 100.69 
  
 
 
TABLE- 14  
 
OPTICAL CHARACTERISTICS OF MONTELUKAST SODIUM AT 365.5 nm 
BY FIRST ORDER DERIVATIVE SPECTROPHOTOMETRY 
PARAMETERS MONTELUKAST SODIUM at 365.5 nm* 
Beer’s law limit (μg/ml) 2 - 12 
Molar Absorptivity 
(L mol-1 cm-1) 
1589.63088 
Sandell’s Sensitivity 
(μg/ cm2/0.001 A.U.) 
0.381473795 
Correlation Coefficient (r) 0.9992 
Regression Equation (y=mx+c) Y=0.0026x+(-0.00028) 
Slope (m) 0.00264273 
Intercept (c) -0.0002894 
LOD (μg/ml) 0.69616629 
LOQ (μg/ml) 2.0883827 
Standard Error 0.00009362 
 
  *Mean of six observations 
 
 
 
 
  
 
 
TABLE- 15 
 
OPTICAL CHARACTERISTICS OF AMBROXOL HYDROCHLORIDE  
AT 256.5 nm BY FIRST ORDER DERIVATIVE SPECTROSCOPY 
 
PARAMETERS 
AMBROXOL 
HYDROCHLORIDE 
at 256.5 nm* 
Beer’s law limit (μg/ml) 10 - 70 
Molar Absorptivity 
(L mol-1 cm-1) 
726.528916 
Sandell’s Sensitivity 
(μg/ cm2/0.001 A.U.) 
0.5697066 
Correlation Coefficient (r) 0.9989 
Regression Equation (y= mx+c) Y = 0.001761+0.00009027 
Slope (m) 0.00176138 
Intercept (c) 0.000090277 
LOD (μg/ml) 1.728272 
LOQ (μg/ml) 5.237189 
Standard Error 0.0001965 
 
  *Mean of six observations 
 
 
 
  
 
TABLE- 16  
 
OPTICAL CHARACTERISTICS OF MONTELUKAST SODIUM AND 
LEVOCETIRIZINE HYDROCHLORIDE AT 248 nm 
BY FIRST ORDER DERIVATIVE SPECTROSCOPY 
 
PARAMETERS 
MONTELUKAST 
SODIUM 
at 248 nm* 
LEVOCETIRIZINE 
DIHYDROCHLORIDE 
at 248 nm* 
Beer’s law limit (μg/ml) 2 - 12 2 - 12 
Molar Absorptivity 
(L mol-1 cm-1) 
372.832369 259.3062 
Sandell’s Sensitivity 
(μg/ cm2/0.001 A.U.) 
1.503564 1.50551854 
Correlation Coefficient 
(r) 0.9993 0.9993 
Regression Equation 
(y=mx+c) Y=0.0006x+(-0.000016) Y =  0.00066x+0.000013690 
Slope (m) 0.000669 0.0006681 
Intercept (c) -0.00001666 0.000013690 
LOD (μg/ml) 0.4568765 0.4483850 
LOQ (μg/ml) 1.384474 1.3587425 
Standard Error 0.000116 0.000012426 
 
*Mean of six observations 
 
 
  
 
TABLE – 17 
 
QUANTIFICATION OF FORMULATION (RENEA)  
BY FIRST ORDER DERIVATIVE SPECTROSCOPY 
 
Drug 
Sample 
No. 
Labelled 
amount 
(mg/tab) 
Amount 
found 
(mg/tab)* 
Percentage 
Obtained* 
Average 
(%)        
± SD 
% 
RSD 
SE 
 
CI@ 
 
MON 
 
1 
2 
3 
4 
5 
6 
10 
10 
10 
10 
10 
10 
10.06 
9.99 
9.85 
9.92 
9.85 
9.85 
100.6 
99.9 
98.5 
99.2 
98.5 
98.5 
99.2 
± 
0.8854 
0.8925 0.0245 
 
 
98.27     
to   
100.12  
 
 
LEVO 
 
 
1 
2 
3 
4 
5 
6 
5 
5 
5 
5 
5 
5 
5.04 
5.14 
5.03 
5.06 
5.02 
5.02 
101.6 
102.8 
100.57 
101.2 
100.55 
100.55 
101.21 
± 
0.8900 
0.8794 0.0247 
 
 
100.27   
to    
102.14 
AMB 
1 
2 
3 
4 
5 
6 
75 
75 
75 
75 
75 
75 
75.47 
75.9 
74.97 
75.13 
74.34 
73.64 
100.62 
100.93 
99.99 
100.17 
99.12 
98.1 
99.82 
± 
1.0461 
1.0479 0.0290 
 
 
98.72     
to   
100.91 
 
MON = Montelukast Sodium, LEVO = Levocetirizine Dihydrochloride,  
AMB = Ambroxol Hydrochloride 
*Mean of six observations 
CI@ = confidence interval (95 %) 
 
 
  
 
TABLE – 18 
 
INTRADAY AND INTERDAY ANALYSIS OF FORMULATION  
(RENEA) BY FIRST ORDER DERIVATIVE SPECTROSCOPY 
 
Drug Sample No. 
Labelled 
amount 
(mg/tab) 
Percentage obtained* ± SD % RSD 
Intraday 
(mg) 
Interday 
(mg) 
Intra 
day 
Inter 
 day 
Intra 
day 
Inter 
day 
MON 
1 
2 
3 
10 
10 
10 
98.8 
99.8 
98.8 
98.9 
98.8 
98.9 
0.5253  0.0115 0.5296 0.0116 
Mean 
Confidence interval (95 %) 
99.19 
98.63-99.74 
98.89 
99.67-99.90 
 
LEVO 
1 
2 
3 
5 
5 
5 
100.89 
102.2 
100.89 
102.8 
102.6 
102.8 
0.7678 0.1154 0.7579 0.1123 
Mean 
Confidence interval (95 %) 
101.31 
100.50-102.11 
102.73 
102.60-102.85 
 
AMB 
1 
2 
3 
75 
75 
75 
100.48 
100.15 
102.54 
99.79 
101.9 
99.71 
1.2951 1.2419 1.2816 1.2361 
Mean         
 Confidence interval (95 %) 
101.05 
99.69-102.409 
100.46 
99.15-101.76 
 
 
 
MON = Montelukast Sodium, LEVO = Levocetirizine Dihydrochloride,  
AMB = Ambroxol Hydrochloride 
*Mean of three observations 
 
  
 
TABLE – 19 
 
RUGGEDNESS STUDY OF FORMULATION (RENEA) BY    
 FIRST ORDER DERIVATIVE SPECTROSCOPY 
(DIFFERENT ANALYST) 
 
S. 
No 
Drug Condition 
Mean 
%* 
± SD 
% 
RSD 
SE 
 
CI@ 
1 
Montelukast 
Sodium 
Analyst 1 99.2 0.8854 0.8925 0.0245 
98.27 to 
100.12 
2 Analyst 2 99.16 0.7076 0.7136 0.0196 
98.41 to 
99.90 
3 
Levocetirizine 
Dihydrochloride 
Analyst 1 101.21 0.8900 0.8794 0.0247 
100.27 to 
102.14 
4 Analyst 2 101.14 1.8824 1.8801 0.0522 
99.16 to 
103.11 
5 
Ambroxol 
Hydrochloride 
Analyst 1 99.82 1.0461 1.0479 0.0290 
98.72 to 
100.19 
6 Analyst 2 99.45 0.7324 0.7363 0.0203 
98.68 to 
100.21 
 
 *Mean of six observations 
CI@ = confidence interval (95 %) 
 
 
 
 
 
 
 
 
 
 
  
 
TABLE – 20 
 
RUGGEDNESS STUDY OF FORMULATION (RENEA) BY    
 FIRST ORDER DERIVATIVE SPECTROSCOPY 
(DIFFERENT INSTRUMENT) 
 
S. 
No 
Drug Condition 
Mean 
%* 
± SD 
% 
RSD 
SE 
 
CI@ 
1 
Montelukast 
Sodium 
Instrument 1 99.35 0.7007 0.7053 0.0194 
98.61 to 
100.08 
2 Instrument  2 100.15 1.1023 1.1018 0.0306 
98.99 to 
101.30 
3 
Levocetirizine 
Dihydrochloride 
Instrument  1 100.90 1.7913 1.7752 0.0497 
99.02 to 
102.77 
4 Instrument 2 101.19 0.8402 0.8363 0.0235 
100.30 to 
102.07 
5 
Ambroxol 
Hydrochloride 
Instrument 1 100.40 0.8096 0.8063 0.0224 
99.55 to 
101.24 
6 Instrument  2 100.85 1.1940 1.1839 0.0331 
99.59 to 
102.10 
 
 *Mean of six observations 
CI@ = confidence interval (95 %) 
 
 
 
 
 
 
 
 
 
 
  
 
TABLE – 21 
 
RECOVERY ANALYSIS OF FORMULATION (RENEA) 
BY FIRST ORDER DERIVATIVE SPECTROSCOPY (80 % Recovery) 
 
MON = Montelukast Sodium, LEVO = Levocetirizine Dihydrochloride,  
AMB = Ambroxol Hydrochloride 
*Mean of three observations 
CI@ = confidence interval (95 %) 
 
 
 
 
 
 
 
 
Drug Sample No 
Amount 
present 
(µg/ml) 
Amount 
added 
(µg/ml) 
Amount 
recovered 
(µg/ml) 
% Recovered* SD % RSD 
 
MON 
1 
2 
3 
6.99 
6.94 
6.95 
2.99 
3.01 
3.02 
2.99 
2.94 
2.95 
100 
98 
97.68 
 
1.2572 
 
 
1.2756 
 
Mean 
CI@ 
98.56 
97.24 – 99.87 
 
LEVO 
1 
2 
3 
3.48 
3.28 
3.28 
1.50 
1.30 
1.30 
1.48 
1.28 
1.28 
98.66 
98.46 
98.46 
 
0.1154 
 
 
0.1171 
Mean 
CI@ 
98.52 
98.39 – 98.64 
 
AMB 
1 
2 
3 
51.62 
49.98 
49.96 
 
21.72 
20.07 
20.16 
21.62 
19.98 
19.96 
99.53 
99.55 
99 
 
0.3119 
 
0.3139 
Mean 
CI@ 
99.36 
99.03 – 99.68 
  
 
TABLE – 22 
 
RECOVERY ANALYSIS OF FORMULATION (RENEA) BY  
FIRST ORDER DERIVATIVE SPECTROSCOPY (100 % Recovery) 
 
MON=Montelukast Sodium, LEVO=Levocetirizine Dihydrochloride,  
AMB=Ambroxol Hydrochloride 
*Mean of three observations 
CI@ = confidence interval (95 %) 
 
 
 
Drug Sample No 
Amount 
present 
(µg/ml) 
Amount 
added 
(µg/ml) 
Amount 
recovered 
(µg/ml) 
% Recovered* SD % RSD 
 
MON 
1 
2 
3 
8.42 
8.46 
8.42 
 
4.48 
4.50 
4.50 
4.44 
4.48 
4.44 
99.10 
99.55 
98.66 
 
0.4450 
 
 
0.4490 
 
Mean 
CI@ 
99.10 
98.63 – 99.56 
 
LEVO 
1 
2 
3 
4.92 
5.06 
4.93 
 
2.94 
2.99 
2.94 
2.90 
3.00 
2.91 
98.63 
103.4 
98.97 
 
2.0612 
 
 
2.0524 
Mean 
CI@ 
100.33 
98.16 – 102.49 
 
AMB 
1 
2 
3 
57.99 
58.36 
58.65 
 
28.42 
29.06 
29.56 
27.94 
28.31 
28.6 
98.81 
97.91 
96.89 
 
0.9930 
 
1.0163 
Mean 
CI@ 
99.76 
98.71 – 100.80 
  
 
TABLE – 23 
 
RECOVERY ANALYSIS OF FORMULATION (RENEA) BY  
FIRST ORDER DERIVATIVE SPECTROSCOPY (120 % Recovery) 
 
MON = Montelukast Sodium, LEVO = Levocetirizine Dihydrochloride,  
AMB = Ambroxol Hydrochloride 
*Mean of three observations 
CI@ = confidence interval (95 %) 
 
 
 
Drug Sample No 
Amount 
present 
(µg/ml) 
Amount 
added 
(µg/ml) 
Amount 
recovered 
(µg/ml) 
% Recovered* SD % RSD 
 
MON 
1 
2 
3 
9.86 
9.91 
9.90 
 
5.94 
6.02 
6.01 
5.88 
5.93 
5.92 
98.98 
98.50 
98.50 
 
0.2771 
 
 
0.2808 
 
Mean 
CI@ 
98.66 
98.36 – 98.95 
 
LEVO 
1 
2 
3 
6.37 
6.43 
6.21 
 
4.41 
4.37 
4.42 
4.35 
4.42 
4.19 
98.63 
99.37 
98.71 
 
1.3975 
 
 
1.4041 
Mean 
CI@ 
99.53 
98.06 – 100.99 
 
AMB 
1 
2 
3 
65.29 
64.86 
64.51 
 
36.26 
35.03 
34.91 
35.24 
34.81 
34.46 
97.18 
99.37 
98.71 
 
1.1234 
 
1.1414 
Mean 
CI@ 
98.42 
97.24 – 99.59 
  
 
 
TABLE- 24 
 
OPTICAL CHARACTERISTICS OF MONTELUKAST SODIUM, 
LEVOCETIRIZINE DIHYDROCHLORIDE AND  
AMBROXOL HYDROCHLORIDE BY HPTLC 
 
PARAMETERS 
MONTELUKAST 
SODIUM 
LEVOCETIRIZINE 
DIHYDROCHLORIDE 
AMBROXOL 
HYDROCHLORIDE 
Detection 
wavelength 
224 nm 224 nm 224 nm 
Linearity range 
(ng/l) 
20 - 200 20 - 200 75 - 750 
Correlation 
Coefficient (r) 0.9992 0.9990 0.9993 
Regression 
Equation 
(y=mx+c) 
Y=17.3154x+63.7566 Y = 12.6776x+(-6.4515) Y = 4.1748x+11.5865 
Slope (m) 17.315487 12.677624 4.174865 
Intercept (c) 63.756667 -6.451515 11.586515 
LOD (ng/l) 1.0238 2.1260 6.7883 
LOQ (ng/l) 3.1025 6.4424 20.5708 
Standard Error 3.8085 0.9013 1.8381 
 
 
 
  
 
 
TABLE – 25 
 
QUANTIFICATION OF FORMULATION (RENEA)  
BY HPTLC 
 
Drug Sample No. 
Labelled 
amount 
(mg/tab) 
Amount 
found 
(mg/tab)* 
Percentage 
Obtained* 
 
Average 
(%)  ± 
SD 
 
% 
RSD SE 
 
 
CI@ 
 
MON 
 
1 
2 
3 
4 
5 
6 
10 
10 
10 
10 
10 
10 
10.018 
10.075 
10.004 
9.934 
9.979 
9.967 
100.18 
100.75 
100.04 
99.34 
99.79 
99.67 
99.97 
± 
0.4881 
0.4882 0.0134 
 
 
99.45   
to    
100.48 
 
 
LEVO 
 
 
1 
2 
3 
4 
5 
6 
5 
5 
5 
5 
5 
5 
4.975 
5.013 
5.09 
5.15 
5.16 
5.18 
99.5 
100.26 
101.8 
103 
103.2 
103.6 
101.89 
± 
1.6881 
1.6567 0.0468 
 
 
100.11 
to   
103.66 
AMB 
1 
2 
3 
4 
5 
6 
75 
75 
75 
75 
75 
75 
75.452 
75.042 
75.394 
75.101 
74.808 
74.339 
100.6 
100.05 
100.52 
100.13 
99.74 
99.11 
100.02 
± 
0.5487 
0.5486 0.0152 
 
 
98.39   
to   
101.64 
 
MON = Montelukast Sodium, LEVO = Levocetirizine Dihydrochloride,  
AMB = Ambroxol Hydrochloride 
*Mean of six observations 
CI@ = confidence interval (95 %) 
 
 
 
  
 
TABLE – 26 
 
INTRADAY AND INTERDAY ANALYSIS OF FORMULATION (RENEA) 
 BY HPTLC 
 
Drug Sample No. 
Labelled 
amount 
(mg/tab) 
Percentage obtained* ± S.D % R.S.D. 
Intraday 
 (mg) 
Inter day 
(mg) 
Intra 
day 
Inter 
 day 
Intra 
day 
Inter 
day 
MON 
1 
2 
3 
10 
10 
10 
99.79 
99.34 
99.67 
99.77 
100.38 
99.34 
0.2330  0.5225 0.2379 0.5234 
Mean                      
Confidence interval 
99.60 
99.71-100.70 
99.83 
99.61-100.62 
 
LEVO 
1 
2 
3 
5 
5 
5 
101.8 
99.5 
100.26 
101.76 
102 
102.4 
1.1718 0.3233 1.1657 0.3168 
Mean 
Confidence interval 
100.52 
99.44-101.95 
102.05 
101.91-102.31 
 
AMB 
1 
2 
3 
75 
75 
75 
100.05 
100.13 
100.52 
100.05 
100.08 
99.5 
0.2514 0.3265 0.2508 0.3269 
Mean 
Confidence interval 
100.23 
100.06-101.03 
99.87 
99.13-100.12 
 
 
MON = Montelukast Sodium, LEVO = Levocetirizine Dihydrochloride,  
AMB = Ambroxol Hydrochloride 
*Mean of three observations 
  
 
 
TABLE – 27 
 
RECOVERY ANALYSIS OF FORMULATION (RENEA) 
BY HPTLC (80 % Recovery) 
 
MON = Montelukast Sodium, LEVO = Levocetirizine Dihydrochloride,  
AMB = Ambroxol Hydrochloride 
 *Mean of three observations 
CI@ = confidence interval (95 %) 
 
 
Drug Sample No 
Amount 
present 
(ng/µl) 
Amount 
added 
(ng/µl) 
Amount 
recovered 
(ng/µl) 
% Recovered* SD % RSD 
 
 
LEVO 
1 
2 
3 
36.9656 
36.7216 
36.8162 
16 
16 
16 
16.1319 
15.8881 
15.9825 
100.73 
99.37 
99.90 
 
0.6854 
 
 
0.6872 
 
Mean 
CI@ 
100.00 
99.28 – 100.71 
 
MON 
1 
2 
3 
72.4001 
71.9316 
71.8621 
32 
32 
32 
31.5478 
31.0858 
31.0098 
98.58 
97.14 
96.90 
 
0.9086 
 
 
0.9115 
Mean 
CI@ 
97.54 
96.58 – 98.49 
 
AMB 
1 
2 
3 
546.2793 
547.4460
545.2160 
 
240 
240 
240 
239.6874 
240.8541 
238.6241 
99.87 
100.35 
99.42 
 
0.4650 
 
0.4663 
Mean 
CI@ 
99.88 
99.39 – 100.36 
  
 
 
TABLE – 28 
 
RECOVERY ANALYSIS OF FORMULATION – RENEA 
BY HPTLC (100 % Recovery) 
 
MON = Montelukast Sodium, LEVO = Levocetirizine Dihydrochloride,  
AMB = Ambroxol Hydrochloride 
 *Mean of three observations 
CI@ = confidence interval (95 %) 
 
 
Drug Sample No 
Amount 
present 
(ng/µl) 
Amount 
added 
(ng/µl) 
Amount 
recovered 
(ng/µl) 
% Recovered* SD % RSD 
 
 
LEVO 
1 
2 
3 
40.7285 
40.8320 
40.1031 
20 
20 
20 
19.8945 
19.9989 
19.2694 
99.47 
99.99 
96.34 
 
1.9744 
 
 
2.0024 
 
Mean 
CI@ 
98.60 
96.52 – 100.67 
 
MON 
1 
2 
3 
79.8327 
80.8527 
80.1021 
40 
40 
40 
38.9804 
40.0004 
39.2498 
97.45 
100 
98.12 
 
1.3291 
 
 
1.3417 
Mean 
CI@ 
98.54 
97.14 – 99.93 
 
AMB 
1 
2 
3 
606.4750 
605.5963 
601.1230 
 
300 
300 
300 
299.8831 
299.0044 
299.5311 
99.96 
99.66 
98.17 
 
0.9586 
 
0.9657 
Mean 
CI@ 
99.26 
98.25 – 100.26 
  
 
 
TABLE – 29 
 
RECOVERY ANALYSIS OF FORMULATION – RENEA 
BY HPTLC (120 % Recovery) 
 
MON = Montelukast Sodium, LEVO = Levocetirizine Dihydrochloride,  
AMB = Ambroxol Hydrochloride 
 *Mean of three observations 
CI@ = confidence interval (95 %) 
Drug Sample No 
Amount 
present 
(ng/µl) 
Amount 
added 
(ng/µl) 
Amount 
recovered 
(ng/µl) 
% Recovered* SD % RSD 
 
 
LEVO 
1 
2 
3 
44.9442 
44.7352 
44.6121 
24 
24 
24 
 
24.1105 
23.9015 
23.7784 
100.50 
99.55 
98.99 
 
0.7633 
 
 
0.7657 
 
Mean 
CI@ 
99.68 
98.87 – 100.47 
 
MON 
1 
2 
3 
87.9237 
88.0970 
88.6136 
48 
48 
48 
47.0714 
47.2447 
47.7613 
98.06 
98.42 
99.50 
 
0.7494 
 
 
0.7595 
Mean 
CI@ 
98.66 
97.87 – 99.44 
 
AMB 
1 
2 
3 
667.6606 
665.5049 
666.7160 
 
360 
360 
360 
361.0741 
358.9125 
360.1241 
100.29 
99.69 
100.34 
 
0.3517 
 
0.3613 
Mean 
CI@ 
100.10 
99.73 – 100.46 
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